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Several factors have helped significantly to make anesthesia as safe as it is today: an 
improving knowledge of pharmacology and better methods of drug titration, technology 
(monitoring and safeguarding of vital functions, delivery systems of anesthetic drugs and 
monitoring of drug effect) and a better recognition of the role of, and how to reduce the 
influence of human factors (errors, communication, crew resource management 
training) with lessons learned from the aviation industry. Mainly the first two have 
ensured that mortality from anesthesia has decreased from  1:2250 in patients in good 
condition and 1:360 in patients in poor condition in the early 1950s1 to as low as 
1:250,000 in healthy patients and about 1:1800 in patients in very poor condition in 
1999.2 In more recent years, human factors have played a greater role, but the first two 
are still important and progress can still be made in anesthetic pharmacology and 
technology.  
This thesis attempts to contribute to advances in knowledge and technology in 
anesthetic pharmacology, by investigating the following topics: 
- the development of improved pharmacokinetic and pharmacodynamic models
for single drugs,
- the development of drug interaction models that describe the combined
effects of multiple drugs and the performance of several commonly used
surrogate parameters of anesthetic effect,
- the development of a new parameter of anesthetic potency based on the
interaction models, which can be used in clinical practice to guide anesthesia
in an intuitive manner.
In the next paragraphs, detailed background information is provided to highlight the 
gaps in knowledge that need to be explored further and to present the aims of this thesis 
within this field. 
Pharmacokinetics (PK) 
Pharmacokinetics describe the time-course of the plasma concentration of the drug, or 
‘what the body does to the drug’. Absorption, distribution, metabolism and elimination 
are all processes that play a part in how much of the drug circulates in the bloodstream, 
resulting in the plasma concentration of a drug. This is a dynamic process, where the 
concentration changes continuously, depending on the aforementioned processes, as 
well as continuation or cessation of drug administration. 
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Figure 1. Three-compartment pharmacokinetic model with a central compartment and two 
peripheral compartments. V1-3 = volume of the respective compartments (CMT); Cl1-3 = 
clearance to and from the respective compartments, kij = equilibration rate constant from 
compartment i to compartment j. 
PK modeling is often used to quantify the pharmacokinetics of a drug. There are several 
methods for PK modeling, one of the most often used methods being population-based 
compartmental PK modeling. With this method, one or multiple compartments, each 
with a certain volume and a certain distribution clearance, are used to evaluate the 
plasma concentration of the drug at a certain point in time. A single-compartment model 
has only one compartment of a certain volume, in which the drug is administered into, 
and the drug is also cleared out of the compartment (by elimination and/or metabolism). 
Often this compartment roughly resembles the vascular compartment, i.e. the 
bloodstream. Multiple-compartment models also describe the distribution of a drug out 
of the bloodstream (central compartment 1), into one or more peripheral 
compartments, for which equilibration rate constants (k) describe the movement of 
drug into and out of the peripheral compartments, as well as a clearance out of the 
central (vascular) compartment (again, by elimination and/or metabolism). The often-
used three compartment model comprises of a central compartment and two peripheral 
compartments: one compartment with a relatively low volume and high equilibration 
rate, which roughly resembles well-perfused tissues in which the drug can rapidly 
distribute into and out of, and a compartment with a high volume and low equilibration 
rate. This compartment roughly resembles poorly perfused tissues which the drug 
slowly distributes into, but when saturated also keeps distributing back into the 
bloodstream for a long time after drug administration is terminated. Figure 1 shows an 
example of a three-compartment PK model, with a central compartment and two 
peripheral compartments with certain volumes and equilibration rate constants 
between compartments. Figure 2 shows the time-concentration relationship as 
described by a three-compartment model following a bolus dose into the central 
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compartment, also depicting the movement of drug in and out of the compartments at 
different time points in the process, in the form of communicating vessels. One must 
keep in mind though, that these compartments are mathematical in nature, and are not 
strictly analogous with any physiological compartment. Compartmental 
pharmacokinetics allow for the use of relatively simple mathematics to describe the 
time-concentration relationship, without the immense complexity of human physiology 
and pharmacology, and they manage to do so with clinically acceptable accuracy.3 
Figure 2. Plasma concentration vs. time, depicting the different pharmacokinetic phases 
(distribution and elimination) after a bolus dose of a certain drug. Cp = plasma concentration. 
Pharmacodynamics (PD) 
Pharmacodynamics describe ‘what the drug does to the body’, or more accurately, the 
relation between the concentration at the site of drug effect and the actual effect. To 
enable pharmacodynamics analysis, one needs to be able to measure the effect. This 
can be both desired effects and unwanted side-effects. For anesthetic drugs, the desired 
effect may for instance be adequate anesthesia, and side-effects may be hemodynamic 
in nature, such as on blood pressure (hypo- or hypertension), heart rate (bradycardia) 
or cardiac output, or delayed recovery from anesthesia. These effects are not always 
easy to quantify, as the actual effect cannot always be measured, and surrogate 
measurements are often used. “Adequacy of anesthesia” in itself cannot be measured, 
and is actually a combined effect of hypnosis, analgesia (or rather: balance between 
nociception and antinociception) and immobility. A dichotomous measurement can be 
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used to determine adequacy of anesthesia, such as a motor response to skin incision, or 
an increase in heart rate and blood pressure in response to a painful stimulus, sweating 
or pupillary dilatation. During surgery, the anesthesiologist will seek to prevent these 
responses, and therefore needs a parameter that can predict whether a patient will or 
will not tolerate a painful stimulus such as skin incision. Electroencephalograph (EEG) 
derived monitors are often used, which measure to a certain extent the hypnotic 
component of anesthesia by measuring the drug-induced changes in the electrical 
activity of the brain. Monitoring systems that attempt to measure the balance between 
nociception and antinociception are under development, but it remains to be seen how 
these monitors perform. 
Even the effects that we consider to be hemodynamic side effects (such as low blood 
pressure) are often only surrogates of true side effects (i.e. organ/tissue damage), and 
although there is little doubt that intraoperative hypotension plays a role in 
development of perioperative tissue damage (myocardial ischemia, kidney injury, 
ischemic stroke etc.), there is no consensus to what ‘intraoperative hypotension’ is and 
at what level it is actually harmful, as many different definitions exist in the medical 
literature.4 
Figure 3. Sigmoidal Emax curve, with three different values for C50 (2, 3 and 4, respectively). 
In short, there is as of yet no accurate method to assess whether a patient is under 
adequate anesthesia, without over- or underdosing. Therefore, surrogate 
measurements will have to suffice, and that is what is currently available for the 
assessment of pharmacodynamic effects, as is the case in this thesis. Pharmacodynamics 
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are often referred to as the dose-response relationship, but a more accurate term would 
be the concentration-effect relationship, as ‘dose’ implies that pharmacokinetic 
processes are included in the pharmacodynamic descriptions, while these are separate 
processes. Pharmacodynamics may appear to be linear at clinically applied 
concentrations for some drugs, in which case a concentration-effect curve would be a 
straight line, but more often, the relationship is non-linear, and can be described by a 
sigmoidal Emax curve, or Hill equation:  
Effect = 𝐸𝐸0 + (𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 − 𝐸𝐸0) 𝐶𝐶𝛾𝛾𝐶𝐶50𝛾𝛾+𝐶𝐶𝛾𝛾   (1) 
where E0 is the effect at baseline, Emax is the maximum effect, C is the concentration, C50 
is the concentration associated with 50% maximum effect and γ describes the steepness 
of the concentration-effect curve (also called the Hill coefficient). Figure 3 shows an 
example of a sigmoidal Emax curve. 
Figure 4. Three-compartment model with the addition of an effect site compartment with 
negligible volume, which makes k1e small and inconsequential, with ke0 being the primary 
determinant of the concentration in the effect site. V1-3 = volume of the respective compartments 
(CMT); CL1-3 = clearance to and from the respective compartments, kij = equilibration rate 
constant between compartment i to compartment j. 
Pharmacokinetics/pharmacodynamics (PKPD) 
Pharmacodynamic effects, or their surrogates, can be linked to pharmacokinetic models. 
Ideally, the drug concentration at the site of effect would be measured. However, this is 
impossible in most situations, as the site of drug effect is usually inaccessible (for 
instance, in the brain, or more accurately, at receptor level). The concentration at the 
site of drug effect and its time course are therefore estimated from the data. Often this 
is done by ‘attaching’ a so-called effect-site compartment to the compartmental PK 
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model. This effect-site compartment has negligible volume, and an elimination rate 
constant ke0, which ultimately describes the lag that occurs between the rise or decline 
in plasma concentration and the increase or decrease in effect. Figure 4 shows the 
previously shown three-compartment model with the addition of an effect-site 
compartment. Figure 5 shows the lag that can occur between plasma concentration and 
effect, and it is this lag or hysteresis (Figure 6) that the PKPD model attempts to explain, 
also called ‘collapsing the (hysteresis) loop’. Again, these models are purely 
mathematical in nature, and the addition of an effect-site compartment with negligible 
volume is not in itself translatable to an anatomical structure, but allows for modeling 
of the lag between the rise in plasma concentration and effect. 
Figure 5. Plasma concentration during and after a 10-minute infusion, and corresponding lag in 
measured effect (for instance, EEG-derived indices). Cp = plasma concentration. 
As PKPD models are used to describe and predict the time course of the drug 
concentration and effect, they can be used to calculate dosing schemes for use in clinical 
practice, i.e. a bolus dose and adjusting maintenance rates over time to account for the 
distribution of the drug into the peripheral tissues, instead of a bolus dose and 
maintaining the same infusion rate throughout the procedure. Limitations are that the 
calculation of these bolus doses and infusion rates should not be too complicated, 
usually based on patient weight. Additional covariates make the calculations more 
difficult and prone to error. Computers nowadays are also capable of calculating and 
displaying the concentration time course on the basis of manual drug delivery (bolus 
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and infusion rates), and the user can adjust infusion rates to target a certain plasma or 
effect-site concentration. PKPD models can also be implemented in target-controlled 
infusion (TCI) pumps, which allow the user to target a certain plasma (PK) or effect-site 
(PKPD) concentration for a certain drug, and the TCI pump will automatically adjust the 
infusion rate to maintain a stable concentration (in plasma or the effect site). Also, when 
targeting effect-site concentrations, the TCI-pump calculates the loading dose required 
to reach the targeted effect-site concentration the fastest, which requires an ‘overshoot’ 
of the plasma concentration to drive the drug into the effect site, without overshooting 
the effect-site concentration. This cannot be done accurately without the use of PKPD 
models, and dosing by hand commonly results in a large overshoot in both plasma and 
effect-site concentrations. The use of TCI-pumps reduces the risk of overdosing in the 
initial loading dose, and also reduces the risk of overdosing as time progresses, or 
underdosing when the infusion rate is lowered too far or too soon in an attempt to 
prevent overdosing. 
Figure 6. Hysteresis between plasma and effect-site concentrations. Arrows indicate which part 
of the loop occurs during increasing or decreasing plasma concentrations, respectively. Cp = 
plasma concentration; Ce = effect-site concentration. 
Model development studies 
Setting up a study for the purpose of developing PKPD models requires consideration of 
several aspects, as the model is only as good as the data it is derived from. First, one 
must consider the study population: healthy volunteers or patients. The major 
advantage of the former is the absence of co-morbidities and chronic co-medication, as 
well as the use of other anesthetic drugs such as opioids and muscle relaxants, and 
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allows for good base models for investigating drug interactions and interaction 
modeling. A disadvantage is that models developed from healthy volunteers may be less 
accurate when extrapolated to patient populations. Second, one must decide whether 
to use arterial or venous blood samples for concentration measurements. Arterial 
sampling provides a more accurate approximation to the concentration which is 
delivered to the target organ, whereas venous samples convey more information on the 
uptake of drug in tissues distal to the sampling site (for instance, the forearm), which is 
usually not the site of interest, and this may pose problems for the accuracy of the 
model.5 Arterial line placement is however associated with more serious complications 
than venous line placement (dissection or thrombosis of the artery), even though these 
complications are very rare in healthy volunteer populations. A third consideration is 
the dosing of the drug in question. For this, a thorough understanding of the drug is 
necessary, including what is already known about the drug’s pharmacokinetics and –
dynamics, and if possible, even simulating beforehand to determine the best dosing 
scheme and/or blood sampling schedule. In some cases, PK and/or PKPD models may 
already be in existence, but lack accuracy, reducing its use in clinical practice and future 
research. These models require optimization, but these models may still be used for 
drug dosing during optimization studies.6  
Not only is drug dosing important, but the time of sampling also plays a great role in how 
accurate a model is. Considering the drug for which the concentration vs. time graph is 
shown in Figure 2: if one were to only take samples from 10 minutes after the bolus 
onwards, and stop sampling after an hour, the measured concentrations would all be in 
a somewhat straight line (the ‘slow distribution’ phase in Figure 2). This would suggest 
that a one-compartment model would best describe the data, resulting in the conclusion 
that the drug follows one-compartment pharmacokinetics (and therefore this would not 
be the slow distribution phase, as there is no distribution, only the terminal elimination 
phase). Though it does indeed describe the data well, the data does not describe the 
actual pharmacokinetics well, due to poor sampling. Therefore, when modeling PKPD, 
one must make sure to take samples early enough in the drug administration to be able 
to capture the rapid distribution, but also late enough to be able to capture the terminal 
elimination phase. Clinical trial simulations, based on existing knowledge about the 
pharmacokinetics of a drug, may help in determining the best sampling scheme for a PK 
or PKPD study, thereby determining the optimal experimental design. 
Dexmedetomidine 
As mentioned, the development of PKPD models requires a thorough understanding of 
the drugs in question. One of the drugs that is investigated extensively in this thesis is 
dexmedetomidine. Dexmedetomidine is a selective α2-adrenoceptor agonist, with 
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sedative, analgesic and anxiolytic effects. It is more selective than its closest relative, 
clonidine.7 Although α1-adrenoceptor activation antagonizes the α2 sedative effects, 
this is markedly less so for dexmedetomidine than for clonidine.8 An interesting property 
of α2-adrenoceptor agonists is that subjects remain rousable even at relatively high 
concentrations.9 This makes it an interesting drug for the use in situations where 
sedation is desired, but some amount of interaction with the patient is required. This 
may for instance be in sedation in Intensive Care Units (ICU), in procedural sedation, or 
for awake craniotomies, where the patient is required to perform certain tasks to ensure 
no vital parts of the brain are damaged.10 Also, the respiratory drive is largely maintained 
in dexmedetomidine sedation.11, 12 
Whereas most anesthetic drugs tend to induce hypotension, α2-adrenoceptor agonists 
like dexmedetomidine have a biphasic effect on blood pressure. This is due to the fact 
that dexmedetomidine influences α2-adrenoceptors both in the central nervous system 
and in the vascular wall. At low concentrations, dexmedetomidine activates mainly 
presynaptic α2-adrenoceptors in the central nervous system and α2-adrenoceptors in 
the vascular endothelial cells. This results in vasodilation and lowering of the heart 
rate.13, 14 At higher concentrations, α2-adrenoceptors in the vascular smooth muscle are 
activated, resulting in vasoconstriction and hypertension (and a further decrease in 
heart rate).15, 16 
Several PK models exist for dexmedetomidine, like the Dyck model.17 This model is fairly 
accurate at lower concentrations, but underestimates concentrations in the higher 
ranges.12 One of the goals of this thesis was therefore to develop an optimized 
dexmedetomidine PK model (Chapter 2). Whereas several PK models are in existence, 
no PKPD models exist for dexmedetomidine. A second goal was therefore to explore 
both the sedative (Chapter 3) and the hemodynamic (Chapter 4) effects of 
dexmedetomidine, and develop PKPD models for both types of effect, increasing the 
probability of rapidly titrating dexmedetomidine to the desired effect within the limits 
posed by the hemodynamic side effects. 
Interactions 
Another issue that makes titrating a general anesthetic more difficult, is not just the 
complexity of the pharmacokinetics and –dynamics of individual drugs, but also the 
interaction between drugs. A general anesthetic is rarely administered through one drug 
only, often two or more drugs are combined to achieve anesthesia, with at least a 
hypnotic and an analgesic drug. Examples of the hypnotic drugs are the volatile 
anesthetics such as sevoflurane, and the intravenous drug propofol. Examples of the 
analgesics are the opioids, such as morphine, fentanyl, or the rapidly acting remifentanil. 
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It would be too simple to say these drugs only have an effect on either sedation or 
analgesia, as combining them may very well influence the total effect of both sedation 
and analgesia beyond what would be expected by simply ‘adding up’ the effects. 
Interactions can be both on a pharmacokinetic and pharmacodynamic level. On a 
pharmacokinetic level, certain drugs may influence the absorption of other drugs, the 
volume of distribution, or (hepatic) metabolism of a drug, increasing or decreasing the 
plasma concentration of either the drug itself or perhaps its active metabolites. 
Pharmacokinetic interactions will eventually influence pharmacodynamics, as an 
increase or decrease in drug concentration or that of active metabolites, increases or 
decreases the availability of the active component to be distributed to the site of drug 
effect. 
Figure 7. Three-dimensional response surface model of the interaction between two drugs, and 
the effect. Ce = effect-site concentration. 
Pharmacodynamic interactions take place at the site of drug effect. Interactions can be 
described as being additive, synergistic (supra-additive) or antagonistic (infra-additive). 
Often, the manner of interaction is not clearly elucidated, and may comprise of 
competitive binding at the receptor level or identical pathways (often additive 
interaction), or different actions at separate receptor types or different pathways (often 
synergism or antagonism). Most drug interaction studies only quantify the magnitude of 
the interaction in a limited fashion, and sometimes only on a pharmacokinetic level, or 
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only for a dose or concentration corresponding with 50% of maximum effect (D50 or 
C50, respectively).  
However, anesthetic drugs can have profound pharmacodynamic interactions, and the 
presence of these interactions is used in daily practice, for instance by using the 
synergism between opioids and hypnotic drugs to be able to limit the amount of both 
drugs given to achieve adequate anesthesia. In addition, 50% of maximum effect is 
unacceptable if the desired effect is for instance probability of tolerance of a painful 
stimulus; a 95% probability or higher would be desirable in clinical practice. 
Figure 8. Five isoboles of the response surface model in Figure 6, corresponding with 5%, 25%, 
50%, 75% and 95% of maximum effect, respectively. Emax = maximum effect, Ce = effect-site 
concentration. 
Rather than only investigating the interaction at the level of 50% maximum effect, 
response surface modeling explores the full spectrum of effects, from (near) 0 to (near) 
maximum effect, at a range of combinations of the two drugs. An example of response 
surface modeling is shown in Figure 7. The effect can be both a continuous 
measurement such as an EEG-derived hypnotic monitor, and a dichotomous 
measurement such as probability of tolerance of a stimulus. Another way to visualize 
two-drug interactions is through the use of isoboles, which are two-dimensional 
representations of a slice of the response surface model. Figure 8 shows five isoboles 
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derived from the response surface model in Figure 7, corresponding with 5%, 25%, 50%, 
75% and 95% of maximum effect. 
Interactions can be described using various models. The term U is often used in 
interaction modeling, and can be seen as the combined potency of the drugs that are 
used, normalized to their respective C50s. In short, U can be seen as the concentration 
of a new, virtual drug, with the characteristics of the drugs that are investigated. U can 
be used to describe a certain probability of effect P (for dichotomous endpoints): 
𝑃𝑃 = 𝑈𝑈𝛾𝛾1 + 𝑈𝑈𝛾𝛾  (2) 
where γ is the slope parameter, or steepness of the concentration-effect relationship. 
This is actually a sigmoid Emax equation (Eq. 1) with E0 = 0 and Emax = 1. Heyse et al.18 
describes the different interaction models in detail in their appendix. A more simplified 
explanation will be presented here, describing only models relevant to this thesis. The 
simplest interaction model is the additive model: 
𝑈𝑈 = 𝑈𝑈𝐴𝐴 + 𝑈𝑈𝐵𝐵  (3) 
where UA is the normalized concentration of drug A (CA/C50A) and UB is the normalized 
concentration of drug B (CB/C50B). Equation 3 is a form of the Greco model (Eq. 4), which 
has the addition of an interaction parameter α. If α = 0, the interaction is additive, and 
is the same as Eq. 3. If α > 0, the interaction is synergistic and if α < 0, the interaction is 
infra-additive. 
𝑈𝑈 = 𝑈𝑈𝐴𝐴 + 𝑈𝑈𝐵𝐵 + 𝛼𝛼 × 𝑈𝑈𝐴𝐴 × 𝑈𝑈𝐵𝐵   (4) 
The third model is the reduced Greco model, which assumes α in Eq. 4 to be equal to 1, 
and removes the additive component of drug B: 
𝑈𝑈 =  𝑈𝑈𝐴𝐴 × (1 + 𝑈𝑈𝐵𝐵)  (5) 
In this model, the C50 of drug B is the concentration that apparently reduces the C50 of 
drug A by 50%, and assumes drug B had no effect on its own (if UA = 0, U = 0). 
Bouillon introduced the Hierarchical model19, which is more complex than the Greco and 
reduced Greco models. It was developed with the clinical effects of opioids and 
hypnotics in mind. The idea is that a stimulus with a certain (preopioid) intensity is 
administered to a patient. The preopioid intensity is attenuated by the opioid. The 
attenuated (postopioid) stimulus is then affected by the hypnotic, which determines 
whether the patient ultimately responds to the stimulus or not (Figure 9). 
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Figure 9. The Hierarchical model. The stimulus with a preopioid intensity undergoes attenuation 
by the opioid. This attenuation (the postopioid intensity) determines in part the shape of the 
concentration-effect curve of the hypnotic drug. The hypnotic concentration then determines the 
probability of tolerance of the stimulus. 
In the original model, the probability of tolerance to a stimulus is described as: 
𝑃𝑃 = 𝐶𝐶𝐻𝐻𝛾𝛾(𝐶𝐶50𝐻𝐻 × 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 )𝛾𝛾 + 𝐶𝐶𝐻𝐻𝛾𝛾   (6) 
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 = 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × �1 − 𝐶𝐶𝑂𝑂𝛾𝛾𝑜𝑜(𝐶𝐶50𝑂𝑂 × 𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 )𝛾𝛾𝑜𝑜 + 𝐶𝐶𝑂𝑂𝛾𝛾𝑜𝑜�   (7) 
where postopioid is the stimulus intensity after attenuation by the opioid, preopioid is 
the stimulus intensity in absence of the opioid, CH is the concentration of the hypnotic, 
CO is the concentration of the opioid, C50H is the concentration of the hypnotic resulting 
in 50% of maximum effect, C50O is the concentration of the opioid resulting in 50% of 
maximum effect, γ is the slope parameter for the probability of tolerance, and γO is the 
slope parameter for the opioid vs. stimulus intensity relationship.  
If U = UH / postopioid, then this model can be described as such: 
𝑈𝑈 = 𝑈𝑈𝐻𝐻
𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 × �1 + � 𝑈𝑈𝑂𝑂𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝 �𝛾𝛾𝑜𝑜�   (8) 
where UH is the normalized concentration of the hypnotic (CH/C50H) and UO is the 
normalized concentration of the opioid (CO/C50O).  
This model is considered to be overparameterized, because several parameters 
(preopioid intensity and the C50s for both hypnotic and opioid) cannot be estimated 
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independently. For studies with only a single stimulus, intensity can be set to 1 to solve 
this problem. The model can then be simplified to: 
𝑈𝑈 = 𝑈𝑈𝐻𝐻 × (1 + 𝑈𝑈𝑂𝑂𝛾𝛾𝑜𝑜)  (9) 
This model is in fact similar to the reduced Greco model in Eq. 5, with the addition of a 
slope factor γO for the opioid effect (drug B in Eq. 5). In case of multiple stimuli, solving 
the problem of overparameterization can be done in several ways, but the reader is 
referred to the appendix of the sevoflurane-remifentanil interaction study by Heyse et 
al.18 for further explanation, as this thesis does not investigate multiple stimuli in 
interaction studies. 
In clinical practice, as is the case with the basics of pharmacokinetics and 
pharmacodynamics, the way most anesthesiologists use this knowledge is arbitrary and 
based on rough dosing schemes and mainly experience. Interaction modeling may 
increase the accuracy of drug dosing even in the presence of multiple drugs,20 limiting 
the risks of under- and overdosing and as such, undesired effects such as awareness or 
pain sensation on the one hand, and hemodynamic instability or delayed recovery on 
the other. Three studies have been done to extensively quantify the interactions 
between propofol and remifentanil (Bouillon et al.19), propofol and sevoflurane 
(Schumacher et al.21) and sevoflurane and remifentanil (Heyse et al.18), on tolerance of 
noxious and non-noxious stimuli. Bouillon and Schumacher also modeled the interaction 
on continuous measurements, such as the bispectral index and other hypnotic monitors. 
All three studies used response surface modeling to visualize the interaction between 
the two drugs. Chapter 5 expands on the sevoflurane-remifentanil interaction by 
exploring the combined effect on not only hypnotic monitors, as Bouillon and 
Schumacher did previously, but also on marketed ‘analgesic’ monitors, and the effect 
that noxious stimulation has on these continuous measurements, also using response 
surface modeling. 
In anesthetic practice, it is not uncommon to use more than two drugs. For instance, 
anesthesia may be induced by using an intravenous drug such as propofol, combined 
with an opioid, and as soon as the airway is secured, anesthesia can be maintained using 
volatile anesthetics such as sevoflurane, with the addition of an opioid. Thus, to be able 
to maintain a stable anesthesia with three drugs with differing methods of 
administration (propofol and perhaps the opioid in bolus doses, sevoflurane at a certain 
continuous rate, with the opioid in bolus doses or continuous infusion), not only is a 
good understanding of the interactions necessary, but also some way to visualize or 
even help titrate the drugs. This is where triple interaction modeling comes into play. 
Chapter 6 explores the interaction between sevoflurane, propofol and remifentanil, on 
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tolerance of laryngoscopy – a noxious stimulus – by combining the data from the three 
previously mentioned studies by Bouillon19 (propofol-remifentanil), Schumacher21 
(propofol-sevoflurane) and Heyse18 (sevoflurane-remifentanil). These three studies 
were all performed in a similar manner, with reproducible drug administration, very 
similar trial designs and similar, clinically relevant endpoints (in particular: tolerance of 
laryngoscopy). The trial design used was a modification of the crisscross trial design as 
described by Short et al.22 In this design, study subjects receive one of the tested drugs 
at a stable concentration, while the second drug is titrated stepwise, where 
measurements are done after ample time for equilibration (12-15 minutes) to ensure 
pseudo-steady state conditions. Due to the similar design and similar endpoints, these 
studies can be combined to model a triple interaction. These (two or three drug) 
interaction models can be visualized on advanced monitors such as the SmartPilot View 
(Drägerwerk, Lubeck, Germany) or the Navigator (GE Healthcare, Chicago, IL, USA). 
Apart from aid through visualization, Chapter 6 also focusses on the Noxious Stimulation 
Response Index (NSRI), which has previously been described by Luginbühl et al. for the 
propofol-remifentanil interaction. The NSRI has been expanded in Chapter 6 to include 
the triple interaction model. The NSRI is a transformation of the probability of tolerance 
of laryngoscopy, scaled from 100 (no drug effect) to 0 (profound drug effect). This index 
allows for better quantification of the interaction drug effect, as an NSRI of 20 by the 
use of any two-drug combination between sevoflurane, propofol and remifentanil, or 
the three drugs together, all correspond with a probability of 90% that the patient will 
tolerate laryngoscopy. 
Aims of this thesis 
The aim of this thesis is to explore several strategies in quantifying the pharmacology of 
anesthetic drugs in order to enable more accurate titration of individual drugs or 
multidrug combinations.  
- The very basis on which all other models rely, is an adequate pharmacokinetic
model. For dexmedetomidine, an optimized PK model was developed.
- The next step is to incorporate pharmacodynamics to create a PKPD model. The 
previously developed dexmedetomidine PK model was expanded to include a
PD component based on the desired sedative effects.
- In a unique way, for the same drug, a PD model was developed on the
hemodynamic side effects of dexmedetomidine, again using the previously
developed PK model as a basis. This may increase the safety of
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dexmedetomidine administration by titrating to desired sedative levels while 
maintaining a safe hemodynamic profile. 
- The next step is pharmacodynamic interaction modeling, where two drugs are
delivered to stable effect site concentrations, and the interactive effect
between these two drugs can be investigated. In an expansion of an existing
interaction model for sevoflurane-remifentanil for tolerance of different
stimuli, additional modeling was performed to investigate the interaction
between these two drugs on hypnotic and analgesic monitor measurements.
- A step above and beyond two-drug interaction modeling is multiple drug
interaction modeling. A first great step has been made by investigating the
interaction between sevoflurane, propofol and remifentanil, and by expanding
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Background: Several pharmacokinetic models are available for dexmedetomidine, but 
these have been shown to underestimate plasma concentrations. Most were developed 
with data from patients during the postoperative phase and/or in intensive care, making 
them susceptible to errors due to drug interactions. The aim of this study is to improve 
on existing models using data from healthy volunteers. 
Methods: After local ethics committee approval, the authors recruited 18 volunteers, 
who received a dexmedetomidine target-controlled infusion with increasing target 
concentrations: 1, 2, 3, 4, 6, and 8 ng/ml, repeated in two sessions, at least 1 week apart. 
Each level was maintained for 30 min. If one of the predefined safety criteria was 
breached, the infusion was terminated and the recovery period began. Arterial blood 
samples were collected at preset times, and NONMEM (Icon plc, Ireland) was used for 
model development. 
Results: The age, weight, and body mass index ranges of the 18 volunteers (9 male and 
9 female) were 20 to 70 yr, 51 to 110 kg, and 20.6 to 29.3 kg/m2, respectively. A three-
compartment allometric model was developed, with the following estimated 
parameters for an individual of 70 kg: V1 = 1.78 l, V2 = 30.3 l, V3 = 52.0 l, CL = 0.686 
l/min, Q2 = 2.98 l/min, and Q3 = 0.602 l/min. The predictive performance as calculated 
by the median absolute performance error and median performance error was better 
than that of existing models. 
Conclusions: Using target-controlled infusion in healthy volunteers, the 
pharmacokinetics of dexmedetomidine were best described by a three-compartment 
allometric model. Apart from weight, no other covariates were identified. 
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Dexmedetomidine is an α2-adrenoceptor agonist with sedative, analgesic, and anxiolytic 
properties. Patients receiving low doses of dexmedetomidine remain rousable despite 
otherwise appearing to be deeply asleep. This makes it a useful drug for conscious 
sedation, specific surgical procedures such as awake craniotomies, and sedation in 
intensive care units (ICUs). In experimental settings, dexmedetomidine is used in the 
context of “opioid-reducing anesthesia” techniques1 and to attenuate perioperative 
inflammatory responses.2 To compensate for the rather slow pharmacokinetic profile of 
the drug, which results in increasing plasma concentrations over time with fixed-rate 
infusions, target-controlled infusion (TCI) using an accurate pharmacokinetic model is 
likely to be helpful in managing and titrating sedation by maintaining stable and 
predictable plasma concentrations. 
Few dexmedetomidine pharmacokinetic models have been developed with data from 
healthy volunteers. The Dyck model combines pharmacokinetic data derived from the 
studies of plasma concentrations after a bolus dose3 with data acquired during and after 
a computer-controlled infusion.4 However, this is a very preliminary model, with height 
as the only covariate, and the model has been shown to be inaccurate at higher target 
concentrations.5 The Dutta model is derived from the data from a healthy population, 
using computer-controlled infusion with an unpublished model.6 Venous blood samples 
were used, although this is likely not an accurate measurement of drug delivery to target 
organs in non-steady-state conditions, and may have influenced the accuracy of the 
parameters of the Dutta model. Most of the existing pharmacokinetic models for 
dexmedetomidine were obtained from trials involving postoperative and/or ICU 
patients, using either computer-controlled infusion with an unpublished model7 or 
continuous infusion.8-10 This approach is sensitive to the influence of confounding drugs 
such as subtherapeutic levels of anesthetic drugs, additional sedation or analgesia, and 
other medications. The resulting pharmacokinetic models are thus less applicable to 
single drug pharmacokinetic modeling. Of the available “ICU” models, the Talke model7 
is often used, but similar to the Dyck model, it also has been shown to underestimate 
plasma concentration at higher target concentrations of dexmedetomidine.11 Shafer et 
al.12 suggested that using TCI administration during model development may provide 
more appropriate parameters for use in subsequent TCI. Only the Dyck, Dutta, and Talke 
models used TCI administration (Dutta and Talke used unpublished models) for model 
development.  
For these reasons, we believe that some improvement is desirable for pharmacokinetic 
models of dexmedetomidine. The aim of this study is to develop a pharmacokinetic 
Chapter 2 
30 
model for dexmedetomidine, using TCI administration in healthy volunteers, using data 
from a population with a wide range of ages and weights and a wide range of drug 
concentrations.  
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Materials and Methods 
The study was approved by the local Medical Ethics Review Committee (University 
Medical Center Groningen, Groningen, The Netherlands; Medical Ethics Review 
Committee number: 2012/400) and was registered in the ClinicalTrials.gov database 
(NCT01879865). Written informed consent was obtained from 18 healthy volunteers, 
who were recruited and screened by QPS (a contract research organization based in 
Groningen, The Netherlands). Subjects were stratified according to age and sex (6 
subjects, 3 male and 3 female, for each age group: 18 to 34 yr, 35 to 54 yr, and 55 to 72 
yr). Inclusion criteria were American Society of Anesthesiologists physical status I, 
absence of any medical history of significance, and absence of chronic use of medication 
(oral contraceptives excluded), alcohol, drugs, or tobacco. Exclusion criteria were known 
intolerance to dexmedetomidine and body mass index (BMI) less than 18 kg/m2 or 
greater than 30 kg/m2. Women who were pregnant or nursing were also excluded. 
Subjects were instructed not to use medication or drugs in the 2 weeks before the study 
days, not to drink coffee or alcohol or smoke tobacco in the 2 days before each study 
day, and to fast from 6 h before the start of the study. To study the intraindividual 
variability of pharmacokinetic estimations more effectively, the volunteers were 
enrolled in two separate sessions, at least 1 week and at most 3 weeks apart. We 
hypothesized that there may be a difference between the first and second sessions due 
to currently unknown but identifiable causes such as the variation in level of anxiety or 
adrenergic tone between sessions. 
Monitoring 
An 18- or 20-gauge IV cannula was placed in a vein on the subject’s nondominant arm 
or hand. A 20-gauge arterial cannula was placed in the radial artery of the same arm 
under local anesthesia (lidocaine 1%), using the Seldinger technique, and used for 
continuous arterial blood pressure monitoring and blood sampling. Standard anesthetic 
monitoring was performed using a Philips MP50 monitor (Philips Healthcare, The 
Netherlands). Noninvasive blood pressure was measured and recorded at 5-min 
intervals on the arm opposite the IV and arterial line. All subjects maintained 
spontaneous ventilation, with a nasal cannula (O2/CO2 Nasal Filterline®; Covidien, USA) 
for oxygen delivery as needed, from 0 to 4 l/min. Capnography was monitored by means 
of side-stream sampling through the nasal cannula (Microstream® carbon dioxide 
extension; Philips Healthcare).  
All monitored parameters were captured by a computer running RUGLOOP II software 
(Demed, Belgium). RUGLOOP II also controlled the syringe pump (Orchestra® Module 




Dexmedetomidine was delivered through TCI using the Dyck model.4 Computer 
simulations with the Dyck model were performed during study design to determine 
optimal infusion scheme and sampling times. Various sampling schedules were tested 
with 10 to 15 samples per patient. In each simulated sampling schedule, samples were 
included before each increase in target concentration and before the start of the 
recovery period. For each schedule, 1,000 sets of 20 patients were simulated, taking into 
account log-normally distributed interindividual variability of 40% and proportional 
residual variability of 20%. Each dataset was analyzed with NONMEM 7.2 (Icon plc, 
Ireland) (as described in the section Modeling) assuming log-normally distributed 
interindividual variability, and its performance was evaluated by calculating the root-
mean-squared-error (RMSE, in percentage) of the estimated population values for V1, 
CL, and the maximum value of all parameters (V1, V2, V3, CL, Q2, and Q3) as measures 
of the precision of the estimated model parameters. The sampling times were varied 
until the lowest RMSE values were obtained. These simulations revealed that for more 
accurate determination of the central volume V1, a short initial infusion was necessary, 
followed by the first TCI period starting at 10 min, with sampling times at 2 min and 
before the first TCI period. With 13 sampling points (excluding blank), the optimal 
sampling scheme (as described in the section Arterial Blood Sampling and 
Dexmedetomidine Analysis) resulted in RMSEs of 23% (V1), 19% (CL), and a maximum 
of RMSE 36%.  
The initial drug infusion was given at 6 μg kg−1 h−1 for 20 s. To ensure accurate infusion 
history for the TCI system, this infusion was controlled by the TCI steering algorithm (TCI 
target set to 1 ng/ml for 20 s, then returned to 0). After 10 min, TCI was restarted with 
stepwise increasing targets of 1, 2, 3, 4, 6, and 8 ng/ml. Each target was maintained for 
30 min.  
Because dexmedetomidine bolus doses can induce hypertension and reflex bradycardia, 
the infusion rate of dexmedetomidine was limited to 6 μg kg−1 h−1 for the first four steps 
using a limiting infusion rate algorithm as part of the TCI control system. For 6 and 8 
ng/ml, the maximum infusion rate was increased to 10 μg kg−1 h−1 to facilitate reaching 
the target within a reasonable time. 
The following criteria were used to ensure the safety of the subjects: 
• 30% increase from baseline mean arterial blood pressure for more than 5 min;
• 30% decrease from baseline mean arterial blood pressure for more than 5 min;
• Heart rate less than 40 beats/min for more than 5 min;
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• Changes in cardiac conduction or cardiac rhythm;
• Inability to maintain a patent airway and/or a decrease of oxygen saturation (Spo2)
less than 93% despite the use of simple airway maneuvers and/ or supplementation
of up to 4 l/min O2 via nasal cannula;
• Modified Observer’s Assessment of Alertness/Sedation score of 0 (no response to
painful stimulus), as assessed before each increase in target concentration.13
If any of these criteria were met, or if the last TCI step was completed, dexmedetomidine 
infusion was halted, and the recovery period started, which lasted 5 h. 
Arterial Blood Sampling and Dexmedetomidine Analysis 
We performed simulations using the Dyck model to determine optimal sampling times 
for optimal model parameter estimations. Arterial blood samples were taken at 
baseline, 2 min after the initial 20-s infusion, before each increase in target 
concentration (at 10 min and every 30 min thereafter), before the start of the recovery 
period, and at 2, 5, 10, 20, 60, 120, and 300 min in the recovery period. EDTA tubes (4 
ml) were used for blood sample collection. Each sample was stored on ice and
centrifuged within 30 min after obtaining the sample. The obtained plasma samples
were stored at −80°C until the study was finished.
The samples were analyzed by contract research organization QPS, using reverse-phase 
high-performance liquid chromatography triple quadrupole mass spectrometry. Ten 
microgram of deionized water and 10 μg of internal standard working solution (10 ng/ml 
of medetomidine-13C,d3 [Toronto Research Chemicals, Canada] in deionized water) were 
added to 100 μl of plasma sample (thawed at room temperature). Protein precipitation 
was induced by the addition of 300 μl of MeOH (methanol HiPer- Solv Chromanorm 
gradient grade for high-performance liquid chromatography [Merck, Germany]) and 
brief vortexing. The samples were centrifuged at 14,000 rpm for 5 min, and the 
supernatant was transferred to clean 10-ml glass tubes. The solvent was evaporated to 
dryness in a Turbovap LV evaporator (Zymark; Biotage, Sweden) at 45°C under a gentle 
stream of nitrogen. The sample residue was redissolved in deionized water:formic acid 
(100:0.1 v/v):acetonitrile (80:20 v/v) and briefly vortexed. All liquid chromatography-
mass spectrometry analysis was conducted on an API 4000 triple quadrupole mass 
spectrometer (AB SCIEX, Canada) equipped with a type 1100 liquid chromatograph 
(Agilent, USA) comprising a thermostatted well plate autosampler, a thermostatted 
column compartment, and a binary pump. Liquid chromatography was done with an 
xBridge C18 column (3.5 μm, 2.1 × 50 mm; Waters, The Netherlands) and using an AJO-
04286 guard column (Phenomenex, The Netherlands). The autosampler temperature 
was +4°C, and an injection volume of 10 μl was used. A binary gradient separation at a 
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flow rate of 500 μl/min was used with solvents A (deionized water:formic acid 100:0.1 
v/v) and B (acetonitrile), as follows: 0.00 to 0.20 min 80:20 A:B v/v; 1.00 to 2.00 min 
20:80 A:B v/v; 2.10 to 5.00 min 80:20 A:B v/v. The column was kept at 40°C. Tandem 
mass spectrometry was done by using positive ion turbo ionspray in multiple reaction 
monitoring mode and using the transitions m/z 201.2 → 95.1 for dexmedetomidine and 
m/z 205.2 → 99.0 for medetomidine-13C,d3. The spray voltage was 3,000 V, and the 
probe temperature was 150°C. Other parameters were optimized: collision energy 27 
eV, declustering potential 56.0 V, and collision cell exit potential 6.0 V. Nitrogen was 
used as the collision gas. “Zero air” from a local unit was used for curtain gas, ion source 
gasses 1 and 2 at 35, 50, and 80 psig, respectively. Quantification range limits for this 
method were 0.020 to 20 ng/ml. 
Modeling 
The time course of dexmedetomidine plasma concentration was modeled using a three-
compartment mammillary pharmacokinetic model with volumes V1, V2, and V3, 
elimination clearance CL, and intercompartmental clearances Q2 and Q3. The a priori 
model assumed allometric scaling where volumes scale linearly and clearances scale to 
the ¾ power exponent of the body size descriptor, which was total body weight. Model 
parameters were estimated relative to a reference subject, a 35-yr-old, 70-kg, and 170-
cm individual. Population parameters were assumed to be log-normally distributed and 
a proportional error model was used for residual error. 
During model development, examination of post hoc variability was used to guide 
testing of parameter–covariate relations. Models were compared on the basis of Akaike 
information criteria (AIC) and performance error as described by Varvel et al.14 using 
median performance error (MDPE) and median absolute performance error (MDAPE). 
The performance error was calculated as:  
𝑃𝑃𝐸𝐸 = 𝐶𝐶𝑝𝑝𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 − 𝐶𝐶𝑝𝑝𝑝𝑝𝑜𝑜𝑜𝑜𝑜𝑜𝑝𝑝𝑝𝑝𝑝𝑝𝑜𝑜𝑜𝑜
𝐶𝐶𝑝𝑝𝑝𝑝𝑜𝑜𝑜𝑜𝑜𝑜𝑝𝑝𝑝𝑝𝑝𝑝𝑜𝑜𝑜𝑜
× 100% 
where Cp is dexmedetomidine plasma concentration. We estimated model predictive 
performance for out-of-sample observations, that is, samples not within the estimation 
data set using repeated two-fold cross-validation. This involves random partitioning of 
the observations into two equal (number of individuals) sets: D1 and D2. Model 
parameters were estimated using D1 and the resulting model was used to predict D2. 
The process is repeated exchanging D1 and D2. To reduce Monte-Carlo variability due 
to random partitioning, cross-validation was repeated 10 times, each with different 
random partitions of D1 and D2. All of the out-of-sample predictions were collected, and 
MDPE and MDAPE were calculated.  
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During model building, we required a decrease in AIC of at least 9.2 when adding 
parameters, corresponding to a relative likelihood (Akaike weight) of greater than 0.99 
for the modified model, while removing model parameters required a decrease in AIC. 
In addition, we required model modifications to decrease MDAPE for the out-of-sample 
predictions. CIs for population parameters were described using likelihood profiles. We 
compared the predictive performance of the final model with models by Dyck,4 Dutta,6 




Forty-three volunteers were screened by QPS. Of these, 26 passed the screening and 18 
volunteers were selected to participate, divided into the age-sex–stratified groups. Two 
subjects (1 male, group: 35 to 54 yr; 1 female, group: 18 to 34 yr) withdrew after the 
first session, resulting in 34 completed sessions. The age range was 20 to 70 yr, weight 
range was 51 to 110 kg, and BMI range was 20.6 to 29.3 kg/m2. Of the two subjects who 
had withdrawn after the first session, one reported a hematoma after arterial line 
placement; the other withdrew due to a headache the night after the first session.  
For each step in the infusion stage, the number of completed sessions is as follows (of a 
total of 34 sessions): 1 ng/ml: 34 sessions; 2 ng/ml: 32 sessions; 3 ng/ml: 19 sessions; 4 
ng/ml: 12 sessions; 6 ng/ml: 4 sessions; and 8 ng/ml: 1 session. The reasons for stopping 
the dexmedetomidine infusions were reaching 8 ng/ml in one session, an Observer’s 
Assessment of Alertness/Sedation score of 0 in 22 sessions, bradycardia in 6 sessions (4 
volunteers), hypertension in 2 sessions (2 volunteers), and airway obstruction requiring 
continuous manual airway maneuvers (jaw thrust, chin lift) in 3 sessions (2 volunteers). 
None of the volunteers required any medical intervention at the time of stopping the 
dexmedetomidine infusion.  
Table 1. Dexmedetomidine Model Parameters 
𝑉𝑉1(𝑙𝑙) = 1.78 × (𝑊𝑊𝑊𝑊 70⁄ ) × 𝑝𝑝𝜂𝜂1 × 𝑝𝑝𝜂𝜂2 Variance CV (%) 
𝑉𝑉2(𝑙𝑙) = 30.3 × (𝑊𝑊𝑊𝑊 70⁄ ) η1 (IIV) 0.0356 19.0 
𝑉𝑉3(𝑙𝑙) = 52.0 × (𝑊𝑊𝑊𝑊 70⁄ ) × 𝑝𝑝𝜂𝜂3 η2 (IOV) 0.273 56.0 
𝐶𝐶𝐶𝐶(𝑙𝑙/𝑚𝑚𝑝𝑝𝑚𝑚) = 0.686 × (𝑊𝑊𝑊𝑊 70⁄ )0.75 × 𝑝𝑝𝜂𝜂4 η3 (IIV) 0.0635 25.6 
𝑄𝑄2(𝑙𝑙/𝑚𝑚𝑝𝑝𝑚𝑚) = 2.98 × (𝑉𝑉2 30.3⁄ )0.75 η4 (IIV) 0.0276 16.7 
𝑄𝑄3(𝑙𝑙/𝑚𝑚𝑝𝑝𝑚𝑚) = 0.602 × (𝑉𝑉3 52.0⁄ )0.75 
ηi are normally distributed random variables with a mean of 0 and variances as shown in the table 
CL = elimination clearance; CV = coefficient of variation; Q2-Q3 = intercompartmental clearances 
between compartment 1 and 2 or 3, respectively; V1-V3 = volume of corresponding 
compartments; WT = subject weight; IIV = interindividual variation; IOV = interoccasion variation 
Side effects of dexmedetomidine infusions included obstructive apnea in eight subjects 
(55 to 72 yr age group, as well as two subjects in the 35 to 54 yr age group) requiring 
some degree of manual airway maneuvers, but no airway devices of any kind were 
necessary. Five subjects experienced symptomatic orthostatic hypotension, mostly after 
the end of the study, when they started mobilizing. Slow mobilization and fluid 
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administration (IV or orally) were in most cases sufficient to counter this; however, two 
subjects required atropine 0.5 mg administration for sustained bradycardia after 
orthostatic hypotension, and one subject received 5 mg ephedrine to counter the 
hypotension. Two subjects experienced nausea, one subject also with vomiting. One 
received only ondansetron 4 mg in one session and the other subject received 
dexamethasone 5 mg and ondansetron 4 mg in both sessions. These events are likely 
associated with the hypotensive events. A headache during the following night or day 
was reported by two subjects.  
Figure 1. (A–F) Likelihood profiles show changes in objective function value when fixing model 
parameters at particular values. The red line is the parameter estimate in the final model. The 
parameter interval where the likelihood profile is shaded dark gray corresponds to the 95% CI 
(change in objective function <3.84), and the light gray region corresponds to the 99% CI (change 
in objective function <6.63).  
CL = elimination clearance; Q2–Q3 = intercompartmental clearances between compartment 1 and 
2 or 3, respectively; V1–V3 = volume of corresponding compartments. 
In total, 408 arterial plasma samples were obtained. One sample result was reported as 
being lower than, but close to, the lower limit of quantification (0.019 ng/ml) and was 
treated as a normal observation. Twenty-nine other samples were below the 
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Figure 2. Observations and predictions for individuals and sessions with the best (A), median (B), 
and worst (C) median absolute performance error (MDAPE). Filled circles are measured plasma 
concentrations, the black line is the individual post hoc prediction, gray lines are individual post 
hoc predictions for other individuals in the same session, and the blue line is the population 
prediction. ID = volunteer identification number. 
lower limit of quantification. These samples were excluded from analysis. In all, 379 
samples were used for analysis. When estimating the a priori model, we found that the 
population variability estimates for Q2 and Q3 were very small and these were fixed 
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to 0. Using compartmental allometry, as described by Eleveld et al.,15 for Q2 and Q3 lead 
to a small improvement in model performance (ΔAIC = −6.70; ΔMDAPE [out-of-sample] 
= −0.23). Also, fixing the population variability of V2 to 0 led to an improved model (ΔAIC 
= −1.49; ΔMDAPE [out-of-sample] = −0.05). Covariate search using a two-compartment 
model did not achieve the same level of performance as the three-compartment model. 
No other parameter–covariate relations were found to improve the model, neither did 
using estimated fat-free-mass16 as body size descriptor. Considering systematic 
differences in model parameters between the first and second session did not lead to 
Figure 3. (A) Population-observed/-predicted plasma dexmedetomidine concentrations versus 
time. (B) Post hoc individual-observed/-predicted plasma dexmedetomidine concentrations 
versus time. (C) Population-observed versus population-predicted plasma dexmedetomidine 
concentrations. (D) Post hoc individual-observed versus individual-predicted plasma 
dexmedetomidine concentrations. The black lines are Loess smoothers.  
CIPRED = post hoc individual-predicted plasma concentration; COBS = observed (measured) plasma 
concentration; CPRED = population-predicted plasma concentration. 
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an improved model. Adding interoccasion variance to V1, but not to other parameters, 
improved model fit (ΔAIC = −14.52; ΔMDAPE [out-of-sample] = −0.41). The equations of 
the final model are shown in table 1.  
The likelihood profiles (fig. 1) show the parameter CIs for the estimated parameters and 
suggest that there were no problems with parameter identification. Figure 2 shows the 
best, median, and worst fits of our model. Population and post hoc predictions versus 
time and observed dexmedetomidine concentrations are shown in figure 3. 
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Using TCI administration with a preliminary model in healthy volunteers, the 
pharmacokinetics of dexmedetomidine were best described by a three-compartmental 
model with allometric scaling of weight to the volumes and elimination clearance, along 
with compartmental allometric scaling of the intercompartmental distributions. No 
other covariates were identified.  
We used data from healthy volunteers for our pharmacokinetic study, as volunteer 
studies provide some unique possibilities. A major advantage is the absence of adjuvant 
medication. In a patient population, dexmedetomidine will almost always be 
coadministered with other drugs, including anesthetic and analgesic drugs, as clinical 
indications for dexmedetomidine are limited to procedures in the operating room, 
postanesthesia care unit, and ICU. In our study, we used escape medication in 4 of 34 
sessions (11.8%)—2 sessions (same volunteer): atropine 0.5 mg IV, dexamethasone 5 
mg IV, and ondansetron 4 mg IV; 1 session: ephedrine 5 mg IV; and 1 session: 
ondansetron 4 mg IV. All of these were given in the recovery period, most of these (all 
atropine and ephedrine doses) between 2 and 3.5 h into the recovery period. If there is 
a pharmacokinetic interaction between any of these drugs and dexmedetomidine, the 
influence will have been mostly limited to the last plasma sample.  
Selecting healthy volunteers also provided us with the opportunity to use a stratified 
population, with a larger age range. A wide BMI inclusion range gave us a wider range 
of weights to assess the influence of weight on dexmedetomidine pharmacokinetics. 
None of the existing models were able to include weight as a covariate, and two models 
(Dyck and Lin) included height as the only covariate (for CL). Another feature of our 
model is the use of compartmental allometric scaling,15 which assumes that 
intercompartmental clearances, Q2 and Q3, are better scaled to the volumes of their 
respective compartments, V2 and V3, than with weight. Eleveld et al.15 recently showed 
significant differences in the pharmacokinetics of propofol in volunteers and patients. It 
is as of yet unknown whether there is a systematic difference between patients and 
volunteers for the pharmacokinetics of dexmedetomidine, and whether volunteer 
models can be extrapolated to patient populations. However, our current investigation 
does play an important role in making a comparative study possible, by providing a 
pharmacokinetic model based on volunteers for future comparisons.  
In our study, we studied each volunteer twice. This enabled us to determine whether 
there is interoccasion variability in dexmedetomidine pharmacokinetics. Both sessions 
were similar in drug dosing scheme and sampling times. It is reasonable to expect 
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subjects to be more anxious or have a higher adrenergic tone during the first session, 
when they do not know what to expect, compared with the second session. This may 
cause changes in hemodynamic factors that might influence the pharmacokinetic 
estimations. Although we found that adding interoccasion variance to V1 had a 
significant effect on our model performance, we did not find any significant systematic 
influence of session order on the model parameters, which suggests that variations in 
stress level that occur systematically between the first and second session probably 
have only little effect on the pharmacokinetics of dexmedetomidine. Interestingly, for 
V1, interoccasion variance was greater than interindividual variance, indicating that 
there are factors changing (nonsystematically) between sessions that have a greater 
effect on V1 than the differences between individuals. As of yet, we can only guess at 
what these factors are.  
During experiment design, we determined the optimal sampling times, that is, when the 
pharmacokinetic model parameters could be estimated most precisely, using the Dyck 
model. These simulations revealed that our step-up method, while appropriate for 
determining V2, V3, and clearances, allowed poorer determination of the central 
compartment volume. Therefore, we included a 20-s initial infusion before starting the 
step-up TCI scheme, which would give us more information on V1. The use of a limited 
infusion rate likely also eliminated, at least in part, potential issues concerning front-end 
kinetics, as there is no assumption that a bolus dose is distributed instantaneously 
throughout the vascular system. Avram and Krejcie17 suggested that three-
compartment modeling of drugs given by infusion instead of bolus injection may still 
estimate front-end kinetics with reasonable accuracy.  
Table 2. Parameters of the Final Model and Dexmedetomidine Models in the Literature4,
6-10, for a 35-yr-old Person with a Height of 170 cm and Weight of 70 kg
Final 
Model Dyck Dutta Talke Lin Venn Välitalo 
V1 (l) 1.78 7.99 13 16.6 63.4 44.1 104 
V2 (l) 30.3 13.8 55 85.5 41.3 104.5 - 
V3 (l) 52.0 187 - - 284.3 - - 
CL (l/min) 0.686 0.4177 0.55 0.751 0.694 0.82 0.65 
Q2 (l/min) 2.98 2.26 0.833 1.37 2.43 2.255 - 
Q3 (l/min) 0.602 1.99 - - 0.086 - - 
CL = elimination clearance; Q2-Q3 = intercompartmental clearances between compartment 1 and 
2 or 3, respectively; V1-V3 = volume of corresponding compartments 
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In several articles referenced by Avram and Krejcie, smaller central compartment 
volumes have been found with continuous infusions than with bolus injections. In our 
study, V1 was 1.78 l (for an individual of 70 kg), which is smaller than V1 for other models 
(table 2) thereby modeling the high peak concentrations observed after a fast infusion. 
Another possible explanation for the smaller V1 is the effect of the direct 
vasoconstrictive effect of dexmedetomidine, resulting in a decreased central 
compartment. Because of our early sampling, this effect may have been more 
pronounced in the model than for studies with delayed sampling.  
Figure 4. (A) Context-sensitive 20 (lower line), 30, 40, 50, 60, 70, and 80% (upper line) decrement 
times for dexmedetomidine. (B) Context-sensitive 80% decrement times for dexmedetomidine, 
propofol (Diprifusor,18 Schnider,19 and Eleveld15 models), and remifentanil (Minto20 model). 
The context-sensitive decrement times (fig. 4) of dexmedetomidine plasma 
concentrations show that the shapes of the graphs are similar for the 20 to 80% 
decrement times. For infusions shorter than approximately 10 h, the 80% decrement 
time for dexmedetomidine is longer than those associated with propofol. However, for 
infusions longer than approximately 12 h, the 80% decrement times for propofol 
increase substantially, reaching similar values to dexmedetomidine.  
Our model has a low bias and high accuracy (table 3, MDPE and MDAPE, respectively), 
also in cross-validation (out-of-sample). Figure 3 confirms this, as only in the highest 
concentrations (sparse data), the precision decreases and bias increases. Figure 5 shows 
the population predictions versus time and observed concentrations for previously 
published dexmedetomidine pharmacokinetic models,4, 6-10 showing poorer fits for all 
models compared with our final model.  
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Table 3. MDPE and MDAPE for the Final Model and Models 
from the Literature 
MDPE (%) MDAPE (%) 
Final model 
   In-sample 0.6 14.4 
   Out-of-sample 0.7 15.7 
Dyck 20.7 38.6 
Dutta -26.7 27.7 
Talke 4.9 21.0 
Lin 22.6 33.7 
Venn 23.3 29.6 
Välitalo -0.6 36.1 
Out-of-sample MD(A)PE was obtained from repeated two-fold cross-validation. 
MDAPE = median absolute performance error; MDPE = median performance error 
Also, as seen in the Cobs/Cpred versus time graphs in figures 3 and 5, our model predicts 
initial concentrations more accurately than the existing models, indicating that the 
accuracy concerning front-end kinetics is acceptable.  
Comparison of the final model with the previously published models revealed a lower 
MDAPE for the new model, both in-sample and with out-of-sample cross-validation  
(table 3). The bias of our model, as estimated with MDPE, was low. Figure 5 and table 3 
also show that both “healthy volunteer” models, Dyck (fig. 5, A and G) and Dutta (fig. 5, 
B and H), are biased and imprecise, with high MDPE and MDAPE. The Dyck model 
underestimates the plasma concentrations in the higher concentration ranges, which is 
likely due to a larger volume of distribution, combined with a higher intercompartmental 
clearance for the third compartment Q3 (table 2). Underestimation of the Dyck model 
was previously demonstrated by Hsu et al.5 and our study confirms this. The Dutta model 
overestimates plasma concentrations, with the greatest overestimation in the first 50 
min of infusion. This may be explained by the relatively low volume of distribution and 
low intercompartmental clearance. Whether this can be explained by the site of 
sampling (venous instead of arterial) is unclear. In a study by Persson et al.21 with 
ketamine, “venous models” have higher compartment volumes and 
intercompartmental clearance than “arterial models.”  
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Figure 5. (A–F) Observed/predicted plasma dexmedetomidine concentrations versus time for 
existing pharmacokinetic models. (G–L) Observed versus predicted plasma dexmedetomidine 
concentrations for existing pharmacokinetic models. The black lines are Loess smoothers.  
COBS = observed (measured) plasma concentration; CPRED = population-predicted plasma 
concentration. 
The Talke model performs quite well compared with the other models. The MDPE and 
MDAPE are only slightly higher than that of our model. The Cobs/Cpred versus time graph 
for the Talke model shows that initial infusion results in overestimation, whereas later 
in the period (at higher concentrations), the Talke model underestimates the plasma 
concentration, which confirms the findings by Snapir et al.11 During the last hours of the 
recovery phase, predictions seem to be quite accurate. The Lin model is very inaccurate 
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and biased, and the volumes of all three compartments are very high in this model. One 
needs to keep in mind that this model was developed from data of Chinese patients, 
whereas other models were most likely developed from Caucasian data. It has been 
suggested that ethnicity may have an important influence on drug pharmacokinetics, 
especially if the drug is highly protein bound or undergoes hepatic metabolism.22 
Because dexmedetomidine is highly bound to plasma albumin (94%) and α1-
glycoprotein and is metabolized extensively by the liver, this influence may very well be 
significant between Caucasians and Chinese subjects, as also stated by Lin et al.8 The 
Venn model also has a high MDPE and MDAPE. As with the Dyck model, this is likely due 
to a higher volume of distribution as well as intercompartmental clearance. The Cobs 
versus Cpred graph for the Välitalo model (fig. 5L) shows a large spread, but the most 
illustrative is the Cobs/Cpred versus time graph (fig. 5F), which shows that there is a large 
underestimation in the beginning and a large overestimation in the recovery phase. This 
is not surprising because the Välitalo is a one-compartment model and therefore does 
not describe drug distribution to peripheral compartments. The large (central) 
compartment results in initially low plasma concentration predictions, whereas the 
absence of peripheral distribution results in relatively high late-phase predictions. The 
bias as calculated by the MDPE is very low for this model, as the overestimations and 
underestimations cancel each other out.  
In conclusion, we developed a three-compartmental pharmacokinetic model for 
dexmedetomidine, derived from data from healthy male and female volunteers for a 
wide range in age and weight. The model is also reasonably accurate in the early-phase 
front-end kinetics, while maintaining the simplicity of a standard three-compartment 
model for easier use in TCI. Before implementation, this model should be validated 
prospectively to assess the performance in a patient population. 
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Influence of arousal on bispectral index and sedation 
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Background: Dexmedetomidine, a selective α2-adrenoreceptor agonist, has unique 
characteristics, such as maintained respiratory drive and production of arousable 
sedation. We describe the development of a pharmacokinetic-pharmacodynamic model 
of the sedative properties of dexmedetomidine, taking into account the effect of 
stimulation on its sedative properties. 
Methods: In a two-period, randomized study in 18 healthy volunteers, 
dexmedetomidine was delivered in a step-up fashion by means of target-controlled 
infusion using the Dyck model. Volunteers were randomized to a session without 
background noise and a session with pre-recorded looped operating room background 
noise. Exploratory pharmacokinetic-pharmacodynamic modelling and covariate analysis 
were conducted in NONMEM using bispectral index (BIS) monitoring of processed EEG. 
Results: We found that both stimulation at the time of Modified Observer’s Assessment 
of Alertness/Sedation (MOAA/S) scale scoring and the presence or absence of ambient 
noise had an effect on the sedative properties of dexmedetomidine. The stimuli 
associated with MOAA/S scoring increased the BIS of sedated volunteers because of a 
transient 170% increase in the effect-site concentration necessary to reach half of the 
maximal effect. In contrast, volunteers deprived of ambient noise were more resistant 
to dexmedetomidine and required, on average 32% higher effect-site concentrations for 
the same effect as subjects who were exposed to background operating room noise. 
Conclusions: The new pharmacokinetic-pharmacodynamic models might be used for 
effect-site rather than plasma concentration target-controlled infusion for 
dexmedetomidine in clinical practice, thereby allowing tighter control over the desired 
level of sedation. 
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Dexmedetomidine use in clinical practice is popular because of its unique characteristics 
as a selective α2-adrenoceptor agonist. It is currently licensed for sedation in intensive 
care units in Europe and the USA and for procedural sedation in the USA. Moreover, 
there is frequent off-label use, for instance for procedural sedation (in Europe), sedation 
during awake fibreoptic intubation, and awake craniotomies. Patients under 
dexmedetomidine sedation experience little respiratory depression, are more easily 
roused, and are better able to communicate compared with propofol or midazolam 
sedation.1 Also, dexmedetomidine has been investigated as a possible opioid-reducing 
technique2 and might attenuate perioperative inflammatory responses.3 
For sedation in intensive care units, a slow titration to effect, with or without a loading 
dose, is acceptable, because a fast onset of effect is often not necessary. However, 
during procedural sedation or in the operating room, a faster onset of effect is often 
desired. Fast titration to the desired effect with limited or no overshoot, thereby limiting 
potential side-effects, can be attained using target controlled infusion (TCI). For effect-
site TCI, an accurate pharmacokinetic-pharmacodynamic (PKPD) model is necessary. 
Currently, only pharmacokinetic (PK) models are available for dexmedetomidine; no 
PKPD models.  
We recently published an optimized dexmedetomidine PK model.4 In this twin paper, 
we describe the pharmacodynamic effects of dexmedetomidine in healthy volunteers, 
and model these effects into PKPD models. In this article, we describe and model the 
sedative effects of dexmedetomidine using our previously published PK model, and 
using bispectral index (BIS) and the Modified Observer’s Assessment of 
Alertness/Sedation (MOAA/S) as measures of sedative effects. In an accompanying 





This study was approved by the local medical ethics review committee (METC, University 
Medical Center Groningen, Groningen, the Netherlands; METC number: 2012/400) and 
was registered in the ClinicalTrials.gov database (NCT01879865). Written informed 
consent was obtained from all volunteers. The study conduct was described in detail by 
Hannivoort and colleagues,4 who reported on the development of a pharmacokinetic 
model based on measured dexmedetomidine plasma concentrations collected 
throughout the study.  
In brief, 18 healthy volunteers, nine male and nine female, stratified according to age 
and sex (18-34, 35-54 and 55-72 yr) received dexmedetomidine i.v. on two separate 
occasions, at least 1 week and at most 3 weeks apart. Both sessions were identical in 
protocol, except for the use of acoustic noisecancelling headphones (Bose QuietComfort 
15, Framingham, MA, USA), either without background noise or with pre-recorded 
looped operating room background noise (monitor beeps and alarms, air conditioning 
noise, talking, equipment noise etc.). In both sessions, the volunteers were instructed 
to keep their eyes closed throughout the session, and they were stimulated as little as 
possible apart from at set times for the assessment of depth of sedation. Randomization 
using sealed envelopes was used to determine the order of the ’background silence’ and 
‘background noise’ sessions.  
Standard anaesthesia monitoring was applied, with the inclusion of an arterial line for 
blood pressure monitoring and blood sampling, as described by Hannivoort and 
colleagues.4 An initial short infusion, given at 6 µg kg-1 h-1 for 20 s, was followed by a 10 
min recovery period. Thereafter, dexmedetomidine was delivered as a TCI using the 
Dyck model6 with stepwise increasing targets of 1, 2, 3, 4, 6, and 8 ng ml-1. Each target 
was maintained for 30 min. The maximal infusion rate was limited to 6 μg kg-1 h-1 for the 
first four steps; for the target of 6 and 8 ng ml-1, the maximal infusion rate was increased 
to 10 μg kg-1 h-1 to facilitate attainment of the target within a reasonable time. 
Volunteers were monitored until 300 min after cessation of the TCI dexmedetomidine 
infusion. The syringe pump (Orchestra® Module DPS, Orchestra® Base A, Fresenius Kabi, 
Bad Homburg, Germany) that was used to deliver the dexmedetomidine infusion was 
controlled by RUGLOOP II software (Demed, Temse, Belgium) programmed with the 
Dyck model.6 
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A BIS Vista monitor (Covidien, Boulder, CO, USA) was used to record BIS continuously to 
study depth of hypnosis. The MOAA/S scale was used to quantify the level of sedation 
and rousability of the volunteer at the following time points: immediately before the 
start of dexmedetomidine infusion, 2 min after the start of the initial short infusion, 
immediately before the start of the TCI infusion, and at the end of each TCI target step. 
During the recovery period, MOAA/S scores were recorded every 2 min for the first 30 
min, and every 10 min thereafter, until the volunteer reached the maximal score on the 
MOAA/S scale. All monitored parameters were recorded electronically using RUGLOOP 
II software. 
Data handling 
The final data set contained BIS measurements at a sampling rate of 1Hz, which, for 
some subjects, resulted in >30,000 observations per session. To reduce the 
computational burden, we reduced the number of BIS measurements per subject. We 
also applied a median filter to reduce the influence of artifacts, outlying data, or both 
during model development. The width (span) of the median filter was 60 s. Data 
reduction was performed by retaining the first out of every 50 consecutive median 
filtered observations. 
The data set used for modelling contained a median of 372 (range 115-556) BIS 
measurements per subject per session, corresponding to a sampling rate of 1 min-1. All 
unfiltered MOAA/S observations were retained in the data set, with a median of 25 
(range 8-40) observations per subject per session. 
Population pharmacokinetic-pharmacodynamic modelling 
The PKPD modelling was based on individual PK parameter estimates from the 
dexmedetomidine PK model published previously.4 The individual predicted PK 
parameters (V1, V2, V3, CL, Q2 and Q3) derived from this model were fixed for each 
individual and each session (Hannivoort and colleagues4. reported that V1 was different 
between occasions) during further pharmacodynamic (PD) modelling. 
Different structural models were evaluated to test whether hysteresis exists between 
the individually predicted dexmedetomidine plasma concentrations (IPREDplasma) and PD 
measures. Direct models relating IPREDplasma directly to the PD measure were compared 
against delay drug effect models, such as an effect compartment model or an indirect 
response model. Drug effects were described using linear, Emax and sigmoid Emax models. 
Once the base model structure was established, graphical analysis was conducted to 
identify potential correlations between post hoc predicted PKPD parameters and subject 
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covariates. Subject covariates considered were as follows: weight, height, BMI, age, sex, 
and session (background silence vs background noise). These covariates were tested in 
the model, and the resulting change in goodness-of-fit (GOF) was evaluated. For the 
continuous covariates (age, height and weight), a linear relationship was assumed, 
whereas for the categorical covariate (sex), an additional parameter was added to 
differentiate between males and females. Where appropriate, inclusion of model 
parameters, covariates, or both was tested at the 5% significance level by comparing the 
decrease in objective function (OFV) against the critical quantile of the corresponding χ2 
distribution (e.g. a 3.84 decrease in OFV for inclusion or exclusion of a single parameter). 
Population pharmacodynamic modelling of the confounding effect of the rousability on 
BIS  
During dexmedetomidine sedation, the stimulation inherent in MOAA/S scoring results 
in a transient increase (arousal) in BIS. The MOAA/S observations were regarded as a 
sudden, instantaneous stimulation of the subject, and the perturbation in BIS was 
modelled as a leftward shift in the effect-site concentration necessary to reach half of 
the maximal effect (C50). Thus, there are two BIS curves corresponding to a stimulated 
(aroused) and unstimulated (non-aroused) pharmacodynamic state. The dissipation of 
arousal (equation 1) was modelled using a single parameter (kin), in conjunction with an 
indirect response model (IRM). The pharmacodynamic arousal state is used as a linear 
interpolation between two sigmoid drug effect models (given by equations 2 and 3), as 
described in equation 4: 
𝑝𝑝𝑅𝑅𝐸𝐸𝐶𝐶𝑅𝑅𝑅𝑅
𝑝𝑝𝑝𝑝
= 𝑘𝑘𝑝𝑝𝑖𝑖 × �1 − 𝑅𝑅(𝑅𝑅𝐸𝐸𝐶𝐶𝑅𝑅𝑅𝑅)�  (1) 
𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝,𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 = 𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑙𝑙𝑝𝑝𝑚𝑚𝑝𝑝 𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝 × �1 − 𝐶𝐶𝑜𝑜𝐶𝐶𝑜𝑜 + 𝐶𝐶50,𝑝𝑝�   (2) 
𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝,𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 = 𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑙𝑙𝑝𝑝𝑚𝑚𝑝𝑝 𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝 × �1 − 𝐶𝐶𝑜𝑜𝐶𝐶𝑜𝑜 + (𝐶𝐶50,𝑝𝑝 ∗ (1 + ∆𝐶𝐶50,𝑝𝑝))�   (3) 
𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝(𝑝𝑝) = 𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝,𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 × 𝑅𝑅(𝑅𝑅𝐸𝐸𝐶𝐶𝑅𝑅𝑅𝑅) + 𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝,𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁 × �1 − 𝑅𝑅(𝑅𝑅𝐸𝐸𝐶𝐶𝑅𝑅𝑅𝑅)�  (4) 
In short, an unstimulated subject is in a state of relaxation (i.e. non-aroused), during 
which the ‘amount’ in the relaxation-compartment (i.e. A(RELAX)) equals 1. At the 
moment of stimulation, the compartment is reset, i.e. the ‘amount’ in this compartment 
is set to zero, corresponding to a stimulated, aroused state. Thereafter, the state returns 
to a state of relaxation at a rate of kin. As seen from equation (4), the amount in the 
relaxation-compartment is used as a linear interpolation between an unstimulated 
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(equation 2) and a stimulated (equation 3) BIS model. In equations (2) and (3), the 
dexmedetomidine effect-site concentration (Ce) to achieve half of the maximal decrease 
in BIS in an unstimulated subject is given by C50, whereas the proportional change in the 
C50 for a stimulated subject is described by ΔC50. 
Population pharmacodynamic modelling of categorical MOAA/S observations 
Categorical MOAA/S observations were modelled using a model for ordered categorical 
variables. This model was parameterized such that the parameters estimate cumulative 
probabilities (e.g. the probability of observing an MOAA/S score ≤ 3) on the logit scale. 
Inter-individual variability (IIV) and drug effect were implemented on these baseline 
logits using an exponential and an additive component, respectively. Inclusion of 
random effects beyond the IIV on the baseline logits was not considered to avoid issues 
with identifiability of the model parameters.  Equation (5) gives an example of the model 
for the logit of the cumulative probability (Pr) of observing an MOAA/S score ≤ 3.  
𝐶𝐶𝑝𝑝𝐿𝐿𝑝𝑝𝑝𝑝(Pr[MOAA S⁄ ≤ 3]) = 𝜃𝜃𝐿𝐿𝐿𝐿𝐿𝐿0 × 𝑝𝑝𝜂𝜂𝑖𝑖 + 𝜃𝜃∆01 + 𝜃𝜃∆12 + 𝜃𝜃∆23 + 𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 × 𝐶𝐶𝑜𝑜𝛾𝛾𝐶𝐶50𝛾𝛾 + 𝐶𝐶𝑜𝑜𝛾𝛾  (5) 
The baseline logit is described by a typical value for the logit to be equal to zero (θLLE0), 
including an exponential random effect (ηi) on this logit and additional terms to estimate 
the difference between successive logits (e.g. θΔ01 estimates the difference between the 
logit for an MOAA/S score ≤ 1 and the logit of an MOAA/S = 0). The drug acts to increase 
the baseline logit according to a sigmoid Emax model based on the predicted effect-site 
concentration (Ce). The parameters of this sigmoid Emax model describe the maximal 
change in the logit (Emax), the effect-site concentration necessary to reach half of the 
maximal effect (C50) and the Hill coefficient of the concentration-effect relationship (γ).  
The logits were back-transformed to cumulative probabilities using the inverse of the 
logit transformation. Subsequently, the probabilities for each category were obtained 
by subtraction from the cumulative probabilities with the probability to observe an 
MOAA/S score ≤ 5 being 1. 
Parameter estimation and model evaluation 
The first-order conditional estimation algorithm with interaction (FOCE-I) as 
implemented in NONMEM® (version 7.3; Icon Development Solutions, Hannover, MD, 
USA) was used to fit BIS data. For the categorical MOAA/S data, the Laplacian 
approximation to the likelihood was used. Inter-individual variability and inter-occasion 
variability (IOV) were modelled using an exponential model. Residual unexplained 
variability was described using additive or proportional error models, or both. 
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During model building, the GOF of the different models was compared numerically using 
the Akaike information criterion (AIC) and the median absolute (population-)prediction 
error (MdAPE). At each stage, GOF was graphically evaluated by inspecting plots of the 
individual or population predicted vs observed responses, and plots of the conditionally 
weighted residuals (CWRES) vs individual predictions and time. As a safeguard to over-
parameterization, only models with a condition number of the Fisher information matrix 
(FIM) < 500 were retained in the model building hierarchy. Finally, models were 
validated internally using prediction-corrected visual predictive checks (pcVPC) 
according to Bergstrand and colleagues.7 
All models were fitted to the data using PsN8 and Pirana9 as back- or front-end, or both, 
to NONMEM®. The numerical and graphical assessment of the GOF and the construction 
of the pcVPCs were conducted in R® (R Foundation for Statistical Computing, Vienna, 
Austria). 
All simulations were performed in a Microsoft Excel® Macro-Enabled Worksheet 
(Microsoft Office Professional Plus 2013), which is supplied in the Online Supplementary 
material. The worksheet depends on the ‘PKPD tools for Excel’ package developed by T. 
Schnider and C. Minto, which is available from http://www.pkpdtools.com/excel (last 
accessed April 18th 2017). 
Statistical analysis 
All model parameters are reported as typical values with associated relative standard 
errors (RSE) and 95% confidence intervals (CIs) derived from log-likelihood profiling.10 
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Figure 1 shows the median filtered BIS signal and the observed MOAA/S for four 
representative subjects from our study during the step-up TCI administration. The 
dashed lines indicate when a new TCI target was set. Immediately before changing the 
TCI target, MOAA/S was scored. This figure clearly shows the perturbation in the BIS 
signal induced by stimulating the subjects at the time of MOAA/S scoring and the 
subsequent attenuation of the effect of stimulation. The complete time courses of BIS 
and MOAA/S observations for all subjects used for modelling, are shown in Online 
Supplementary Figures S1 and S2. 
Figure 1. Median filtered BIS values and MOAA/S observations for the step-up TCI administration 
for four representative subjects. Dashed vertical lines indicate when a new TCI target was set. 
Immediately before this, MOAA/S was assessed. 




Model development for BIS 
In a first attempt to describe the effect of dexmedetomidine on BIS measurements, a 
sigmoid Emax model was used. Rousability was accounted for according to equations (1)-
(4) and the delay between plasma PK and BIS effects was described using an effect
compartment model. Modifications to this base structure were evaluated. Firstly, the
Hill coefficient (γ) was fixed to 1, resulting in a decrease in the condition number from
1327 to 120; at the same time, the MdAPE decreased from 13.1 to 13.0%. Secondly, a
logit transform, as shown in equations (6) and (7), was used to describe the intersubject
variability in BIS at baseline. The inclusion of the logit transformation decreased the
MdAPE further to 12.8%. Under this transformation, all baseline BIS predictions are
restricted between 0 and 100. This significantly improved the pcVPC for the BIS model.
𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑙𝑙𝑝𝑝𝑚𝑚𝑝𝑝 𝐵𝐵𝐵𝐵𝐵𝐵𝑝𝑝 = 100 × � 𝑝𝑝(𝐿𝐿𝑜𝑜𝐿𝐿𝑝𝑝𝑝𝑝𝑖𝑖)1 + 𝑝𝑝(𝐿𝐿𝑜𝑜𝐿𝐿𝑝𝑝𝑝𝑝𝑖𝑖)�   (6) 
𝐶𝐶𝑝𝑝𝐿𝐿𝑝𝑝𝑝𝑝𝑝𝑝 = log� (𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑙𝑙𝑝𝑝𝑚𝑚𝑝𝑝 𝐵𝐵𝐵𝐵𝐵𝐵 100⁄ )1 − (𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑙𝑙𝑝𝑝𝑚𝑚𝑝𝑝 𝐵𝐵𝐵𝐵𝐵𝐵 100⁄ )� + 𝜂𝜂𝑝𝑝    (7) 
The significance of the rousability component of the model was evaluated by exclusion 
of this component, as described by equations (1), (2) and (4), from the final model. The 
resulting decrease in GOF (ΔAIC = +2358) and simultaneous increase in the MdAPE to 
13.5%, underpin the importance of accounting for arousal in the BIS model. 
Furthermore, a comparison between the parameter estimates for both models revealed 
a significant shift in ke0 (0.120 vs 0.991 min-1), baseline BIS (96.8 vs 89.7), and C50 (2.63 
vs 4.78 ng ml-1) upon removal of the rousability component. Inclusion of inter-occasion 
variability on the estimated PKPD parameters did not significantly improve the GOF of 
the model. Inclusion of age, weight, height, or sex did not result in a significant decrease 
in the OFV. Therefore, no covariates were included in the final model. 
Final model for BIS 
The final model parameters are described in Table 1. The likelihood profiles, which were 
generated to identify potential problems with parameter identification, are shown in 
Online Supplementary Figure S3. Goodness-of-fit plots, such as post hoc predictions vs 
observations and CWRES vs time, are shown in Figure 2. Online Supplementary Figure 
S4 shows the pcVPC. Overall, these figures demonstrate that the presented model 
adequately describes observed changes in BIS during and after dexmedetomidine 
administration and that all parameters of the model are estimated with acceptable 
precision. 
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Table 1. Final model parameters with associated relative standard errors 
(RSE, %) derived from log-likelihood profiling. 
Final BIS model 
Parameter Estimate (RSE%b) IIVa (RSE%b) 
θ1 BaseBISe  96.8 (1.20) 1.34d (56.3) 
θ2 ke0BIS (min-1) 0.120 (3.80) - 
θ3 C50 (ng ml-1) 2.63 (15.9) 69.5 (40.2) 
θ4 ΔC50e 1.71 (18.3) 81.8 (40.8) 
θ5 kin (min-1) 0.130 (24.6) 122 (41.1) 
σRUV,Additive c 10.6 (1.20) - 
Final MOAA/S model 
Parameter Estimate (RSE%b) IIVa (RSE%b) 
θ6 θLLE0e -10.1 (14.6) 12.5 (37.4) 
θ7 θΔ01e 0.394 (14.0) - 
θ8 θΔ12e 1.83 (5.6) - 
θ9 θΔ23e 1.13 (7.7) - 
θ10 θΔ34e 1.55 (9.1) - 
θ11 ke0MOAA/S (min-1) 0.0428 (17.0) - 
θ12 C50 (ng ml-1) 0.428 (25.6) - 
θ13 Emaxe 10.4 (13.3) - 
θ14 ΔC50,noise cohorte 0.316 (35.0) - 
a calculated according to:  √𝑝𝑝𝜔𝜔 − 1 ∗ 100%; b derived from loglikelihood profiling; c 
expressed as standard deviation; d expressed as standard deviation in the logit 
domain; e dimensionless parameter 
For the volunteer cohort exposed to ambient operating room noise, the C50 is given 
by C50 * (1 - ΔC50,noise cohort); ω = estimated variance of the inter-individual variability 
(IIV); σ = estimated variance of the residual unexplained variability (RUV);  
We found that changes in plasma dexmedetomidine concentrations are reflected in BIS, 
with a half-life of effect-site equilibration of 5.8 min. In unstimulated subjects, half of 
the maximal effect (~ BIS48) is attained at 2.63 ng ml-1. In the stimulated state, subjects 
achieve a BIS value of 48, on average, when the dexmedetomidine effect site 
concentration approaches 7.13 ng ml-1. The post hoc predicted values of C50s and ΔC50s 
were found to be uncorrelated but highly variable within our study population. Inter- 
individual variability was estimated to be 69.5% and 81.8% for C50 and ΔC50, respectively. 
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Figure 2. Goodness-of-fit plots for the final model. The left panels show the observed BIS vs post 
hoc predictions and CWRES vs post hoc predictions and time. The continuous red line depicts a 
non-parametric smoother through the data to illustrate lack of bias in the different plots. The right 
panels show individual GOF plots for the three subjects with the best, median, and worst fit, 
respectively. The continuous black line shows the observed MOAA/S scores, whereas grey circles 
denote the probability of observing the MOAA/S scores, with bigger circles having higher 
probabilities. These probabilities were estimated by simulation using the post hoc predicted 
parameters. Red crosses indicate regions where, according to the simulations, the probability for 
the observed MOAA/S is < 10%. These points served as ‘residuals’ to instruct on how to refine the 
model.  
BIS = bispectral index; CWRES = conditionally weighted residuals; GOF = goodness-of-fit; MOAA/S 
= Modified Observer’s Assessment of Alertness/Sedation. 
The model illustrates that the effect of stimulation attenuates slowly, with an estimated 
half-life of 5.3 min. Moreover, the time for the BIS signal to normalize is highly variable 
within our study population, with 95% of the estimates for the half-life of attenuation 
between 0.82 and 34.6 min. 
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Model development for MOAA/S 
As a starting point, a linear drug effect model was used to describe dexmedetomidine-
induced changes in the logit of the cumulative probabilities. Subsequently, the model 
was refined by introducing the following: (i) an Emax drug effect model (ΔAIC = -173.3) 
and (ii) inter-individual variability on the baseline logit of observing an MOAA/S score 
equal to 0 (θLLE0; ΔAIC = -187.6). 
The assumption of proportional odds was challenged by fitting a differential odds model, 
as described by Kjellsson and colleagues.11 The differential odds model had a slightly 
lower AIC (ΔAIC = -6.7) compared with our final model. However, the condition number 
of the Fisher information matrix (FIM) was high (1110), and no differences were seen 
between the pcVPCs of both models. Based on these findings, we decided not to 
implement the differential odds assumption into our final model. 
In line with our approach to model the influence of the rousability on the BIS signal, we 
evaluated a model with an additional Emax curve to model potential transient changes in 
MOAA/S scores attributable to subject stimulation inherent to MOAA/S scoring. This 
modification led to a marginal improvement in GOF (ΔAIC = -13.9 for two additional 
parameters). The estimate for the half-life of attenuation was significantly lower than 
what was found for the BIS model (0.65 vs 5.3 min, respectively), whereas the estimate 
for the ΔC50 was significantly larger (4.21 vs 1.71). The predictive performance, as 
evaluated by pcVPC, did not improve, and the model suffered from some numerical 
difficulties, resulting in a high condition number (1203). Overall, these findings led us to 
the decision not to include a rousability component, describing the time-varying effect 
of rousability on the MOAA/S, in our final model. 
Covariate screening identified session (background silence vs background noise session) 
as a significant covariate. Inclusion of session as a covariate on the C50 led to a significant 
increase in GOF (ΔAIC = -10.5). The effect of the covariate was confirmed by graphical 
analysis of the raw data stratified by session. This graphical analysis confirmed that the 
distribution of MOAA/S scores as a function of TCI targets was different between both 
sessions (data not shown). Inclusion of the covariate did not increase the condition 
number of the FIM and was therefore retained in the final model. 
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Figure 3. Relationship between effect-site concentrations and BIS and MOAA/S. The continuous 
black line is the predicted BIS, whereas the MOAA/S with the highest probability is shown with a 
continuous red line. Stacked bar plots illustrate the distribution of MOAA/S probabilities at effect-
site concentrations of 0.01, 1, 2.5 and 10 ng ml-1, corresponding to predicted BIS values of 96, 70, 
50 and 20, respectively.  
Ce = effect-site concentration; BIS = bispectral index; MOAA/S = Modified Observer’s Assessment 
of Alertness/Sedation. 
Age, weight, height, and sex were found not to have a significant impact on the OFV. 
Furthermore, introduction of inter-occasion variability also did not improve the GOF of 
the model. 
Final model for MOAA/S 
The final model parameters and associated standard errors are shown in Table 1. Online 
Supplementary Figure S3 shows the likelihood profiles for the final model. The GOF of 
the final model, for three subjects representing the best, median, and worst fit, 
respectively, is shown in Figure 2 (post hoc predicted vs observed MOAA/S scores as a 
Dexmedetomidine pharmacokinetic-pharmacodynamic modelling in healthy volunteers: 1. 
Influence of arousal on bispectral index and sedation 
63 
3  
function of time for all subjects are shown in Online Supplementary Figure S2). 
Simulation-based GOF diagnostic plots are favoured here owing to the inability to 
calculate individually predicted dexmedetomidine plasma concentrations and 
conditionally weighted residuals-based diagnostic plots for ordered categorical models. 
A visual predictive check for the final model is shown in Online Supplementary Figure 
S5. Overall, these diagnostics show that our final model is adequately developed and 
that the predictive performance is sufficient to characterize our observations. 
The equilibration between effect-site concentrations and plasma concentrations for 
dexmedetomidine is fairly slow, with an estimated half-life for effect-site equilibration 
of  14 min. Subjects who were deprived of normal ambient background noise from the 
operating room achieved half of the maximal MOAA/S effect at an effect-site 
concentration of 0.43 ng ml-1. Volunteers who were exposed to background noises were 
somewhat more sensitive to the sedative effects of dexmedetomidine and achieved half 
of the maximal effect at an effect-site concentration that was, on average, 32 % lower 
(i.e. 0.29 ng ml-1). 
According to the model, the difference between the logit of observing an MOAA/S of 0 
and an MOAA/S score ≤ 1 is small (Δ01 = 0.394). Compared with the other estimates for 
the differences in logits, this small estimate results in a fairly low predicted probability 
of observing an MOAA/S 1. This is in line with our observations. Indeed, when we look 
at the observed proportion of MOAA/S 1 across time (black line in Online Supplementary 
Figure S5) we see that, as opposed to the other MOAA/S categories, the profile for 
observing an MOAA/S 1 is relatively flat, not exceeding 10%. An overview of the 
probability of observing the different MOAA/S scores as a function of effect-site 





We developed a PKPD model that characterizes the relationship between 
dexmedetomidine plasma concentrations and the resulting changes in BIS and MOAA/S. 
Owing to the specific characteristics of dexmedetomidine, our models were built taking 
into account the time-varying rousability that was introduced by stimulation of the 
subject during MOAA/S scoring. Furthermore, our study protocol was such that we were 
able to determine the confounding effect of another type of stimulation, continuous  
background auditory stimulation, on the sedative properties of dexmedetomidine. 
A unique characteristic of our model is that it incorporates the rousability effect on BIS. 
Stimulation of subjects at the time of MOAA/S scoring induced a transient increase in 
the BIS signal. The effect of the stimulus diminishes over time and typically disappears 
within 21 min (4 x t½) in the absence of stimulation. However, if the subject is stimulated 
more frequently, accumulation occurs and the ‘stimulated’ state persists for prolonged 
periods of time. 
Our model also explains the potential for an apparent paradoxical response of 
transiently increasing hypnosis (decreasing BIS) in the presence of decreasing drug 
concentrations as the individual transitions from a stimulated to an unstimulated 
pharmacodynamic state. This is visible in Figure 4 where the observed BIS signals during 
step-up TCI administration and the subsequent recovery for three subjects representing 
examples of the best, median, and worst fit of our model against the observed data are 
shown. The good agreement between the observed BIS signal and the post hoc 
predicted BIS curves (shown in blue) after single and repeated stimulation inspires 
confidence in the validity of our proposed PKPD model. 
The basis for our MOAA/S model is an Emax model, using the logit of cumulative 
probabilities of MOAA/S scores rather than the MOAA/S scores themselves. A time-
varying rousability effect similar to the effect found for BIS was not retained in our final 
PKPD model describing MOAA/S observations. When we tried to estimate the half-life 
of attenuation, we found an estimate for Kin of 1.1 min-1, corresponding to a t½ of 0.65 
min, indicating that, for the typical patient, the effect of stimulation disappears within 
2.6 min. In the context of our protocol, in which MOAA/S were scored at least 2 min 
apart, inclusion of the time-varying rousability had no significant impact on the 
predicted probabilities. However, in other situations, where stimulation occurs more 
frequently, this might be important, and our suggested approach could be used to take 
the confounding effect of stimulation into account. 
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Figure 4. Observed (black lines) and post hoc predicted BIS (blue lines) for the individuals with the 
best, median, and worst fit. The dashed vertical lines indicate when a new TCI target was set. 
Immediately before this, MOAA/S was assessed.  
BIS = bispectral index; MOAA/S = Modified Observer’s Assessment of Alertness/Sedation; TCI = 
target-controlled infusion. 
Our analysis showed that the C50 for MOAA/S was significantly higher, and thus subjects 
were more responsive, when deprived of ambient noise in comparison to exposure to 
ambient operating room noise. This could be because auditory impulses, such as the 
name of the volunteer being spoken, are more clearly perceived against a silent 
background. However, our model indicates that even responsiveness towards a painful 
stimulus was significantly different between sessions. This finding was confirmed by 
graphical analysis (data not shown) that showed that, after controlling for the TCI target, 
the frequency of MOAA/S 0 was significantly different between sessions. These results 
suggest that other more complex physiological phenomena might govern the interaction 
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between the presence of background noise and the sedative properties of 
dexmedetomidine. 
Surprisingly, we found no influence of age on sensitivity to the sedative effects of 
dexmedetomidine. Inclusion of age as a covariate on θLLE0 and C50 in the MOAA/S and 
BIS model did not result in a significant decrease in the OFV. In contrast to this finding, 
Schnider and colleagues12 and Minto and colleagues13 found that for propofol and 
remifentanil the sensitivity to EEG effects increases with age. By including volunteers 
into our study in age- and sex-stratified cohorts, we maximized the a priori possibility of 
detecting a potential influence of age and sex on the sedative properties of 
dexmedetomidine. Nevertheless, the limited number of subjects in our study could have 
obscured an age effect. In contrast, the different receptor pathways involved in 
dexmedetomidine sedation (α2-receptor agonist) vs propofol (GABAA receptor agonist) 
and remifentanil (opioid) sedation might explain the lack of an age effect.  
Table 2. BIS50 values and corresponding Ce dexmedetomidine for five levels of the 
MOAA/S score for subjects exposed to and deprived from ambient operating room 
noise. 
Ambient noise cohort Silent cohort 
Ce (ng ml-1) BIS50 Ce (ng ml-1) BIS50 
Loss of MOAA/S 5  0.29 87 0.43 83 
Loss of MOAA/S 4 0.54 80 0.79 74 
Loss of MOAA/S 3 0.91 72 1.34 64 
Loss of MOAA/S 2 4.10 38 5.99 29 
Loss of MOAA/S 1 9.88 20 14.4 15 
Our PKPD models allow us to define target effect-site concentrations that maximize the 
possibility of attaining a particular level of sedation and inform us on the BIS values that 
correspond to these sedation levels. In a subject exposed to ambient operating room 
noise, loss of responsiveness to verbal stimulation (i.e. MOAA/S score ≤ 2) is predicted 
to occur at an effect-site concentration of 0.91 ng ml-1. At this effect-site concentration, 
BIS immediately before the MOAA/S stimulation is 72. Volunteers deprived of ambient 
noise lose responsiveness to verbal stimulation at a Ce of 1.3 ng ml-1 and BIS value of 64. 
Based on a study in healthy volunteers, Kasuya and colleagues14 found that the 
correlation between BIS and MOAA/S scales is significantly different between 
dexmedetomidine and propofol. When considering the same level of sedation, BIS 
values for dexmedetomidine were generally lower than those in the propofol group. Our 
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analysis contradicts these findings. The results in Table 2 are in (very) good agreement 
with earlier work on propofol. Struys and colleagues15 found that for propofol the BIS 
values where 50% of the population loses responsiveness (BIS50) to MOAA/S scales 5, 
4, and 3 were 85, 74, and 66, respectively. However, earlier findings by Kearse and 
colleagues16 and Iselin-Chaves and colleagues17 showed that the BIS50 for loss of 
responsiveness to verbal stimulation was 65 and 64, respectively. These results are in 
good agreement with our estimates for dexmedetomidine, indicating that the 
calibration for BIS is very similar between dexmedetomidine and propofol. Overall, 
these findings suggest that target BIS values between 60 and 40, which generally 
indicate adequate general anaesthesia, are appropriate when dexmedetomidine-based 
deep sedation is required. Between these target BIS values, corresponding to a Ce of 1.6 
and 3.6 ng ml-1, loss of responsiveness to verbal stimulation is predicted to occur in 58 
and 81% of patients, respectively, and MOAA/S scores will be ≤ 2. 
Besides the discrepancy with the work of Kasuya and colleagues,14 our results are 
generally in line with earlier reports from experimental studies with dexmedetomidine 
in healthy volunteers. In a study where healthy volunteers received dexmedetomidine 
in a step-up TCI titration, Kaskinoro and colleagues18 found that, on average, loss of 
responsiveness to verbal stimulation occurred at 1.9 ng ml-1. Although it is not entirely 
clear whether volunteers were exposed to or deprived of ambient noise, this 
concentration is in agreement with our predictions, considering the variability 
associated with assessment of loss of responsiveness to verbal stimulation. In a study 
where healthy volunteers received a 10 min 6 µg kg-1 h-1 loading dose followed by a 0.2 
or 0.6 µg kg-1 h-1 i.v. infusion, Hall and colleagues19 found that BIS decreased by 31% and 
36% after 60 min. When we simulated a similar experimental study, we found a 21% and 
28% decrease in BIS, which is slightly lower, but still inspires confidence given that we 
are dealing with an independent data set and that it is not clear whether volunteers in 
the study by Hall and colleagues19 were stimulated, which could explain the higher BIS 
values. 
The approach we present, which models the drug effect in both the unstimulated and 
the stimulated state, was used previously by Heyse and colleagues20 to account for the 
differences in hypnotic and analgesic effects between stimulated and unstimulated 
volunteers receiving sevoflurane-remifentanil anaesthesia. However, in contrast to the 
analysis of Heyse and colleagues,20 we used this approach to account for the time-
varying effect of stimulation. Correcting for the confounding effect of stimulation is 
pivotal for modelling dexmedetomidine. Not only does it significantly increase the GOF, 
without the rousability component in the model a significant bias is seen in estimated 
PKPD parameters. For example, the C50 for BIS, which is the parameter of primary 
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interest, increases by 82% after stimulation. Dosing regimens taking into account both 
the pre- and post-stimulation effects with dexmedetomidine, could result in better 
titration, targeting values with the highest probability for the desired MOAA/S. If deep 
sedation is required, the target that results in the least increase in BIS without 
oversedating the patient could be chosen. Whenever BIS is used to target a specific 
degree of sedation with dexmedetomidine, one should be aware of the confounding 
effect of stimulation. An applied stimulus is expected to disturb the BIS signal for up to 
20 min. Implementing our model into a drug display could correct for this time-varying 
effect of stimulation and could provide a more robust system to titrate 
dexmedetomidine-based sedation. 
In conclusion, we present a PKPD model that adequately describes the sedative and 
hypnotic effects of dexmedetomidine in healthy volunteers. This model integrates the 
well-known rousability associated with dexmedetomidine sedation and accounts for 
changes in responsiveness between volunteers attributable to repeated auditory 
stimulation. After validation of our PKPD model in a patient population, our model might 
be used to transition towards effect-site TCI rather than plasma concentration TCI for 
dexmedetomidine in clinical practice, thereby allowing tighter control over the desired 
level of sedation. 
Supplementary material 
Supplementary material is available at British Journal of Anaesthesia online. 
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Background: Dexmedetomidine, a selective α2-adrenoreceptor agonist, has unique 
characteristics, with little respiratory depression and rousability during sedations. We 
characterized the haemodynamic properties of dexmedetomidine by developing a 
pharmacokinetic-pharmacodynamic (PKPD) model with a  focus on changes in mean 
arterial blood pressure (MAP) and heart rate. 
Methods: Dexmedetomidine was delivered i.v. to 18 healthy volunteers in a step-up 
fashion by target-controlled infusion using the Dyck model. Exploratory PKPD modelling 
and covariate analysis were conducted in NONMEM. 
Results: Our model adequately describes dexmedetomidine-induced hypotension, 
hypertension, and bradycardia, with a greater effective concentration for the 
hypertensive effect. Changes in MAP were best described by a double-sigmoidal Emax 
model with hysteresis. Covariate analysis revealed no significant covariates apart from 
age on the baseline MAP, and the covariates incorporated in the population 
pharmacokinetic model used to develop this PKPD model. Simulations revealed good 
general agreement with published descriptive studies of haemodynamics after 
dexmedetomidine infusion.  
Conclusions: The present integrated PKPD model should allow tighter control over the 
desired level of sedation, while limiting potential haemodynamic side-effects. 




Dexmedetomidine, a selective α2-adrenoceptor agonist, is widely used in clinical 
practice as a sedative drug. Owing to its high affinity and selectivity for the α2-
adrenoceptors, dexmedetomidine produces a typical biphasic haemodynamic 
response.1 At low plasma concentrations, the sympatholytic effect predominates, and 
dexmedetomidine tends to lower mean arterial blood pressure (MAP) and heart rate 
(HR) through activation of presynaptic α2-adrenoceptors in the central nervous system 
and through activation of α2-adrenoceptors in vascular endothelial cells, which causes 
vasodilation.2, 3 At higher concentrations, peripheral vasoconstrictive effects 
attributable to activation of α2-adrenoceptors in vascular smooth muscle become 
dominant, resulting in an increase in MAP and a further decline in HR.4, 5 
The haemodynamic effects of dexmedetomidine have been descriptively summarized 
after short (2, 5 or 10 min) infusions1, 6-8 at doses between 0.25 and 4 µg kg-1 or target-
controlled infusion (TCI) systems4, 5 at target concentrations ranging between 0.5 and 8 
ng ml-1. Although a significant dose-response relationship was observed, only very 
limited pharmacokinetic-pharmacodynamic (PKPD) models exist relating the time 
course of dexmedetomidine plasma concentrations to its effects on MAP and HR.6, 8 In 
order to gain a better understanding and predict these haemodynamic alterations, an 
integrated PKPD model would be useful to characterize these relationships. 
We previously developed a pharmacokinetic model for dexmedetomidine9 based on 
data from an extensive healthy volunteer study. In an accompanying paper, we describe 
the sedative effects of dexmedetomidine, using the EEG-derived bispectral index (BIS®, 
Medtronic, Dublin, Ireland)  and Modified Observer’s Assessment of Alertness/Sedation 
(MOAA/S) scale.10 In this article, we present a PKPD model describing the 
haemodynamic effects of dexmedetomidine to characterize the relationship between 
dexmedetomidine plasma concentrations, effect-site concentrations (Ce) and resulting 





This study was approved by the local Medical Ethics Review Committee (METC, 
University Medical Center Groningen, Groningen, the Netherlands; METC number: 
2012/400), and was registered in the ClinicalTrials.gov database (NCT01879865). The 
study conduct has been described in detail 9 including development of a 
pharmacokinetic (PK) model based on the study data. In brief, after obtaining written 
informed consent, 18 healthy volunteers, stratified according to age and sex (18-34, 35-
54 and 55-72 yr; three males and three females in each group) received 
dexmedetomidine i.v. on two separate occasions. Dexmedetomidine was delivered 
through TCI using the Dyck model,11 as described in the accompanying paper.10  
Pharmacodynamic measurements 
Continuous arterial blood pressure monitoring was performed via an arterial cannula, in 
the same arm as the i.v. cannula used to deliver the drug. Heart rate was monitored via 
a continuous ECG wave (lead II) that was recorded throughout the study at a frequency 
of 500 Hz. Vital signs were monitored using a Philips MP50 monitor (Philips, Eindhoven, 
The Netherlands). Heart rate was derived from the raw ECG wave, by measuring the R-
R interval using a Visual Basic macro in Microsoft Excel (Microsoft, Redmond, WA, USA). 
All monitored parameters and raw waveforms were recorded electronically using 
RUGLOOP II software (Demed, Temse, Belgium). 
Data handling 
The final data set contained MAP and HR measurements at a sampling rate of 1Hz, which 
resulted in > 50,000 observations per session for some individuals. In an attempt to 
reduce the computational burden during model development, we reduced the number 
of MAP and HR measurements per subject. We also applied a median filter to reduce 
the influence of artifacts, outlying data, or both during model development. The width 
(span) of the median filter was 60 s. Data reduction was performed by retaining only the 
first out of every 50 consecutive median filtered observations in the data set. 
The data set used for modelling contained a median of 458 (range 268-672) MAP 
measurements and 394 (range 234-542) HR measurements per subject per session, 
corresponding to a reduced sampling rate of 1 min-1. 
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Population PKPD modelling 
For pharmacodynamic (PD) modelling we used the parameter estimates from the 
dexmedetomidine PK model published earlier by our group.9 The individual predicted 
PK parameters (V1, V2, V3, CL, Q2 and Q3) were fixed for each individual and each 
session (Hannivoort and colleagues9 reported that V1 was different between occasions) 
during further PD modelling. 
Different structural models were evaluated to test whether hysteresis exists between 
the individually predicted dexmedetomidine plasma concentrations (IPREDplasma) and 
the PD measures. Direct models relating IPREDplasma directly to the PD measure were 
compared against delay drug effect models, such as an effect compartment model or an 
indirect response model. Drug effects were described using linear, Emax, and sigmoid Emax 
models. In the event of numerical difficulties with the estimation algorithm, leading to 
imprecise estimates of Emax and C50, an alternative Emax model (shown in equation 1), as 
described by Schoemaker and colleagues,12 was evaluated. This equation relies on a 
parameter (S0) equal to Emax/C50 and could be advantageous for PD model estimation 
when few data are available near the maximal effect. 
𝐸𝐸 =  𝐵𝐵0 × 𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 × 𝐵𝐵𝑃𝑃𝑅𝑅𝐸𝐸𝐼𝐼𝑝𝑝𝑝𝑝𝑚𝑚𝑜𝑜𝑚𝑚𝑚𝑚
𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 + 𝐵𝐵0 × 𝐵𝐵𝑃𝑃𝑅𝑅𝐸𝐸𝐼𝐼𝑝𝑝𝑝𝑝𝑚𝑚𝑜𝑜𝑚𝑚𝑚𝑚  (1) 
Once the base model structure was established, graphical analysis was conducted to 
identify potential correlations between post hoc predicted PKPD parameters and subject 
covariates. The covariates considered were: weight, height, BMI, age, sex and session. 
Subsequently, these covariates were tested by inclusion in the model, and the resulting 
change in goodness-of-fit was evaluated. Hereto, for the continuous covariates (age, 
height and weight) a linear relationship was assumed, whereas for the categorical 
covariate (sex) an additional parameter was added to the model to differentiate 
between males and females. Where appropriate, inclusion of model parameters, 
covariates, or both was tested at the 5% significance level by comparing the decrease in 
objective function (OFV) against the critical quantile of the corresponding χ2 distribution 
(e.g. 3.84 for inclusion or exclusion of a single parameter). 
Parameter estimation and model evaluation 
The first-order conditional estimation algorithm with interaction (FOCE-I) as 
implemented in NONMEM® (version 7.3; Icon Development Solutions, Hannover, MD, 
USA) was used to fit the continuous MAP and HR data. Inter-individual variability (IIV) 
and inter-occasion variability were modelled using exponential models. Residual 




During model building, the goodness-of-fit (GOF) of the different models was compared 
numerically using the Akaike information criterion (AIC) and the median absolute 
(population-)prediction error (MdAPE). At each stage, GOF was graphically evaluated by 
inspecting plots of the individual or population predicted vs observed responses and 
plots of the conditionally weighted residuals (CWRES) vs individual predictions and time. 
To ensure numerical stability, only models with a condition number of the estimated 
variance-covariance matrix < 500 were retained. Finally, models were validated 
internally using prediction-corrected visual predictive checks (pcVPC) as described by 
Bergstrand and colleagues.13 
Models were fitted to the data using PsN14 and Pirana15 as back- or front-end, or both, 
to NONMEM®. The numerical and graphical assessment of the GOF and the construction 
of the pcVPCs, were conducted in R® (R Foundation for Statistical Computing, Vienna, 
Austria). 
Simulations were performed in a Microsoft Excel® Macro-Enabled Worksheet (Microsoft 
Office Professional Plus 2013) which is supplied in the Online Supplementary material 
to this paper. The worksheet depends on the ‘PKPD tools for Excel’ package developed 
by T. Schnider and C. Minto, available from http://www.pkpdtools.com/excel (last 
accessed April 18, 2017). 
Statistical analysis 
Model parameters are reported as typical values with associated relative standard 
errors (RSE) and 95% confidence intervals derived from log-likelihood profiling.16 





Figure 1 shows the median filtered HR and MAP signals for four representative subjects 
from our study during the step-up TCI administration. The dashed lines indicate when a 
new TCI target was set. This figure clearly shows the monotonic decrease in HR and the 
biphasic behaviour of the MAP with increasing dexmedetomidine plasma 
concentrations.  
Figure 1. Mean arterial pressure (continuous grey lines; grey y-axis labels) and heart rate 
(continuous black lines; black y-axis labels) for four representative subjects. The nominal times (as 
indicated by the study protocol) at which TCI settings were changed are indicated by vertical 
dashed lines. A bolus infusion was followed by a 10 min recovery period, after which (the first 
dashed line indicates the end of this phase) TCI targets were increased in a stepwise fashion.  
HR = heart rate; MAP = mean arterial pressure; TCI = target-controlled infusion. 
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Median filtered MAP and HR observations for all subjects throughout the entire study 
are shown in Online Supplementary Figures S1 and S2. 
Mean arterial pressure model development 
As a starting point for model building, we used two Emax models to characterize the 
dependency between IPREDplasma and the MAP. This model was deemed necessary to 
describe the biphasic effect of dexmedetomidine on MAP adequately. As seen in Figure 
1, at low dexmedetomidine concentrations the hypotensive effect dominates, whereas 
at higher concentrations this effect is counteracted and then reversed to profound 
hypertension. 
The model was further modified by fixing the Emax term for the hypotensive effect to 
increase numeric stability (ΔAIC for fixing Emax to 1 = -0.8) and by adding a parameter 
describing the correlation in IIV in baseline MAP (BaseMAP) and the EC50 for the 
hypertensive effect (ΔAIC = -16). In addition, an effect compartment model was included 
to characterize the hysteresis between IPREDplasma and MAP. Two effect compartments, 
with a separate ke0 for the hypotensive (Ce,Hypo) and the hypertensive effect-site 
concentrations (Ce,Hyper), gave the highest improvement in OFV and were retained in the 
model (ΔAIC = -1552.8). Finally, a specific parameterization, as shown in equation 2, of 
this double Emax model was favoured to ensure that for every subject, the estimated EC50 
for the hypertensive effect is greater than the EC50 for the hypotensive effect. 
𝑀𝑀𝑅𝑅𝑃𝑃𝑝𝑝𝑖𝑖 = 𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑁𝑁𝐴𝐴𝑀𝑀,𝑝𝑝 × �1 − 𝐶𝐶𝑜𝑜,𝐻𝐻𝐻𝐻𝑝𝑝𝑜𝑜𝐸𝐸𝐶𝐶50𝐻𝐻𝐻𝐻𝑝𝑝𝑜𝑜 + 𝐶𝐶𝑜𝑜,𝐻𝐻𝐻𝐻𝑝𝑝𝑜𝑜 + �1 + 𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚,𝐻𝐻𝐻𝐻𝑝𝑝𝑜𝑜𝑜𝑜� × 𝐶𝐶𝑜𝑜,𝐻𝐻𝐻𝐻𝑝𝑝𝑜𝑜𝑜𝑜�𝐸𝐸𝐶𝐶50𝐻𝐻𝐻𝐻𝑝𝑝𝑜𝑜 + Δ𝐸𝐸𝐶𝐶50� + 𝐶𝐶𝑜𝑜,𝐻𝐻𝐻𝐻𝑝𝑝𝑜𝑜𝑜𝑜�   (2) 
In the next step, the post hoc predicted parameters for which IIV was included in the 
model (BaseMAP, EC50Hypo, and ΔEC50) were plotted against the covariates to detect 
potential covariate relationships. For age a correlation was observed with BaseMAP. 
Subsequently, this dependency vs BaseMAP was formally tested in the model. Inclusion 
of age on BaseMAP according to equation 3, resulted in a significant improvement in GOF 
(ΔAIC = -9.6) and a reduction in the population MdAPE from 9.4% to 7.8%. 
𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑁𝑁𝐴𝐴𝑀𝑀,𝑝𝑝 = 𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝑁𝑁𝐴𝐴𝑀𝑀 × 𝑝𝑝�𝜃𝜃𝑎𝑎𝑎𝑎𝑎𝑎×(𝐴𝐴𝐴𝐴𝐿𝐿−20)�  (3) 
Inclusion of age, weight, height or sex on EC50Hypo or ΔEC50 did not result in a significant 
decrease in the OFV; therefore, these covariates were not included in the final model. 
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Table 1. Final model parameters with associated relative standard errors (RSE, %) 
derived from log-likelihood profiling. 
Final HD model 
Parameter Estimate (RSE%2) IIV1 (RSE%2) IOV1 (RSE%2) 
θ1 BaseMAP (mmHg) 80.4 (3.60) 10.9 (16.0) - 
θ2 θage (yrs-1) 0.00507 (20.2) - - 
θ3 ke0MAP,Hypo (min-1) 0.0529 (2.80) - - 
θ4 ke0MAP,Hyper (min-1) 0.0902 (2.80) - - 
θ5 C50,Hypo (ng ml-1) 0.364 (10.0) 
51.1 (16.0) 
ρBaseMAP: 0.755 (11.8) 
- 
θ6 ΔC50 (ng ml-1) 1.20 (12.0) 41.8 (37.7) - 
θ7 Emax,Hyper (rel.) 0.43 (0.70) - - 
θ8 BaseHR (bpm) 59.6 (3.30) 13.4 (38.2) 2.24 (42.7) 
θ9 HRMIN (bpm) 22.5 (3.90) - - 
θ10 ke0HR (min-1) 0.396 (7.50) - - 
θ11 S0 (bpm ml ng-1) 4.37 (22.4) 110 (37.7) - 
θ12 θHRV (bpm-1) 0.0613 (3.10) - - 
σRUV,Additive (mmHg)3 5.77 (1.10) - - 
σRUV,Additive (bpm)3 5.58 (11.4) 48.6 (37.6) - 
1calculated according to:  √𝑝𝑝𝜔𝜔 − 1 ∗ 100%; 2derived from log-likelihood profiling; 3expressed as 
standard deviation. 
IIV = interindividual variability; IOV = interoccasion variability; MAP = mean arterial pressure; HR 
= heart rate; HRV = heart rate variability; ω = estimated variance of the interindividual variability; 
σ = estimated variance of the residual unexplained variability (RUV) 
Final MAP model 
The final model parameters are described in Table 1. The likelihood profiles, which were 
generated to identify potential problems with parameter identification, are shown in 
Online Supplementary Figure S3. Goodness-of-fit plots, such as post hoc predictions vs 
observations and CWRES vs time are shown in Online Supplementary Figure S4. Online 
Supplementary Figure S5 shows the pcVPC. Overall, these figures demonstrate that the 
presented model adequately describes the observed changes in MAP during 
dexmedetomidine administration and that all parameters of the model are estimated 
with acceptable precision. In the recovery phase, there is increased MAP variability 
around the model predictions. This is seen in the individual post hoc predicted vs 
observed MAP plots, shown in Online Supplementary Figure S1. As subjects were not 
restrained during the recovery phase of the experiment, (small) movements probably 
led to the increased noise in the MAP signal. 
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The baseline MAP in our study, for a 20-yr-old individual, was estimated to be 80 mmHg 
and was found to increase by 5.2% for every 10 yr increase in age. The half-lives for 
effect-site equilibration for the hypotensive and hypertensive effect-site compartments 
were estimated to be 13 min and 7.7 min, respectively. Furthermore, a significant 
difference was found between the population typical sensitivity (i.e. EC50) for the 
hypotensive and hypertensive effects, with the latter being 1.20 ng ml-1 higher on 
average. The difference between both (ΔEC50) sensitivities was positively correlated to 
the baseline (ρ = 0.755). Thus, individuals with a higher baseline MAP, tend to show a 
more profound hypotensive phase compared with individuals having a lower baseline 
MAP. 
Figure 2. Change in mean arterial pressure (continuous black line) and heart rate (dashed black 
line), for a typical 20-yr-old individual, as a function of the respective effect-site concentrations.  
Ce = effect-site concentration; HR = heart rate; MAP = mean arterial pressure. 
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A graphical presentation of the change in MAP according to Ce, for a typical 20-yr- old 
individual, is shown in Figure 2. The MAP decreases below baseline at low 
dexmedetomidine Ce, followed by a return to baseline at 2.4 ng ml-1. Above this 
concentration, dexmedetomidine induces hypertension, with a maximal MAP 43% 
higher than the initial baseline. 
Heart rate model development 
Initially, HR data were analysed using a model that assumed a linear decrease in HR as a 
function of IPREDplasma. The model modifications that led to a significant decrease in AIC 
were as follows: (i) use of a non-linear drug effect model according to Schoemaker and 
colleagues12 (ΔAIC = -731.1), (ii) inclusion of an  effect compartment model as opposed 
to a direct model (ΔAIC = -448.9) and (iii) the use of a model that assumed exponentially 
decreasing HR variability (HRV), as shown in equation 4 (ΔAIC = -817.5). 
𝐵𝐵𝐼𝐼𝑝𝑝𝑖𝑖 = 𝜎𝜎𝑅𝑅𝑅𝑅𝑅𝑅,𝐴𝐴𝑜𝑜𝑜𝑜𝑝𝑝𝑝𝑝𝑝𝑝𝑜𝑜𝑜𝑜,𝑝𝑝 × 𝑝𝑝�−𝜃𝜃𝐻𝐻𝑅𝑅𝑅𝑅×�𝐵𝐵𝑚𝑚𝑜𝑜𝑜𝑜𝐻𝐻𝑅𝑅,𝑖𝑖−𝑁𝑁𝑀𝑀𝑅𝑅𝐿𝐿𝐼𝐼𝐻𝐻𝑅𝑅,𝑖𝑖𝑖𝑖��  (4)
This error model was evaluated to give more weight to lower HR values which, in light 
of a potential dexmedetomidine-induced bradycardia, are clinically more important. The 
residual unexplained variability (RUV) was described by an additive error model with an 
SD for subject i at time j (SDij) that exponentially decreased, at a rate equal to θHRV, with 
the difference between baseline HR (BASEHR,i) and the predicted HR at time j (IPREDHR,ij). 
The baseline RUV (i.e. before the start of the dosing) for each subject (σRUV,Additive,i) was 
adequately described by a population SD with an exponential inter-individual variability 
term. 
The relationship between dexmedetomidine effect-site concentrations and HR was best 
described by an adaptation of the model described by Schoemaker and colleagues.12 In 
our version of this model, as illustrated in equation 5, the maximal drug effect was 
dependent on the individual baseline HR and a population parameter describing the 
minimal attainable HR during dexmedetomidine administration (HRMIN). Other 
approaches to model the drug effect, using an Emax or a sigmoid Emax model, failed as a 
result of numerical instability of the estimation algorithm. 
𝐸𝐸𝑚𝑚𝑚𝑚𝑚𝑚 = 𝐵𝐵𝐵𝐵𝑝𝑝𝑝𝑝𝐻𝐻𝑅𝑅,𝑝𝑝 − 𝐻𝐻𝑅𝑅𝑁𝑁𝑁𝑁𝑁𝑁    (5)
A graphical exploration of the post hoc predicted PKPD parameters (BaseHR, S0, and SD) 
from this base model vs subject covariates revealed no apparent correlations. Inclusion 
of age, weight, height or sex on S0 did not result in a significant decrease in the OFV, 
therefore, no covariates were included in the final model. 
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Final HR model 
The final model adequately describes the time course of HR during/after 
dexmedetomidine administration (Online Supplementary Figure S4). This conclusion is 
further supported by the pcVPC shown in Online Supplementary Figure S5. The final 
model parameters and associated standard errors (derived from the log-likelihood-
profiles in Online Supplementary Figure S3) are presented in Table 1. Again, post hoc 
predicted vs observed HR as a function of time for all individuals in the study are shown 
in Online Supplementary Figure S2.  
In the final model, baseline HR variability was described by a combination of inter-
individual and inter-occasion variability, accounting for 13% and 2.2% of baseline 
variability, respectively. Changes in dexmedetomidine plasma concentrations induced 
relatively rapid changes in HR, with a half-life for effect-site equilibration of 1.75 min 
( ln 2
𝑘𝑘𝑜𝑜0𝐻𝐻𝑅𝑅
 = 1.75).  
The estimated lower boundary for the HR during dexmedetomidine therapy was found 
to be 22 bpm and was significantly different from zero (the OFV increased by 226 when 
this lower boundary was fixed to zero). The slope parameter (S0) was estimated to be 
4.37 bpm ml ng-1 and had considerable inter-individual variability (110%).  
The RUV in HR at baseline was relatively high and variable between subjects. We found 
a population SD for the RUV of 5.6 bpm and an inter-individual variability of 48%, 
respectively. On an individual level, the RUV varied between 2.9 bpm and 12.5 bpm at 
baseline. During dexmedetomidine administration, HRV was found to be correlated with 
the post hoc predicted HR, with an approximate reduction in RUV of 45% with every 10 
bpm decrease in HR. 
Effects of infusion duration and dose on MAP and HR 
To get a clearer clinical picture of the effects of dexmedetomidine on MAP and HR, 
several drug infusions with varying infusion durations and doses were simulated. The 
top and bottom panels of Figure 3 show the influence of increasing dexmedetomidine 
doses and infusion duration on the MAP (left panels) and HR (right panels) for doses 
ranging from 0.25 to 4.0 µg kg-1 for a 27-yr-old healthy volunteer weighing 77 kg (the 
Excel® worksheet used to simulate these dosing regimens is available from the Online 
Supplementary material of Colin and colleagues).10 
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Figure 3. Influence of dexmedetomidine dose (top panels) and infusion duration (lower panels) 
on mean arterial pressure (left panels) and heart rate (right panels) for short (30 min at most) 
infusions.  
BaseHR = baseline heart rate; BaseMAP = baseline mean arterial pressure. 
For MAP, dexmedetomidine administration up to 1 µg kg-1 over 5 min causes no 
hypertension, but with higher doses (2 and 4 µg kg-1), profound hypertension occurs, 
with an increase from baseline MAP of 7% and 19%, respectively (Table 2). For all 
simulated drug regimens, profound postinfusion hypotension is predicted, although the 
decrease in MAP levels off at around 25-27% below baseline, even at increasing doses. 
Furthermore, our model predicts that the recovery period (time necessary to return to 
baseline MAP once the infusion is stopped) increases from 3.7 to 13 h for the 0.25 and 
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For HR, there is a clear dose-response relationship between infused dose and infusion 
duration and decrease in HR (Table 2). For increasing doses from 0.25 to 4.0 µg kg-1 over 
5 min, the decrease in HR increases from 5.5% to 38% from baseline. Increasing the 
infusion duration gives a smaller effect on HR decrease, and increases the time until 
maximal HR reduction is reached. 
Figure 4. Post hoc predicted change in BIS (top panels) and probability for loss of MOAA/S 3 
(bottom panels) as a function of the simultaneous change in heart rate (left panels) and mean 
arterial pressure (right panels). The individually predicted trajectories for all subjects are shown 
with grey continuous lines. The population average trajectory is shown with a thick continuous 
black line. Clinically interesting targets for BIS and probability for loss of MOAA/S 3 are shown with 
grey shaded areas.  
BIS = bispectral index; HR = heart rate; MAP = mean arterial pressure; MOAA/S = Modified 
Observer’s Assessment of Alertness/Sedation; Pr = predicted,
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Comparison between the haemodynamic and sedative properties of dexmedetomidine 
We used our combined PKPD model to investigate whether the haemodynamic 
responses after dexmedetomidine administration could be used as a surrogate marker 
for the sedative effects.10 The individual responses across different end points were 
predicted from the post hoc PKPD parameters, and plasma concentrations, effect-site 
concentrations and the resulting haemodynamic and sedative effects were predicted for 
all subjects during the time course of the study. In order to increase the interpretability 
of these results, differences in baseline MAP and HR across subjects had to be accounted 
for. This was achieved by expressing the changes in haemodynamic end points relative 
to individually predicted baseline values. 
The decrease in BIS and the increase in the probability of achieving an MOAA/S < 3 (i.e. 
loss of responsiveness) are shown in Figure 4 as a function of the simultaneous changes 
in HR and MAP. For HR,a straightforward correlation is seen with the predicted sedative 
effects. For the typical individual, we expect that BIS values between 60 and 40 are 
accompanied by a decrease in HR of 10% and 20%, respectively. This HR reduction 
corresponds to a high probability (i.e. ≥ 80%) for loss of responsiveness. 
The relationship between MAP and the sedative effects of dexmedetomidine is less 
straightforward. Nevertheless, for the typical individual, the point where MAP 
normalizes, (after the hypotensive phase and before the hypertensive phase), appears 
to indicate sufficient sedation depth. At this point, BIS is predicted to be between 60 and 
40, and the probability of loss of responsiveness is high (i.e. ≥ 80%). 




We present a PKPD model describing dexmedetomidine-induced changes in mean 
arterial pressure and heart rate in healthy volunteers. Knowledge of these relationships 
is crucial for optimizing dexmedetomidine drug administration profiles to avoid 
undesirable haemodynamic side–effects. Dexmedetomidine-induced changes in MAP 
were best described by a double-sigmoidal Emax model, which characterizes the biphasic 
effect of hypotension at low concentrations and hypertension at higher concentrations. 
We also found a hysteresis between plasma concentration and both hypotensive and 
hypertensive effects, and this hysteresis is different for both effects. This results in two 
effect compartments with two different equilibration constants, ke0. This can be 
physiologically explained by the hypertensive and hypotensive effects occuring at 
different receptor sites. The hypertensive effect is thought to originate from α2-receptor 
activation in the vascular smooth muscle, whereas the hypotensive effect is mediated 
by α2-receptor activation in the vascular endothelium and in the central nervous system. 
The concentration at which the hypertensive effect overcame the hypotensive effect 
was 2.4 ng ml-1, in good agreement with information from other groups. For example, 
the assessment report of the European Medicines Agency17 on dexmedetomidine and 
Ebert and colleagues5 report significant hypertension starting at plasma concentrations 
of 3.2 and 1.9 ng ml-1, respectively. The only covariate found was the effect of age on 
baseline MAP, where older volunteers had a higher baseline MAP, but no effect was 
found between age and dexmedetomidine-induced MAP changes. 
The effect of dexmedetomidine on HR was best described by a non-linear model, as 
described by Schoemaker and colleagues.12 This model provides greater numerical 
stability compared with the Emax model, when estimating maximal effect from 
observations made predominantly around C50. The increased precision in the estimated 
maximal drug effect (i.e. the lower HR range) is also clinically the most important range 
to evaluate, as bradycardia could be one of the limiting factors in dexmedetomidine 
administration at higher concentrations. This is especially true in patients with pre-
existing bradycardia or in patients who perform better with a higher HR, such as patients 
with dilated cardiac failure. A narrow hysteresis was found between plasma 
concentration and HR effects, with a high ke0, describing a fast change in HR in response 
to changes in plasma concentration. No covariates were found to be associated with 
baseline HR or dexmedetomidine-induced HR changes. 
Our MAP model resembles the model presented by Potts and colleagues,8 with a few 
important differences. While both models include a double-sigmoidal Emax model, 
describing both the sympatholytic and the vasoconstrictor effects of dexmedetomidine, 
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our model uses an effect-site compartment for both the hypertensive and hypotensive 
effects, whereas the Potts model describes an effect-site compartment only for the 
hypotensive effects. Possible explanations are the usually shorter delays in drug effects 
in children, and less frequent non-invasive monitoring of blood pressure (every 5 min), 
obscuring the hysteresis for the vasoconstrictor effects. Also, Potts and colleagues8 
included a parameter describing the maximal sympatholytic effect, whereas we chose 
to omit this parameter from the model because it resulted in numerical difficulties with 
model estimation. The differences in parameter values between the Potts model and 
our model are small, despite the fact that the Potts model describes paediatric data. In 
our model, the EC50 values for the hypotensive (0.36 ng ml-1) and hypertensive (1.6 ng 
ml-1) effects are only slightly higher than in the Potts model (0.10 and 1.1 ng ml-1,
respectively). Furthermore, the maximal decrease and subsequent increase in MAP are
similar between populations, where we found a decrease and increase of 27% and 43%,
respectively, and Potts and colleagues8 described a decrease and increase of 15% and
62%. The ke0 values for the hypo- and hypertensive responses were 0.053 min-1 (t½ =
12.1 min) and 0.090 min-1 (t½ = 7.68 min), respectively, whereas Potts and colleagues8
estimated a ke0 for the sympatholytic effect of 0.072 min-1 (t½ = 9.65 min), corresponding 
to a slightly longer equilibration half-time for our adult volunteer model compared with
the paediatric model.
Yoo and colleagues6 used a mechanism-based PKPD model to describe changes in blood 
pressure and HR after dexmedetomidine administration. Several important differences 
can be noted here. Firstly, the dexmedetomidine dose resulted only in low plasma 
concentrations, below 2.4 ng ml-1, therefore, no hypertensive reaction was seen in their 
study, and also not modelled. Secondly, the predicted lower boundary for the HR was 
50.5 bpm, which is clearly inconsistent with our data, as several volunteers reached 
heart rates of 40 bpm. 
Our simulations are in good agreement with the observations described by Bloor and 
colleagues1 and Dyck and colleagues7 on the effects of dexmedetomidine on HR in 
healthy volunteers. Bloor and colleagues1 found that at 2 min infusions of 1.0 and 2.0 µg 
kg-1 dexmedetomidine, HR decreased from 59 bpm at baseline to 49 and 44 bpm 2-3 
min postinfusion. From our simulations we found a change from baseline of -21% and -
31%, respectively. When taking into account a baseline HR of 59 bpm, this results in a 
predicted minimal HR of 47 and 41 bpm, which is very similar to the results from Bloor 
and colleagues.1 Dyck and colleagues7 found that after a 5 min infusion of 2 µg kg-1 
dexmedetomidine HR decreased to 27% below baseline 4-5 min postinfusion. This is in 
good agreement with what is predicted by our model (-27% change from baseline at 5.1 
min after the start of the infusion). 
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For the predicted effects of dexmedetomidine on the MAP, especially for the 
hypertensive phase, our model somewhat underachieves. For the dexmedetomidine 
infusions of 2 µg kg-1 studied by Bloor and colleagues1 and Dyck and colleagues,7 our 
model predicts an increase in MAP of 7% and 8%, respectively, which is lower than the 
22% and 24% increase observed. In contrast, when we simulate the experimental work 
described by Snapir and colleagues4 and Ebert and colleagues,5 who used TCI 
administration to study the haemodynamic effects of dexmedetomidine at steady-state 
plasma concentrations of 5.1 and 8 ng ml-1, we predict an increase in MAP of 15% and 
23%, which is higher than the 10% and 12% increase reported. The fact that the model 
predictions are not biased when comparing against these independent data sets (i.e. not 
always over- or underpredicting) inspires confidence. Nevertheless, this aspect has the 
potential for improvement as more data become available. 
Our model adequately describes dexmedetomidine-induced postinfusion hypotension, 
which is well known from the work of Bloor and colleagues1 and Dyck and colleagues.7 
These studies found that MAP was reduced (-17% and -22% for the 2 µg kg-1 infusion, 
respectively) up to 4 and 5.5 h after the start of the infusion. Our predicted decreases in 
MAP of -16% and -21% are in good agreement with these findings. Based on our model, 
we expect that it would take 10.4 h for MAP to return to within 5% of its baseline value. 
As the previously mentioned studies ended 4 and 5.5 h after the start of the 
dexmedetomidine infusion, this aspect of the model remains to be validated. 
Based on our PKPD models, we were able to study the interplay between the sedative 
and haemodynamic effects of dexmedetomidine. Dexmedetomidine-induced changes 
in HR and MAP are reflected in the sedative properties and could therefore, at least in 
theory, be used as surrogate markers for the degree of sedation.For the typical 
individual, a HR decrease of 10-20% and a normalization of MAP after the initial 
hypotensive phase could serve as a surrogate marker to target a shallow state of 
sedation (i.e. BIS between 60 and 40 and ≥ 80% chance of loss of responsiveness). 
Individual variability in sensitivity to the sedative and haemodynamic responses means 
that these haemodynamic targets will be associated with some variability in sedation. A 
larger study should be conducted to refine and validate these targets in a population 
context. Depending on the precision of the haemodynamic monitoring system used, 
these targets might be obscured by measurement noise and, as such, might be of limited 
clinical use in some instances. 
Strengths of our study include the use of stratified age groups, a relatively wide range 
of individual heights and weights, and both male and female volunteers, increasing our 
chances of detecting relevant covariates. However, apart from an effect of age on 
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baseline MAP, we found no other covariates for baseline values or dexmedetomidine 
effects on MAP and HR. This is in line with other PKPD analyses,6, 8 which also did not 
find a significant influence of patient characteristics on estimated PKPD parameters. 
Use of healthy volunteers allowed development of a PKPD model that avoids 
confounding influences of concomitant medications or patient co-morbidity. For 
example, a study by Talke and colleagues2 showed that the sympatholytic effect of 
dexmedetomidine is attenuated under general anaesthesia, while the vasoconstrictive 
effect remains. It is uncertain whether co-morbidity and concomitant medications might 
limit or, conversely, increase the haemodynamic effects of dexmedetomidine. 
The volunteers in our study mostly did not return to baseline values of HR and MAP. One 
reason may be the long-lasting effect that dexmedetomidine has on haemodynamics, 
and our recovery period of 5 h was too short for a full return to baseline, as is also shown 
in our simulations. Another explanation may be that ‘baseline’ is not the true baseline 
at rest, and nervousness and stress may cause volunteers to have higher HR and MAP 
before the start of the study than in the recovery period. 
Given that our infusion rate was limited to 6 or 10 µg kg-1 h-1, our simulations with higher 
infusion rates are not validated. One of the characteristics of our model is that even at 
high infusion rates, there is initial hypotension, followed rapidly by a hypertensive 
reaction. This phenomenon is not described in the literature. Although this could be 
explained by the fact that blood pressure monitoring is often too slow to capture this 
effect, it could also simply be an artifact of the model, and that, physiological feedback 
mechanisms prevent this phenomenon in vivo. Attempts to incorporate such feedback 
mechanisms in our PKPD model failed because of numerical issues with the estimation 
algorithm. Further research, focusing on high-resolution haemodynamic monitoring 
during different infusion rates, is required to validate this effect. 
In conclusion, we developed a PKPD model for dexmedetomidine effects on HR and MAP 
in healthy volunteers. The model accurately describes the reduced HR and the clear 
biphasic effect on MAP, with two effect-site compartments corresponding to different 
physiological α2-receptor effects. No additional subject covariates beyond those that 
were already included in the previously developed PK model9 had an impact on 
dexmedetomidine-induced changes in the haemodynamics. The sedative and 
haemodynamic effects of dexmedetomidine are highly correlated, so our model 
provides surrogate haemodynamic markers to guide dexmedetomidine sedation. 
Further prospective clinical validation should be conducted to assess the performance 
of our model and the proposed surrogate haemodynamic markers. 
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Chapter 5: A response surface model approach for 
continuous measures of hypnotic and analgesic effect during 
sevoflurane–remifentanil interaction 
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Background: The authors studied the interaction between sevoflurane and remifentanil 
on bispectral index (BIS), state entropy (SE), response entropy (RE), Composite 
Variability Index, and Surgical Pleth Index, by using a response surface methodology. The 
authors also studied the influence of stimulation on this interaction. 
Methods: Forty patients received combined concentrations of remifentanil (0 to 12 
ng/ml) and sevoflurane (0.5 to 3.5 vol%) according to a crisscross design (160 
concentration pairs). During pseudo–steady-state anesthesia, the pharmacodynamic 
measures were obtained before and after a series of noxious and nonnoxious 
stimulations. For the “prestimulation” and “poststimulation” BIS, SE, RE, Composite 
Variability Index, and Surgical Pleth Index, interaction models were applied to find the 
best fit, by using NONMEM 7.2.0. (Icon Development Solutions, Hanover, MD). 
Results: The authors found an additive interaction between sevoflurane and 
remifentanil on BIS, SE, and RE. For Composite Variability Index, a moderate synergism 
was found. The comparison of pre- and poststimulation data revealed a shift of C50SEVO 
for BIS, SE, and RE, with a consistent increase of 0.3 vol%. The Surgical Pleth Index data 
did not result in plausible parameter estimates, neither before nor after stimulation. 
Conclusions: By combining pre- and poststimulation data, interaction models for BIS, SE, 
and RE demonstrate a consistent influence of “stimulation” on the pharmacodynamic 
relationship between sevoflurane and remifentanil. Significant population variability 
exists for Composite Variability Index and Surgical Pleth Index. 
A response surface model approach for continuous measures of hypnotic and analgesic effect 




Two important components of general anesthesia are hypnosis and analgesia: The 
hypnotic component may be defined as probability of tolerance to a nonnoxious 
stimulus (e.g., name calling or shake and shout), whereas the analgesic component (also 
called: the balance between nociception and antinociception) may be considered as the 
probability of tolerance to a noxious stimulus.1 Tolerance means “the absence of a 
response” being either a somatic response (e.g., movement, sweating, eye opening), a 
hemodynamic response (increase in heart rate or blood pressure), or an arousal on the 
electroencephalogram of the frontal cortex, which is a reflection of a decreased cerebral 
hypnotic drug effect due to an insufficient analgesic effect. This “component” definition 
is based on the notion that tolerance to verbal and noxious stimulation will be mediated 
through different neuronal networks, which are located in the higher cortical versus 
subcortical structures of the brain, respectively.1 These networks are independently 
affected by the interaction between a hypnotic and an analgesic drug. As an example of 
this, Heyse et al.2 showed different response surface models for tolerance to nonnoxious 
and noxious stimulation. 
In addition to the dichotomous observations of tolerance to stimulation, several 
neurophysiology-derived measures of anesthesia effect have been developed to 
monitor the anesthesia state of the patient in a continuous way. 
Electroencephalographic measures, such as bispectral index (BIS; Covidien, Boulder, 
CO), state entropy (SE), and response entropy (RE) (M-Entropy; GE Healthcare, Helsinki, 
Finland), have a stronger correlation with the hypnotic component than with the 
analgesic component of anesthesia.3 More recently, new continuous measures with 
different neurophysiological background, such as the Surgical Pleth Index (SPI; GE 
Healthcare) and the Composite Variability Index (CVI; Covidien), attempt to quantify the 
balance between nociception and antinociception.4, 5 All these continuous surrogate 
measures of hypnotic or analgesic effect are influenced by the interaction between 
hypnotic and analgesic drugs and should therefore be studied with this multidrug reality 
in mind. Eventually, the ultimate goal of continuous monitoring is to effectively counter 
deviating measurements with an adequate change in the balance between opioids and 
hypnotics so that better clinical results are obtained. This performance can only be 
expected if a well-described dose-response relationship exists between the 
measurements and the applied drug combinations. 
To depict this dose-response relationship in the presence of multiple drugs, it is common 
to use population-derived response surface interaction models.2 For BIS, SE, RE, CVI, and 
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SPI, the interaction between sevoflurane and remifentanil on continuous measures has 
not yet been described. 
Therefore, the primary goal of this study was to develop response surface models that 
best describe the dose-response relationship between the combined administration of 
sevoflurane and remifentanil versus BIS, SE, RE, CVI, and SPI. Overall, we hypothesized 
that the nature of the various interactions should be synergistic for the continuous 
measures as this is in concordance with the interaction on dichotomous clinical 
endpoints as described by Heyse et al.2 The secondary goal of the study was to 
investigate whether noxious stimulation significantly affects the model structure or the 
model parameters. 
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Materials and Methods 
The data presented in this article were collected during a previous study as published by 
Heyse et al.2 This study presents the results of a secondary analysis focusing on the 
continuous measurements of drug effect, whereas the previous study focused on 
dichotomous endpoints of anesthetic effect (clinical signs of responsiveness). The 
studied patients, the crisscross study design, and drug administration methods applied 
in this study have been described elsewhere in detail.2 
Subjects 
After obtaining Institutional Review Board (Ghent University Hospital Ethics Committee, 
Gent, Belgium) approval and prospective trial registration at ClinicalTrials.gov 
(NCT00522587) and after obtaining written informed consent, 40 patients with 
American Society of Anesthesiologists status I or II, aged 18 to 60 yr, and scheduled to 
undergo surgery requiring general anesthesia were included. Exclusion criteria were 
weight less than 70% or more than 130% of ideal body weight, neurological disorders, 
diseases involving the cardiovascular system, pulmonary diseases, gastric diseases, 
endocrine diseases, and recent use of psychoactive medication or use of more than 20 
g of alcohol daily. The complete study was executed in a quiet operating room before 
the start of the surgical procedure. 
Study Design 
This study was performed as a randomized, prospective, open-label study. No 
participant of the study received premedication. After the patients arrived in the 
operating room, standard monitors (electrocardiogram, noninvasive blood pressure, 
and hemoglobin oxygen saturation), M-Entropy using a Datex S/5 Anesthesia Monitor 
(GE Healthcare), and BIS using an Aspect A-2000 monitor (Covidien) were connected, 
and a large forearm vein was cannulated. Thereafter, the patients were preoxygenated 
with 6 l/min of O2 at an FI = 1.0 for 5 min using a tightfitting face mask, which also served 
to sample exhaled air for end-tidal carbon dioxide measurement. Vital signs and end-
tidal sevoflurane concentrations, respiratory data (tidal volume, minute volume, and 
end-tidal carbon dioxide), and infusion-related data (predicted concentrations and 
infused volumes) were continuously recorded on a computer hard disk using RUGLOOP 
II data-recording software (Demed, Temse, Belgium). 
Drug Administration 
Technical Aspects. Remifentanil was administered by a target-controlled infusion 
technique by using RUGLOOP II TCI software (Demed) based on a three-compartment 
model with an effect-site compartment as published by Minto et al.6, 7 Sevoflurane was 
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administered in 50% O2 and 50% air by using a standard out-of-circle vaporizer and a 
standard breathing circuit of an ADU anesthesia workstation (Datex/Ohmeda; GE 
Healthcare). 
Dosing Regimen. We randomized 40 patients to receive four prespecified combinations 
of sevoflurane (0.5 to 3.5 vol%) and remifentanil (0 to 12 ng/ml) according to a 
modification of the crisscross design proposed by Short et al.8 In half of the patients, 
remifentanil was held constant, and sevoflurane was stepwise increased; in the other 
half, sevoflurane was held constant and remifentanil was stepwise increased. The dosing 
schedule is shown in table 1 in the study by Heyse et al.2 No muscle relaxants were 
administered throughout the study. 
Assessment of Clinical Response 
For each concentration step, the clinical response was assessed 12 min after reaching 
the target concentrations to allow for plasma effect-site equilibration. The patient was 
exposed to the following series of stimuli, with increasing intensity: (1) verbal and 
nonpainful tactile stimuli according to the Modified Observer’s Assessment of Alertness/ 
Sedation (OAA/S) score9; (2) a tetanic stimulus of the ulnar nerve for 5 s by using the 
standard neurostimulator; (3) insertion of a laryngeal mask airway (size 3 for women 
and 4 for men, LMA Unique® [The Surgical Company, Amersfoort, The Netherlands]); 
and (4) laryngoscopy aiming at full visualization of the vocal cords by using a size-3 
curved Macintosh- type blade (HEINE Optotechnik GmbH & Co KG, Herrsching, 
Germany). All stimuli – Including laryngoscopy – were performed by a single 
anesthesiologist (B.H.) to minimize interindividual variability in stimulation. Between 
each stimulus, a 1-min delay was maintained to evaluate the somatic responsiveness on 
each stimulus. If there was no response to a stimulus, the next stimulus was applied 1 
min after the response assessment of the previous stimulus.  
In this study, we only compared data before OAA/S score (unstimulated state) with data 
after laryngoscopy (stimulated state). For the data that were obtained in between 
stimuli, we did not estimate separate models. We could not exclude a bias evoked by 
influences of the preceding stimulus on the next one. However, by performing 
simultaneous model estimations on data before and after the sequence of four clinically 
relevant stimulations, we explore pharmacodynamic differences between a generally 
“unstimulated” versus a “stimulated” anesthesia state. 
Data Acquisition and Management 
BIS, SE, and RE. The spectral entropy monitor (M-Entropy; GE Healthcare) calculated SE 
and RE. BIS was simultaneously derived from the frontal electroencephalogram ( At-
Fpzt) by using a quatro BIS™ sensor with four electrodes (Covidien). The smoothing time 
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of the BIS monitor was set at 15 s. All data were recorded electronically using RUGLOOP 
II software (Demed) with a 5-s time interval. 
The median of the recorded values during 1 min before the assessment of the OAA/S 
score was used for the analysis of the BIS, SE, and RE data. 
CVI. The raw electroencephalographic signal was captured by the BIS™ monitor with a
128-Hz sample rate and allowed post hoc calculation of CVI. The calculation of CVI has
been described by Mathews et al.5 The CVI is a composite index that combines the
variability in BIS with frontal electromyographic changes over time. A high CVI reflects
activation of the frontal electromyography and increased input of sensory information
from deep brain structures to the cortex. A low CVI reflects an adequate inhibition of
this sensory input and adequate analgesia. The CVI was calculated with a 5-s time
interval. The median of the recorded values during 1 min before the assessment of the
OAA/S score was used for the analysis. In the case that one or more values were missing
during the last minute before the assessment of OAA/S score due to a technical reason,
the CVI was regarded as a missing value and was not taken into account in the analysis.
SPI. The SPI is derived from plethysmographic pulse wave characteristics combined with 
heart rate variability and is a surrogate measure of the orthosympathetic and 
parasympathetic nervous system response to noxious stimulation. The calculation of SPI 
has been described by Huiku et al.4 The SPI was calculated with a 1-s time interval. The 
median of the recorded values during 1 min before the assessment of the OAA/S score 
was used for the analysis. In the case that there were less than seven values during the 
last minute before the assessment of OAA/S score, the SPI was regarded as a missing 
value and was not taken into account in the analysis. 
Data after Stimulation. A moving median technique was applied on the raw data 
measured during 1 min after laryngoscopy. For the NONMEM analysis, the highest value 
of the moving median over several consecutive values was used. By doing so, the effect 
of single outlier values on the average behavior of each measurement was minimized 
without losing sensitivity for detecting a relevant response on BIS, SE, RE, CVI, and SPI 
after stimulation. For measurements that were logged every 5 s (BIS, SE, RE, and CVI), 
or every second (SPI), we performed the moving median technique over a sequence of 
respectively five or seven consecutive values. In the case that there were less than five 
or seven consecutive values during 1 min after application of laryngoscopy, or if 
laryngoscopy was not applied because the patient was responsive to a previous stimulus 
(see the study by Heyse et al.2), the measurement was considered as missing and was 
not taken into account in the analysis. 
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Pharmacodynamic Analysis of the Continuous Variables 
For the continuous data, a negative sigmoid Emax model was used10: 
 Effect = 𝐸𝐸0 − (𝐸𝐸0 − 𝑅𝑅𝐸𝐸𝐵𝐵𝑊𝑊) × � 𝑈𝑈𝛾𝛾1 + 𝑈𝑈𝛾𝛾�   (1) 
where E0 is the baseline value in the absence of drug, REST is a nonsuppressible effect 
(the lowest possible value of the effect variable), U represents the normalized combined 
potency of one or more drugs, and γ is the slope parameter reflecting the steepness of 
the concentration–effect relationship. The normalized combined potency U is a function 
of the drug effect-site concentrations and model parameters, as described in detail in 
the appendix in the study by Heyse et al.2 The following models were tested: 
a. Greco model
𝑈𝑈 = 𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂
𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 + 𝐶𝐶𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁 + 𝛼𝛼 × 𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 × 𝐶𝐶𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁  (2) 
where CSEVO is the effect-site concentration of sevoflurane, CREMI is the effect-site 
concentration of remifentanil, C50SEVO is the effect-site concentration of sevoflurane 
with 50% effect, C50REMI is the effect-site concentration of remifentanil with 50% effect, 
and α is a dimensionless interaction parameter. 
b. Reduced Greco model without effect of the opioid alone
𝑈𝑈 = 𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂
𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 × �1 + 𝐶𝐶𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁�   (3) 
c. Minto model11
𝑈𝑈 = 𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 + 𝐶𝐶𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁1 − 𝛽𝛽𝑅𝑅50 × 𝜃𝜃 × (1 − 𝜃𝜃)    (4) 
where βU50 is a dimensionless interaction parameter, and θ is defined by: 
𝜃𝜃 = 𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂
𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 + 𝐶𝐶𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁   (5)
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𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 × �1 + � 𝐶𝐶𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁�𝛾𝛾𝑂𝑂�   (6) 
where γO is the slope parameter reflecting the steepness of the concentration–effect 
relationship for remifentanil.  
Because each pharmacodynamic endpoint was analyzed separately, the Scaled C50O and 
Fixed C50O Hierarchical models are identical.2 
For BIS, SE, and RE, it was assumed that the measure approaches zero for high 
concentrations of sevoflurane or remifentanil, so REST is zero, reducing the model to a 
fractional Emax model.10 For CVI and SPI, the nonsuppressible effect REST was modeled 
as a function of the drug concentrations according to the procedure described by Minto 
et al.11: 
𝑅𝑅𝐸𝐸𝐵𝐵𝑊𝑊 = 𝑅𝑅𝐸𝐸𝐵𝐵𝑊𝑊𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 × 𝜃𝜃 + 𝑅𝑅𝐸𝐸𝐵𝐵𝑊𝑊𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁 × (1 − 𝜃𝜃) − 𝛽𝛽𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁 × 𝜃𝜃 × (1 − 𝜃𝜃)  (7) 
where RESTSEVO, RESTREMI, and βREST are model parameters. 
Parameter Estimation 
The model parameters were estimated using NONMEM 7.2.0 (Icon Development 
Solutions, Hanover, MD), using first-order conditional estimation. Platform was 
Windows XP (Microsoft, Redmond, WA) and compiler was G95. For all parameters, 
interindividual variability was assumed either to be absent or to have a lognormal 
distribution. It was tested whether a single value for the individual deviation from the 
typical value (eta in NONMEM) could be used for C50 of sevoflurane and remifentanil, 
in accordance with the assumption that this value reflects the sensitivity of that 
individual for hypnotic and opioid drugs. Residual intraindividual variability of the 
continuous variables was modeled using standard additive or proportional error models. 
Parameters were tested for significance by comparing the objective function which is 
minus two times log-likelihood (−2LL). Significance level for hypothesis tests was 0.01 
( chi-square test), or a 6.84 difference in the −2LL adding one parameter for nested 
models. The goodness-of-fit for the models was also assessed by visual inspection of the 
predicted versus observed plots and the distribution of residuals for each of the 
continuous endpoints. 
Model building was performed starting with the simplest form of each model and 
expanding the model with parameters and interindividual variability until the decrease 
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of the objective function value was not statistically significant using the chi-square test. 
In addition, model building was started with the most complex model, reducing the 
model by fixing parameters to zero. The NONMEM analysis was performed with various 
values for initial estimates and boundary values. The results were accepted as valid only 
if both minimization and covariance steps were successful, unless stated otherwise. 
To evaluate the final model, a bootstrap analysis was performed, based on 2,000 sets of 
40 patients each, randomly selected from the available 40 patients, using a custom 
program written in c. Results were analyzed in Excel (Microsoft) to obtain nonparametric 
95% CIs. 
The poststimulation data after laryngoscopy were analyzed by using an identical 
modeling approach as applied on the prestimulation data. To investigate the effect of 
the stimulations on the model parameters, we performed a simultaneous fitting of the 
data before OAA/S (= unstimulated anesthesia state) and after laryngoscopy (= 
stimulated anesthesia state) in a stepwise model-building process, starting with fixed 
common parameters for both data sets, followed by testing the addition of parameters 
for the difference between before OAA/S and after laryngoscopy. 
Statistical Analysis 
All model parameters are reported as typical values with relative standard error (in % of 
the typical value) within parentheses, and clinical data are given as mean and SD or as 
median and range, when appropriate. 
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Table 1. Population Model Estimates for BIS, SE, RE and CVI 
BIS SE RE CVI 
Interaction 
Model 
Greco/Minto Greco/Minto Greco/Minto Reduced Greco 
C50REMI 









































































Values are typical values, relative standard error (% of the typical value) and 95% CI obtained by 
bootstrapping. 
* Not significantly different from 0; † Common value for remifentanil and sevoflurane; ‡ Additive
error; § Proportional error; || Could not be estimated (for detail, see text). 
BIS = bispectral index; SE = state entropy; RE = response entropy; CVI = Composite Variability
Index; C50REMI = effect-site concentration of remifentanil with 50% effect; C50SEVO = effect-
site concentration of sevoflurane with 50% effect; ΔC50SEVO = increase of C50SEVO after 
laryngoscopy, as obtained in a separate analysis (see text); E0 = baseline value in absence of
drugs; γ = model parameter reflecting the steepness of the concentration-effect relationship;
IIV(C50REMI) and IIV(C50SEVO) = interindividual variability for C50REMI and C50SEVO,
respectively (calculated as the square root of interindividual variance, multiplied by 100%);
Residual SD = SD of the differences between the observed and predicted responses (calculated
as the square root of the residual variance).
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Figure 1. Response surface for electroencephalographic endpoints before stimulation (A, C, E, G) 
and after stimulation (B, D, F, H) was applied: Bispectral index (BIS), state entropy (SE), response 
entropy (RE), and Composite Variability Index (CVI), as a function of the end-tidal steady-state 
sevoflurane concentration and the predicted remifentanil effect-site concentration, calculated 
from the data listed in table 1. Measured values above the surface are shown as filled circles and 
below the surface as open circles. 
Unstimulated Stimulated 
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In total, 40 patients (26 women and 14 men) were included in this study. The 
demographics are as follows: body weight, 66 ± 11 kg; height, 172 ± 8 cm; and age, 30 ± 
11 yr. All patients were classified as American Society of Anesthesiologists status I. 
Data 
In total, the data sets contained 159 periods of testing (40 patients with 4 periods per 
patient minus 1 missing period where no stimulus was given). 
Model Development for BIS 
Initially, BIS data were analyzed using the Greco, Reduced Greco, Minto, and 
Hierarchical models, using a fractional Emax model (REST = 0). For both the Greco model 
and the Minto model, the interaction term for C50 did not differ significantly from zero. 
Similarly, the interaction term for γ in the Minto model did not differ significantly from 
zero. Consequently, both models yield identical results. The objective function value for 
the Greco model (808.5) was markedly lower than that for the Reduced Greco model 
(823.0) and Hierarchical model (822.2), and therefore, the Greco model was considered 
as the most appropriate method. The additional error model fitted better to the data 
than the proportional error model, as concluded from the objective function value and 
diagnostic plots of residuals. 
Final Model for BIS 
The final results for this model are shown in table 1. In the final model, interindividual 
variability was included in C50REMI and C50SEVO with a common eta. The value for C50 for 
remifentanil (27.3 ng/ml) exceeds the upper range of concentrations in the study (12 
ng/ml), but its precision was satisfactory (relative standard error 12%). 
The response surface of the final model is shown in figure 1. Figure 2 depicts the 
observed BIS values (filled symbols) and predicted BIS (solid line) versus the normalized 
combined potency UBIS, which has a sigmoidal Emax relationship. 
Model Development for SE and RE 
The Greco model was found to be the most appropriate model for SE and RE, in 
accordance with the best model for BIS. 
Final Models for SE and RE 
The results of the final models are summarized in table 1. The variability in SE and RE is 
larger than for the BIS data, as reflected in larger relative standard errors, larger 
interindividual variability, and larger residual SD.  
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The response surfaces of the final models for SE and RE are shown in figure 1. Figures 3 
and 4 depict the observed (filled symbols) and predicted (solid line) SE and RE versus the 
normalized combined potencies USE and URE, respectively, which also have a sigmoidal 
Emax relationship. 
Model Development for CVI 
In four patients, the CVI could not be calculated due to missing data. In 17 patients, the 
CVI could not be calculated from the available electroencephalogram registration in one 
or more periods. In total, 122 CVI values in 36 patients were available.  
For CVI, the objective function value of the Reduced Greco model was lower than for 
the Greco model and Minto model. The proportional error model fitted better to the 
data than the additional error model, as concluded from the objective function value 
and diagnostic plots of residuals. Using the Hierarchical model, the slope factor γ for 
remifentanil (0.289) and C50SEVO (0.266 vol.%) was very low, E0 (10.2) was much higher 
than the highest observed CVI value, and standard errors were high; therefore, this 
model was not accepted as a valid model. 
Final Model for CVI 
The results for the final Reduced Greco model are shown in table 1. The residual error 
of 27% is large and the CIs for the model parameters are wide, reflecting the poor fit.  
The response surface of the final model for CVI is shown in figure 1. Figure 5 depicts the 
observed (filled symbols) and predicted CVI values (solid line) versus the normalized 
combined potency UCVI. The CVI has a sigmoidal Emax relationship with UCVI, which is 
comparable in behavior to BIS, SE, and RE. 
Model Development for SPI 
In two patients, the SPI could not be calculated due to missing data. In four patients, the 
SPI could not be calculated from the available plethysmography data in one or more 
periods. In total, SPI data from 145 periods in 38 patients were available.  
Modeling of the SPI data did not result in reliable results. Plotting the SPI data against 
the sevoflurane or remifentanil concentration revealed that the SPI value is hardly 
affected by sevoflurane or remifentanil, in contrast to the BIS, SE, RE, and CVI (data not 
shown). 
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model and the observed bispectral index (BIS) (squares, n = 159) and predicted BIS (solid line; 
calculated from the data listed in table 1) for unstimulated (filled symbols) and stimulated (open 
symbols). 
Figure 3. Relationship between the normalized combined potency USE according to the Greco 
model and the observed state entropy (SE) (squares, n = 159) and predicted SE (solid line; 




Figure 4. Relationship between the normalized combined potency URE according to the Greco 
model and the observed response entropy (RE) (squares, n = 159) and predicted RE (solid line; 
calculated from the data listed in table 1) for unstimulated (filled symbols) and stimulated (open 
symbols). 
Figure 5. Relationship between the normalized combined potency UCVI according to the Reduced 
Greco model and the observed Composite Variability Index (CVI) (squares, n = 122) and predicted 
CVI (lines; calculated from the data listed in table 1) for unstimulated (filled symbols, solid line) 
and stimulated (open symbols, dashed line). 
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Data after Stimulation 
The data after stimulation were first analyzed using an identical modeling approach as 
applied on the unstimulated data. For BIS, SE, and RE, the number of data points was 
114 (in 45 periods, laryngoscopy was not applied for ethical or other reasons). The 
optimal models were identical and the parameters were broadly comparable with the 
results before the assessment of OAA/S, except for C50SEVO, which was consistently 
higher after the series of stimulation (data not shown). 
Next, to investigate this effect of stimulation on the model parameters, we performed 
a simultaneous fitting of the data before OAA/S (= unstimulated anesthesia state) and 
after laryngoscopy in a model-building process (= stimulated anesthesia state), starting 
with fixed common parameters for both data sets, followed by adding parameters for 
the difference between before OAA/S and after laryngoscopy. This analysis revealed 
that C50SEVO was significantly higher after laryngoscopy for BIS, SE, and RE, with an 
average increase of 0.3 vol% sevoflurane (table 1), whereas the other parameters did 
not change. The response surfaces of the final models for BIS, SE, and RE are shown in 
figure 1. Figures 2–4 depict the observed values (open symbols) and predicted values 
(solid line) versus the normalized combined potency U for BIS, SE, and SE, respectively. 
Because the baseline values, maximal effect and steepness of the model are not affected 
by the stimulation, the relationship between U and predicted value is not affected, and 
the solid line is identical for unstimulated and stimulated conditions. For each 
combination of sevoflurane and remifentanil, the value UBIS (similar for USE and URE) after 
stimulation is lower compared with the unstimulated state as a result of the higher 
C50SEVO. Consequently, the predicted BIS after stimulation will be higher than in the 
unstimulated state, reflecting a reduction of the combined drug effect. In other words, 
stimulation moves UBIS to the left, and the predicted BIS upwards along the solid lines of 
figures 2–4. 
In contrast, simultaneous analysis of the CVI data before OAA/S and after laryngoscopy, 
with parameters fixed to the values from the analysis of the data before OAA/S alone 
(table 1), resulted in a lower value for C50REMI (3.09 ng/ml; CI, 1.78 to 4.68 ng/ml), a 
higher value for γ (1.62; CI, 1.28 to 1.79), and E0 (13.1; CI, 9.4 to 17.2). Also, the residual 
SD (46%; CI, 37 to 53%) after stimulation was higher, indicating an even larger variability 
in the dose–response relationship of CVI compared with the unstimulated condition. 
Figure 5 depicts the observed values (open symbols) and predicted CVI (dashed line) 
versus the normalized combined potency UCVI, respectively. Figure 5 also shows the shift 
in dose–response relationship of CVI versus UCVI between the unstimulated  (solid line) 
and stimulated condition (dashed line). Because the baseline and steepness are affected 
by the stimulation, the relationship between UCVI and predicted value is different for the 
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unstimulated and stimulated data. The response surface for CVI after stimulation is 
shown in figure 1. 
The SPI data after stimulation (104 valid SPI values) were analyzed using the same 
approaches. Similar to the unstimulated data, the SPI values after stimulation were 
hardly affected by sevoflurane or remifentanil, and modeling did not result in reliable 
results (data not shown). 
Isoboles 
In figure 6, the isoboles of BIS values from 10 to 80 are depicted for the unstimulated 
(solid lines) and stimulated (dashed lines) condition. The additive nature of the 
interaction results in linear isoboles for the complete range of BIS values. The isoboles 
are shifted upwards after stimulation, reflecting the increase in C50SEVO. 
In figure 7, the isoboles of CVI values from 0.5 to 3 are depicted for the unstimulated 
(solid lines) and stimulated (dashed lines) condition, showing a synergistic nature of the 
interaction, as reflected by the Reduced Greco model. For low CVI values, the isoboles 
of the stimulated condition intersect the isoboles of the unstimulated condition.  
For SPI, no isoboles could be depicted, as we could not fit an appropriate response 
surface model to the data. 
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Figure 6. Isoboles for bispectral index values of 10, 20, 30, 40, 50, 60, 70, and 80 for the 
unstimulated (solid lines) and stimulated (dashed lines) data, as a function of the end-tidal 
sevoflurane concentration and the predicted remifentanil effect-site concentration, calculated 
from the data listed in table 1. 
 
Figure 7. Isoboles for Composite Variability Index values of 0.5, 1, 1.5, 2, 2.5, and 3 for the 
unstimulated (solid lines) and stimulated (dashed lines) data, as a function of the end-tidal 
sevoflurane concentration and the predicted remifentanil effect-site concentration, calculated 




We describe the interaction between sevoflurane and remifentanil on BIS, SE, RE, CVI, 
and SPI. Although opioids have a rather weak effect on the electroencephalogram, we 
found an additive effect of remifentanil on reduction of BIS, SE, and RE by sevoflurane. 
The effect on CVI was synergistic. The SPI was not affected by sevoflurane or 
remifentanil. The Greco model provided the best fit of the data for BIS, SE, and RE, 
whereas the reduced Greco model best described CVI. Interestingly, the structural 
interaction model was not affected by noxious stimulation, but noxious stimulation did 
increase the C50SEVO for BIS, SE, and RE by 20%, whereas the C50REMI did not change. In 
contrast, for CVI all model parameters changed except C50SEVO. 
The findings on (unstimulated) BIS, SE, and RE are in agreement with that reported in 
previous literature. Nieuwenhuijs et al.12 presented an interaction model during 
sevoflurane–alfentanil anesthesia, suggesting additivity for BIS. During propofol 
anesthesia, Vanluchene et al.3 found that remifentanil evoked an increase in the 
threshold for loss of consciousness on BIS, SE, and RE in a dose-dependent way, but no 
conclusion was drawn on the nature of this interaction. Bouillon et al.13 found additivity 
for BIS during propofol–remifentanil anesthesia. Schumacher et al.10 found an additive 
interaction on BIS for combined propofol and sevoflurane. Conversely, the interaction 
of sevoflurane and remifentanil on clinical endpoints of effect, as published by Heyse et 
al.,2 was not additive but synergistic. Also, C50REMI was 10-fold higher for BIS, SE, and RE 
compared with C50REMI for dichotomous endpoints.2 Apparently, the opioid effect on the 
electroencephalogram is weak, despite a strong effect on patient responsiveness. This 
may explain why electroencephalographic variables are poor predictors of 
responsiveness to noxious stimuli. 
According to the parameter estimates (table 1), BIS is least opioid sensitive, followed by 
SE, RE, and CVI, whereas BIS, SE, and RE are equally sensitive to sevoflurane, but less 
than CVI. The slope of the response surfaces is similar for BIS, SE, and RE, but steeper 
than the slope for CVI (fig. 5). The interaction model for BIS is characterized by the lowest 
interindividual (table 1: IIV [C50REMI]) and residual variability. 
Interaction models not only define combined effects of sevoflurane and remifentanil as 
a response surface but also allow expression of the potency of a combination of drugs 
as one dimensionless number. For this purpose, we introduced “U” being units of 
combined potency related to each of the investigated effects variables. For example, 
UBIS is the sum of the sevoflurane and remifentanil concentration both normalized to the 
respective C50s of the BIS dose-response curve (equations 2 and 4). The potency UBIS = 
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1 can be achieved by 1.99 vol% of sevoflurane (=C50SEVO) or (e.g.) by 1.49 vol% of 
sevoflurane (=0.75 × C50SEVO) plus 6.8 ng/ml of remifentanil (=0.25 × C50REMI). As C50 is 
specific for each electroencephalographic variable, one given sevoflurane and 
remifentanil concentration does not yield identical values of “U” for BIS, SE, RE, or CVI. 
According to the final models (table 1), 1.5 vol% of sevoflurane combined with 5 ng/ml 
of remifentanil yields a UBIS, USE, URE, and UCVI of 0.94, 1.13, 1.07, and 2.29, respectively. 
In concordance with Minto et al.,11 we consider the combination of two drugs as a virtual 
new drug. “U” can be used as if it was a drug concentration of that virtual new drug on 
the x-axis of a two-dimensional concentration–response curve (figs. 2–5). With the 
selected interaction models, the combined potency “U” predicted the effect on BIS, SE, 
and RE with an error of approximately 10%, which is comparable to that reported in the 
previous studies.13 
“U” as a number represents potency of a combination of sevoflurane and remifentanil 
to suppress the electroencephalographic variable and has similarities with the Noxious 
Stimulation Response Index.14 The Noxious Stimulation Response Index is based on the 
suppression of a response to laryngoscopy, using the Hierarchical interaction model. The 
C50REMI (1.16 ng/ml) in this model is much lower than the C50REMI in the current study 
(7.5 to 27.3 ng/ml, depending on the type of electroencephalographic variable). This 
makes Noxious Stimulation Response Index much more opioid sensitive compared with 
“U,” which is in agreement with the fact that hypnotics have a stronger effect on 
electroencephalogram than the effects of opioids on electroencephalogram. The clinical 
utility of any of the “U”s or Noxious Stimulation Response Index to titrate opioids and 
hypnotics remains to be determined. 
The CVI as a potential indicator of nociception behaved similar as dichotomous 
endpoints in the previous study2: the interaction was synergistic. The best fit was found 
with the reduced Greco model. As expected, the concentration–response curve of CVI 
was affected by noxious stimulation (figs. 5 and 7), especially due to a substantial 
increase in baseline effect (E0), probably due to an increase in electromyographic 
activity. The dose-response curve was rather flat, and a ceiling effect was observed at 
the level of a CVI of approximately 1 (fig. 5). This explains why a larger increase of the 
sevoflurane concentration is needed to lower CVI from 1 to 0.5 than that required to 
lower CVI from 3 to 2.5 (fig. 7). Although noxious stimulation and opioids evoke a greater 
effect on CVI than on BIS, SE, and RE, CVI may offer lower discriminating capacity 
compared with BIS, SE, and RE. Even in our best-fitted model, the differences between 




The poststimulation data set represents a population that is in a pharmacological 
pseudosteady state (at similar drug concentrations as before stimulation), where the 
applied stimuli may have disrupted the balance between drug concentrations and effect 
variables. Assuming that noxious stimulation might induce an arousal response on the 
electroencephalographic variables, we hypothesized that the parameter estimates from 
the poststimulation data could be different from those of the prestimulation data. We 
expected larger differences in model estimates for CVI and SPI compared with BIS, SE, 
and RE, as the arousal response in BIS is already suppressed by rather low remifentanil 
concentrations.15 
For all poststimulation response surface models, the structural model with the lowest 
objective function was identical to the prestimulation model. For BIS, SE, and RE, the 
model parameters hardly changed, except for C50SEVO (consistently 0.3 vol% higher after 
laryngoscopy). This pharmacodynamic shift is consistent for BIS and entropy and it is 
only little smaller than the difference between C50SEVO for tolerance of shake and shout 
and laryngoscopy, found in the previous article (0.53 vol%).2 Typical accuracy for 
measuring sevoflurane end-tidal concentrations is ±0.15 vol% + 5% of reading. The time 
between nonstimulation and poststimulation sampling did not exceed 6 min and 
therefore was assumed to be constant. Therefore, we consider 0.3 vol% (or 14% of 1 
minimal alveolar concentration) as clinically relevant. The sevoflurane and remifentanil 
concentrations mentioned above (1.5 vol% and 5 ng/ml) yield a poststimulation U for 
BIS, SE, and RE which is approximately 10% lower than the prestimulation U. Therefore, 
both single-model parameters (e.g., C50s) and combined potency U could be used as 
surrogate measures of stimulus intensity. 
For CVI, the changes in the poststimulation model are complex. C50REMI decreased to 
3.09 ng/ml. Gamma and the baseline effect (E0) increased. The increased steepness of 
the dose-response curve and the larger difference between baseline and maximal effect 
suggest an improved descriptive capacity for CVI in stimulated compared with 
unstimulated conditions. However, the residual SD and the standard errors of the 
parameters indicate a larger variability in the dose-response relationship compared with 
the unstimulated condition. Our finding is in agreement with the notion that a noxious 
stimulus is mandatory to measure the balance between nociception and antinociception 
accurately. 
For SPI, we were not able to extract plausible parameter estimates from our data, 
neither from prestimulation nor from poststimulation observations. Either SPI is hardly 
affected by sevoflurane and remifentanil or the inter- and intraindividual variability of 
SPI hides a minimal dose– response relationship. The sympathetic and parasympathetic 
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nerve system may be affected by many confounding factors apart from noxious 
stimulation and anesthetic drug dosages. The inability to detect any dose–response 
relationship in steady-state conditions, both with or without noxious stimulation, lowers 
the expectations for SPI as a guide for titrating sevoflurane and remifentanil anesthesia. 
In conclusion, sevoflurane and remifentanil are additive on BIS and entropy, but they act 
synergistic on CVI. SPI is not correlated to drug concentrations. Noxious stimulation did 
not change structural models but increased the C50 of sevoflurane related to BIS and 
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Background: The probability to tolerate laryngoscopy (PTOL) and its derivative, the 
noxious stimulation response index (NSRI), have been proposed as measures of potency 
of a propofol–remifentanil drug combination. This study aims at developing a triple drug 
interaction model to estimate the combined potency of sevoflurane, propofol, and 
remifentanil in terms of PTOL. We compare the predictive performance of PTOL and the 
NSRI with various anaesthetic depth monitors. 
Methods: Data from three previous studies (n=120) were pooled and reanalysed. 
Movement response after laryngoscopy was observed with different combinations of 
propofol–remifentanil, sevoflurane–propofol, and sevoflurane–remifentanil. A triple 
interaction model to estimate PTOL was developed. The NSRI was derived from PTOL. The 
ability of PTOL and the NSRI to predict observed tolerance of laryngoscopy (TOL) was 
compared with the following other measures: (i) effect-site concentrations of 
sevoflurane, propofol, and remifentanil (CeSEVO, CePROP, and CeREMI); (ii) bispectral index; 
(iii) two measures of spectral entropy; (iv) composite variability index; and (v) surgical
pleth index.
Results: Sevoflurane and propofol interact additively, whereas remifentanil interacts in 
a strongly synergistic manner. The effect-site concentrations of sevoflurane and 
propofol at a PTOL of 50% (Ce50; standard error) were 2.59 (0.13) vol% and 7.58 (0.49) 
μg ml-1. A CeREMI of 1.36 (0.15) ng ml-1 reduced the Ce50 of sevoflurane and propofol by 
50%. The common slope factor was 5.22 (0.52). The PTOL and NSRI predict the movement 
response to laryngoscopy best. 
Conclusions: The triple interaction model estimates the potency of any combination of 
sevoflurane, propofol, and remifentanil expressed as either PTOL or NSRI. 
Probability to tolerate laryngoscopy and noxious stimulation response index as general 




Adequate anaesthesia can be defined as the combination of an accurate level of 
hypnosis with sufficient analgesia to avoid response to a noxious stimulation, where 
‘response’ includes a variety of modalities, such as movement, haemodynamic 
response, or arousal. Most contemporary anaesthetic depth monitors are based on the 
processed EEG and correlate mainly with hypnotic drug effect; however, they do not 
reliably predict a response to noxious stimulation.1, 2 Recent attempts to measure 
analgesia, based on the variability of the processed EEG signal3 or on changes in the 
autonomic nervous system as measured by pulse plethysmography,4, 5 were only partly 
successful. Similar decreasing accuracy was found for the propofol effect-site 
concentration (CePROP) as a measure of drug effect in the presence of opioids.1, 2 
For decades, the probability of response to skin incision, defined as the minimal alveolar 
concentration (MAC), has been used to quantify and compare the potency of volatile 
agents.6-9 More recently, Bouillon and colleagues10 defined tolerance of laryngoscopy 
(TOL) as an absence of movement response to laryngoscopy, and they proposed the 
probability to tolerate laryngoscopy (PTOL) as an alternative to MAC when using propofol 
instead of volatile agents. For ergonomic reasons and in order to cope with the clinical 
conformity of standard depth of anaesthesia monitoring, Luginbühl and colleagues11 
normalized and calibrated PTOL towards a new index called the noxious stimulation 
response index (NSRI). The NSRI is a numerical depth of anaesthesia indicator that is 
directly derived from PTOL and was first described for propofol and remifentanil 
anaesthesia. The NSRI and PTOL are therefore interchangeable; they merely differ in 
scale. The NSRI is scaled between 100 (when no anaesthetic drugs are administered) and 
zero (indicating extensive combined drug effects), whereas PTOL scales from zero to one. 
Until now, specific PTOL results have been found in three different drug interaction 
studies, resulting in separate response surface models for propofol–remifentanil,10 
sevoflurane–propofol,12 and sevoflurane–remifentanil.13 In order to use PTOL (and NSRI) 
as general probabilistic parameters to represent the lack of responsiveness to a noxious 
stimulation in both i.v. and volatile anaesthesia conditions, supplemented with opioids, 
one needs to solve the problems of whether synergy of remifentanil with propofol is 
stronger than synergy with sevoflurane and whether the slope of the propofol–
remifentanil and the sevoflurane–remifentanil response surfaces are different. This may 
be clarified by developing a triple interaction surface model, merging the information 
from the previously published dual drug models,10, 12, 13 hereby also rescaling and 
expanding previously published PTOL and NSRI scales. 
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For clinicians, a general PTOL and its derivative, NSRI, would enable estimation of the 
concentration of sevoflurane that is equipotent to a given propofol concentration when 
used in combination with remifentanil. 
The primary purpose of the present study was to define a triple interaction response 
surface model to express the potency of any combination of sevoflurane, propofol, and 
remifentanil in terms of PTOL and NSRI by merging the raw data from three previously 
published studies.10, 12, 13 The secondary purpose was to test the ability of PTOL and NSRI, 
calculated with the new triple interaction model parameters, to predict the observed 
TOL. We compared the performance of PTOL and NSRI with other measures, such as single 
drug effect-site concentrations of sevoflurane, propofol, and remifentanil (CeSEVO, 
CePROP, and CeREMI), current hypnotic effect monitors, such as the EEG-derived bispectral 
index (BIS; Covidien, Boulder, CO, USA)14 and two measures of the EEG-derived spectral 
entropy, state entropy and response entropy (SE and RE; GE Healthcare, Helsinki, 
Finland),15 and newer analgesic effect monitors, such as the BIS-derived composite 
variability index (CVI; Covidien)3, 16 and pulse plethysmograph-derived surgical pleth 
index (SPI; GE Healthcare).5 
Probability to tolerate laryngoscopy and noxious stimulation response index as general 




We performed a response surface analysis of the pooled raw data from three previously 
published studies on interactions between sevoflurane, propofol, and remifentanil.10, 12,
13, 17 The Ethics’ Committees from these original studies (Ghent University Hospital, 
Gent, Belgium and Stanford University, Stanford, CA, USA) both agreed that the 
anonymized original databases could be re-used for this analysis. As the original studies 
were executed and published long before the introduction of the public registration 
requirements, no registration of the original studies was possible. 
The characteristics of the study populations are summarized in Supplementary File 1 and 
in the Results section. The study design and drug administration protocol have been 
described in detail in each of the studies. Briefly, combinations of propofol–
remifentanil,10 sevoflurane–propofol,12 and sevoflurane– remifentanil13, 17 were 
administered using a modified crisscross design according to Short and colleagues.18 
Propofol and remifentanil were administered as computer-controlled infusions 
targeting effect-site or plasma concentrations using the pharmacokinetic and 
pharmacodynamic models by Schnider19, 20 and Minto,21, 22 respectively. While Bouillon 
and colleagues10 used targeted plasma concentrations and observed an equilibration 
time of 15 min, Schumacher and colleagues12 and Heyse and colleagues13, 17 applied 
target effect-site concentrations with an equilibration time of 12 min. Sevoflurane was 
titrated to achieve predetermined end-tidal concentrations using an ADU ventilator with 
an integrated AS3 monitor (GE Healthcare). These equilibration times are considered 
sufficient for all drugs to allow equilibration between the plasma and effect-site 
concentration. Acceptable prediction errors of the Schnider and Minto models were 
confirmed in the propofol–remifentanil study by means of repetitive blood sample 
analysis for propofol and remifentanil published previously.23 A steady state for 
sevoflurane was confirmed through end-tidal measurements of sevoflurane 
concentrations. In all three studies, after equilibration of plasma and effect-site 
concentrations, a series of stimuli was applied and the presence or absence of 
movement response recorded. However, only TOL was used in our final analysis after 
initial model validation (see Results section). 
The following drug effect monitors were used: BIS (BIS Version 3.22, A1000; Covidien) 
by Bouillon and colleagues;10 BIS (Version 4.0, A-2000; Covidien); and SE and RE (M-
Entropy; GE Healthcare) by Schumacher and colleagues12 and Heyse and colleagues.17 
Additionally, Heyse and colleagues17 computed the composite variability index (CVI; 
Covidien) and the surgical pleth index (SPI; GE Healthcare) off-line from the recorded 
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raw EEG and pulse plethysmograph data, respectively. Detailed information can be 
found in the original publications. 
Pharmacodynamic model 
The synergistic interactions between propofol and remifentanil and between 
sevoflurane and remifentanil were best described by the modified hierarchical model,10,
13, 23 whereas the additive interaction between sevoflurane and propofol was best 
described by the Greco model.12 We therefore postulated that the interaction of the 
three compounds could be described by considering any combination of the three drugs 
as a virtual new drug with the potency ‘U’.13, 24 
Equation (1) is the sigmoidal response function for a dichotomous effect: 
𝑃𝑃𝑁𝑁𝑂𝑂𝐿𝐿 = 𝑈𝑈𝛾𝛾1 + 𝑈𝑈𝛾𝛾  (1) 
where PTOL is the probability of TOL, γ is the slope parameter that represents the 
steepness of the concentration–effect relationship, and U is the combined potency of 
the drugs according to equation (2): 
𝑈𝑈 = � 𝐶𝐶𝑝𝑝𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂
𝐶𝐶𝑝𝑝50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 + 𝐶𝐶𝑝𝑝𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀𝐶𝐶𝑝𝑝50𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀� × �1 + � 𝐶𝐶𝑝𝑝𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶𝑝𝑝50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁�𝛾𝛾𝑜𝑜�   (2) 
where CeSEVO, CePROP, and CeREMI are the effect-site concentrations of sevoflurane, 
propofol, and remifentanil, respectively, Ce50SEVO and Ce50PROP are the effect-site 
concentrations of sevoflurane and propofol, respectively, resulting in PTOL =0.5 if given 
alone, Ce50REMI is the effect-site concentration of remifentanil that results in an increase 
of U by a factor of 2 or an apparent decrease of the Ce50SEVO and Ce50PROP by 50%, and 
γo represents the steepness of the concentration–effect relationship of the opioid. 
According to the parameter estimates of the original studies (Table 1), our hypothesis 
was that Ce50REMI, γo, and γ were different for sevoflurane and propofol, and we 
assumed a linear interpolation. The null hypothesis was that these parameters were 
similar. Linear interpolation was performed according to equations (3)–(5): 
𝐶𝐶𝑝𝑝50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁 = 𝐶𝐶𝑝𝑝50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁(𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂) × 𝐵𝐵𝑆𝑆 + 𝐶𝐶𝑝𝑝50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁(𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀) × (1 − 𝐵𝐵𝑆𝑆)     (3) 
𝛾𝛾𝑜𝑜 = 𝛾𝛾𝑜𝑜(𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂) × 𝐵𝐵𝑆𝑆 + 𝛾𝛾𝑜𝑜(𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀) × (1 − 𝐵𝐵𝑆𝑆)                              (4) 
𝛾𝛾 = 𝛾𝛾(𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂) × 𝐵𝐵𝑆𝑆 + 𝛾𝛾(𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀) × (1 − 𝐵𝐵𝑆𝑆)                                (5) 
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where SF is the sevoflurane fraction defined in equation (6): 
𝐵𝐵𝑆𝑆 = 𝐶𝐶𝑝𝑝𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 𝐶𝐶𝑝𝑝50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂⁄
𝐶𝐶𝑝𝑝𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 𝐶𝐶𝑝𝑝50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂⁄ + 𝐶𝐶𝑝𝑝𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀 𝐶𝐶𝑝𝑝50𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀⁄  (6) 
Thus, SF=0 if CeSEVO=0, and SF=1 if CePROP=0, and SF is between zero and one for mixtures 
of sevoflurane and propofol. Note that the final models in the three original studies10, 12,
13, 17 are equivalent to equations (1)–(6), with the following specific constraints: γo =1 in 
the study by Bouillon and colleagues,10 and γ(SEVO)=γ(PROP) in Schumacher’s study.12 
The purpose of the model developed from the data is to predict PTOL of random 
individuals in a population. Similar to the MAC, a PTOL of 50% is the concentration where 
50% of a population tolerates laryngoscopy without movement response (TOL). The 
individual concentration–response of the ‘typical subject’ was therefore not the focus 
of the study, and inter-individual variability was not included in the parameter 
estimation (naive pooling approach). 
Selection of the final model and parameter estimation 
In the first step, the data from each study were separately fitted to the model [equations 
(1)–(6)] in order to determine the effect of considering only TOL instead of the whole 
series of stimuli as previously published. In the second step, a fit of the pooled TOL data 
was performed. In the pooled fit, the parameters Ce50SEVO, Ce50PROP, Ce50REMI, γ1, and 
γo were estimated assuming that the parameters Ce50REMI, γo, and γ were identical for 
the two hypnotics sevoflurane and propofol. Then we tested whether different values 
for Ce50REMI, γo, or γ for sevoflurane and propofol significantly improved the fit. In 
addition, we tested whether γo was significantly different from one. The results were 
accepted as valid only if both minimization and covariance steps were successful, unless 
stated otherwise. 
The model parameters were estimated using NONMEM 7.2.0 (Icon Development 
Solutions, Hanover, MD, USA), using the Laplace method. The software was installed on 
a GNU Fortran 95 compiler (http://gcc.gnu.org) with Windows XP operating system 
(Microsoft, Redmond, WA, USA). PLT Tools (PLTsoft, San Francisco, CA, USA) was used 
as graphical user interface. 
To determine the final model, non-parametric 95% confidence intervals (CIs) were 
calculated, using a bootstrap analysis based on 2000 sets, stratified according to the 
original studies. Assuming a χ2 distribution with one degree of freedom, an 
improvement of the objective function value of 3.84, corresponding to a value of P<0.05, 
was considered significant. 
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The PTOL was calculated from equation (1) and NSRI from equation (7): 
𝑁𝑁𝐵𝐵𝑅𝑅𝐵𝐵 = 1001 + � 𝑃𝑃𝑁𝑁𝑂𝑂𝐿𝐿1 − 𝑃𝑃𝑁𝑁𝑂𝑂𝐿𝐿�𝑜𝑜   (7) 
where s is a constant (s=0.63093). 
For further information on the transformation of PTOL to NSRI, see Supplementary File 2. 
Model evaluation 
The data of responders and non-responders were plotted together with the 50 and 90% 
isoboles, derived from the original models,10, 12, 13, 17 and the final model for visual 
inspection of the goodness of fit. Additionally, we plotted the observed PTOL against the 
PTOL predicted by all models to compare the ability of the final model for PTOL with the 
previously published models. The observed PTOL was obtained from the raw data 
according to the following procedure. For each observation (response or no response to 
laryngoscopy), the predicted PTOL was calculated from the effect-site concentrations and 
model parameters (Table 1) using equations (1) and (2). Then the predicted PTOL of each 
observation and the related true response (0 or 1) were sorted with increasing value of 
predicted PTOL. The observed PTOL was defined as the average of the response of the 
index observation and the next 10 observations with a lower and a higher predicted PTOL. 
The observed PTOL is thus a moving average over 21 observations, where the missing 
values at the lower and upper end were omitted. The resulting plots allow a visual 
inspection of the goodness of fit, as shown in Supplementary File 3. The mean absolute 
prediction error (MAPE) was calculated as the mean of the absolute value of the 
difference between the observed and predicted PTOL. For clarification to the reader, the 
‘observed PTOL’ is used only for this specific model validation. Otherwise in this work, 
‘PTOL’ always refers to the ‘predicted PTOL’. 
In a second validation, we used the raw data of two original studies for parameter 
estimation and the raw data of the third study for model validation, as shown in the 
Supplementary File 4. 
Assessment of prediction probability 
The prediction probability (PK) is based on multiple comparisons of two data points from 
the total data set, to investigate the degree of association between each predictor and 
the observed tolerance. A PK value of 0.5 implies no association, thus a poor prediction 
probability; a value of one implies complete association, thus an excellent prediction 
probability.25, 26
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We used PK to assess the performance of predicted PTOL, its derivative, NSRI, and the 
observed BIS, SE, RE, CVI, and SPI to predict TOL. For comparison, the PK values of the 
single drug concentrations (CeSEVO, CePROP, and CeREMI) were also determined. Using 
single drug concentrations as estimates of the likelihood of tolerance does not take into 
account the effect of simultaneously administered drugs; therefore, we hypothesized 
that they are less accurate than the predicted PTOL as a result of this limitation. 
The drug concentrations, their related variables, and the monitor records immediately 
before the stimulus series were used as independent variables to predict the response. 
To ensure that the predicted PTOL and its derivative, NSRI, are independent of the 
observed PTOL, the calculation of PK for PTOL and NSRI was performed by a two-fold cross-
validation procedure. The total data set was divided into two subsets, each containing 
60 patients, randomly drawn from the propofol–remifentanil10 (10 patients), 
sevoflurane–propofol12 (30 patients), and sevoflurane–remifentanil13 (20 patients) 
studies. In each subset, a population interaction model was modelled and used for 
calculating PTOL and NSRI in the other subgroup. The parameter estimates for calculating 
PTOL and NSRI from one subgroup were thus used to validate the prediction in the other 
subgroup. 
Bootstrapping (1000 replicates) was used to determine 95% CIs of the PK values for each 
predictor and also the difference between the PK values of each combination of two 
predictors. Significance was achieved if the 95% CI of the difference did not include zero 
(p<0.05). 
All PK calculations were performed in Excel 2003 (Microsoft) using VBA macros. 
Statistical analysis 
In all patients, we were able to compare the predictive performance of predicted PTOL, 
NSRI, CeSEVO, CePROP, CeREMI, and BIS to predict TOL (PK performance comparison 1). In 
data obtained from the sevoflurane–propofol and the sevoflurane–remifentanil studies, 
SE and RE were additionally available as predictors (PK performance comparison 2). In 
the data obtained from the sevoflurane– remifentanil study, SPI and CVI were also 
evaluated, as predictors of TOL (PK performance comparison 3). Results of each 
performance comparison should be seen as a separate test of performance because the 
data sets are different. 
Statistical significance is set to P<0.05 unless stated otherwise. All model parameters are 
reported as typical values with standard error within parentheses. Clinical data are given 
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The characteristics of the populations of the three studies were comparable. The mean 
(range) weight was 69 (50–120), 66 (50– 102), and 64 (50–103) kg in the propofol–
remifentanil,10 the sevoflurane–propofol,12 and the sevoflurane–remifentanil13 trial, 
respectively. The mean height was 169 (155–184), 172 (150– 190), and 172 (157–186) 
cm, the mean age 34 (20–43), 30 (18–58), and 26 (18–54) yr, and the gender ratio 
(female/male) 10/10, 33/27, and 26/14, respectively. 
Common response surface of sevoflurane, propofol, and remifentanil 
The results of the reanalysis of the three studies by separate and pooled analysis of the 
laryngoscopy data are summarized in Table 1, together with the results reported in the 
original papers. The separate reanalysis of each study gave slightly different results from 
those reported in the original paper, because only the laryngoscopy data were included 
and because inter-individual variation of the parameter estimates was not included in 
our analysis. 
In the pooled analysis of the laryngoscopy data from the three studies, we could not 
confirm the hypothesis that Ce50REMI and γ are different for sevoflurane and propofol. 
In addition, γo was not significantly different from one. When the Ce50REMI was allowed 
to vary between sevoflurane and propofol, the parameter estimates were 1.37 and 1.33 
ng ml-1, respectively, with an ‘improvement’ of the NONMEM objective function of 
0.018. When γ was allowed to vary between sevoflurane and propofol, the parameter 
estimates (standard error) were 5.55 (0.74) and 4.71 (0.87), respectively, with an 
improvement of the NONMEM objective function of 0.420. As a result, the data of the 
three studies can be well described with only four model parameters (Ce50SEVO, 
Ce50PROP, Ce50REMI, and γ), with good precision (i.e. the standard error values were 
smaller than in the original papers and in the separate analysis; Table 1). Equation (2) 
may therefore be simplified to: 
𝑈𝑈 = � 𝐶𝐶𝑝𝑝𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂
𝐶𝐶𝑝𝑝50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 + 𝐶𝐶𝑝𝑝𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀𝐶𝐶𝑝𝑝50𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀� × �1 + 𝐶𝐶𝑝𝑝𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶𝑝𝑝50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁�   (8) 
also known as the reduced Greco model.7, 17 Equation (8) is thus the final model of the 
combined effect of sevoflurane, propofol, and remifentanil. 
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Figure 1. The observed movement response and non-response to laryngoscopy is presented as a 
function of the total potency of the drug combination expressed as ‘U’ [equation (8)]. A value of 
one denotes tolerance of laryngoscopy (no movement); a value of zero denotes movement 
response. Data are from the propofol–remifentanil study,10 sevoflurane–propofol study,12 and 
sevoflurane–remifentanil study.13 The sigmoid concentration–response curve represents 
equation (1) with the final model. 
The CIs calculated from the bootstrap analysis are presented in Table 1. In order to 
calculate PTOL using equation (1), U was calculated using equation (8) by entering the 
parameter estimates of the pooled analysis in the formula (Table 1). Figure 1 shows the 
presence or absence of TOL as a function of U. 
Model evaluation 
The 50 and 90% TOL isoboles and the raw data of responders and non-responders are 
shown in Figure 2A-C. The MAPE was calculated for the following three models: (i) a 
model as published (i.e. computed from the raw data of each single study including the 
response to all applied stimuli); (ii) a model reanalysed from the data of each single study 
including the response to laryngoscopy only; and (iii) the final model computed from the 
pooled data of all three studies including response to laryngoscopy only. For propofol–
remifentanil, the MAPEs of the predicted PTOL of the resulting models were 1.8, 2.3, and 
3.9%, respectively. For sevoflurane–propofol, the MAPEs were 14.6, 6.8, and 6.9%, and 
for sevoflurane–remifentanil, the MAPEs were 5.3, 3.0, and 4.1%, respectively. Thus, the 
MAPE values of the triple interaction model are close to those of the separate reanalysis 
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of each study and are lower than those obtained from the published models, except for 
propofol–remifentanil, where MAPE is low for all models. The reason for the rather large 
MAPE for the sevoflurane–propofol data is visible in Figure 1. In the absence of 
remifentanil, the maximal U was only 1.56, which was only little above the range of U 
where responders and non-responders were observed. A plot of observed vs predicted 
PTOL allowing for a visual inspection of the goodness of fit is presented in Supplementary 
File 3. The result of the cross-validation based on parameter estimation from the raw 
data of two studies and validation with the raw data of the third study is presented in 
Supplementary File 4. 
Prediction probability 
Table 2 shows the results for PK to assess the performance of PTOL, its derivative, NSRI, 
and the observed BIS, SE, RE, CVI, and SPI to predict TOL. For comparison, the PK values 
of the single drug concentrations (CeSEVO, CePROP, and CeREMI)were also determined and 
are shown in Table 2. 
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Figure 2. Goodness-of-fit 
plot of the tolerance of 




fentanil (c) combinations. 
Non-responders and res-
ponders to laryngoscopy are 
indicated. To avoid 
superposition of multiple 
responses at the same 
point, concentration values 
were slightly modified by 
adding a random value with 
mean zero and SD 0.1. The 
50% (continuous lines) and 
90% (dashed lines) isoboles 
calculated with the original 
models (blue, green, purple, 
respectively)10, 12, 13 and the 
new interaction model 
(green; Table 1) are plotted 
with the BIS 40 (pink dashed 
line) and BIS 60 (pink 
continous line) isoboles 
according to the original 
response surface model.10,
12, 17 For remifentanil 
concentrations >2 ng ml−1 , 
the 90% PTOL isobole is 
between the BIS 40 and BIS 
60 isobole, which cor-
responds to clinical dosing 
practice. The additive iso-
bole for the sevoflurane and 
propofol interaction 
(straight lines) are well above the BIS 40 isobole, which reflects the fact that the EEG-suppressing 
effect of the two hypnotic drugs is much stronger than the potency to suppress the response to 
laryngoscopy. 
Ce = effect-site concentration; Cet = end-tidal concentration; BIS = bispectral index. 
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With a pooled analysis of data from three previously published studies of similar design 
on dual drug interactions, a triple interaction model was developed to describe the 
anaesthetic potency of combinations of sevoflurane, propofol, and remifentanil in terms 
of PTOL and its derivative, the NSRI. The model that fits the data best can be interpreted 
as an extension of the hierarchical hypnotic–opioid interaction model published 
previously.10, 12, 13, 23 We found that the interaction between sevoflurane and propofol is 
additive when their concentrations are normalized to their respective effect-site 
concentration inducing TOL in 50% of the population. This is a confirmation of earlier 
work.12, 27, 28 Remifentanil has a strong but equally synergistic effect on sevoflurane and 
propofol. In contrast to original publications,10, 12, 13 the pooled analysis did not support 
different Ce50 values for remifentanil nor different slope factors for sevoflurane and 
propofol. This is not surprising, because the standard error values of both parameters 
were ∼20% in the study by Heyse and colleagues13 and ∼40% in the study by Bouillon 
and colleagues10 for Ce50REMI, and the 95% CIs for the slopes were overlapping in all 
three studies. As such, our common Ce50REMI and slope are within the standard error of 
the values published previously (Table 1). 
Various model validation methods were applied and proved that our final model 
describes the data accurately and represents clinical reality. In Figure 2, the 50 and 90% 
PTOL isoboles calculated with the triple interaction model and with the previous two-drug 
interaction model.10, 12, 13 are plotted together with the raw data from the three studies 
to demonstrate the goodness of fit. Additionally, the clinically used BIS 40 and BIS 60 
isoboles as predicted from previous studies are shown.10, 17 The difference in the shape 
of the isoboles is related to the difference in Ce50 values and the different slopes 
between current and previously published models (Table 1). For remifentanil 
concentrations >2 ng ml-1, the 90% PTOL isobole is between the BIS 40 and BIS 60 isobole, 
which corresponds to clinical dosing practice. This is consistent with previous data on 
the sevoflurane–remifentanil interaction by Manyam and colleagues,29 who 
demonstrated that the 95% isobole for suppressing response to tetanic stimulation was 
between the BIS 60 and 70 isobole at remifentanil concentrations greater than ∼3 ng 
ml-1. The additive 50 and 90% isoboles for the sevoflurane and propofol interaction
(straight lines) are well above the BIS 40 isobole, which reflects the fact that the EEG-
suppressing effect of the two hypnotic drugs is much stronger than the potency to
suppress the response to laryngoscopy.
In a general sense, PTOL can be considered an extension of the clinically applied MAC 
concept.6 For the first time, the potency of inhaled and i.v. hypnotic drugs can be 
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compared uniformly. Using our triple interaction model, the potency of any combination 
of sevoflurane, propofol, and remifentanil can be expressed as PTOL or its derivative, 
NSRI. For example, a CeREMI of 3 ng ml-1 combined with either a CePROP of 3 μg ml-1 or a 
CeSEVO of 1.03 vol% will yield a PTOL of 0.7 or an NSRI of 31 and are thus considered 
equipotent. A more detailed clinical application is shown in Supplementary File 5. In a 
simulated anaesthesia induction with a bolus of propofol and a remifentanil target-
controlled infusion, the time when sevoflurane needs to be administered depends on 
the size of the propofol bolus and the remifentanil concentration. The interaction model 
allows compensation for the decay of the propofol effect-site concentration by 
increasing the effect-site concentration of sevoflurane, in order to maintain a 
predefined total potency of the drugs in terms of PTOL. 
In the population, TOL was best predicted by PTOL and NSRI (Table 2), whereas CeSEVO, 
CePROP, CeREMI, and BIS were intermediate (0.7) and CePROP was a poor predictor of TOL. 
In data obtained from the sevoflurane–propofol and the sevoflurane–remifentanil 
studies, SE and RE were also available and showed a moderate predictive accuracy, 
similar to BIS. In the data obtained from the sevoflurane–remifentanil study, CVI was 
found to be a moderately accurate predictor of TOL. The SPI was not able to predict TOL. 
Both PTOL and NSRI outperformed the other measures in both sub-analyses. 
A limitation of our study is that our triple interaction model is based on pooled data from 
three independently performed two- drug interaction studies, so no patient was given a 
combination of all three drugs. As a result, our model neither detects nor excludes a 
superimposed triple interaction in patients who receive all three drugs simultaneously. 
In a large triple interaction study on midazolam, propofol, and alfentanil, Minto and 
colleagues24 found significant synergistic interactions of each pair of these compounds 
but no additional triple interaction when three drugs were combined. A significant and 
relevant triple interaction does not therefore seem likely, considering the additive 
interaction between sevoflurane and propofol, and the strong and similar synergistic 
interaction of remifentanil with both hypnotic drugs. Our model does produce 
predictions about PTOL when all three drugs are administered simultaneously, and these 
predictions are open to hypothesis testing. Outside of our model, these predictions are 
not available because no other triple interaction model exists for these drugs in current 
literature. 
In conclusion, our response surface interaction model allows estimation of the potency 
of any combination of sevoflurane, propofol, and remifentanil as the probability to 
tolerate laryngoscopy. The PTOL and its derivative, the NSRI, are good predictors of TOL. 
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Clinical applicability needs further validation in a prospective study, with surgical and 
other standardized stimuli. 
Supplementary material 
Supplementary material is available at British Journal of Anaesthesia online. 
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Summary and discussion 
Apart from the ever-continuing development of new anesthetic drugs, advances in 
anesthetic pharmacology and its application in clinical anesthetic practice have in recent 
years focused on more accurate titration of anesthesia. This research consists of 
exploration of the pharmacokinetic (PK) and pharmacodynamic (PD) properties of 
anesthetic drugs, development of PKPD models, exploration of the interactions between 
different drugs and modeling these interactions as well. This knowledge and these 
models can then be used in anesthetic practice through the use of target-controlled 
infusion (TCI) systems, and interaction drug displays to increase accuracy of (multi-)drug 
titration. The main aim of this thesis is to contribute to several components of these 
advancements: the development of PKPD models, complex interaction models using 
multiple drugs, and also expanding on an interaction parameter which can be used in 
clinical practice to guide anesthesia. 
Chapter 1 provides a basic overview on what is currently known about 
pharmacokinetics, pharmacodynamics, PK-, PD- and PKPD-modeling, interactions and 
interaction modeling, and an overview of dexmedetomidine, a drug which is 
investigated extensively in this thesis. 
Chapter 2 starts off at the basis of all modeling, the development of an optimal PK 
model, as no PD modeling or interaction modeling can be performed without an 
adequate PK model. In the case of dexmedetomidine, several PK models already exist, 
but these have several flaws that limit their use in clinical practice. As explained in 
Chapter 1, a model is only as good as the data which it describes. Several tactics were 
used to provide optimal conditions for developing a good model: 1) the experiment 
involved healthy volunteers to exclude drug interactions and comorbidities, 2) the 
inclusion of a broad range of subject weight, height and age, 3) the use of arterial blood 
sampling, 4) the use of TCI drug infusion and 5) using simulations before the start of the 
study to determine the best dosing scheme and sampling times to allow for good 
estimation of model parameters. We also studied each volunteer twice, which enabled 
us to investigate whether factors such as stress and ‘uncertainty of the unknown’ in 
session 1 compared to session 2 influences pharmacokinetics of dexmedetomidine, 
perhaps through changes in hemodynamics. 
This resulted in the development of a three-compartment PK model, with allometric 
weight scaling on the volumes of all three compartments and elimination clearance. The 
intercompartmental clearances were found to be better scaled allometrically to the 
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volumes of their respective compartments, rather than to weight. Age, height and fat-
free mass were not found to be covariates for the model. 
One problem with compartmental pharmacokinetic modeling for intravenous drugs is 
that it assumes immediate mixing of a bolus dose in the central compartment. This is 
however not compatible with reality, as a drug injected in a vein is not immediately 
mixed in the whole bloodstream, but has to circulate before it is fully mixed, all the while 
peripheral distribution already takes place (mainly in the lungs as the drug passes 
through the pulmonary circulation before reaching the arterial sampling site). This 
process is called front-end kinetics. Avram et al.1 investigated how to set up a 
compartmental PK study that will accurately describe front-end kinetics as modeled by 
a recirculatory model. They found that data collected during and after a brief infusion 
instead of a bolus may describe front-end kinetics better than a bolus assuming 
instantaneous mixing and no distribution at t=0, combined with early sampling. This can 
prevent extensive back-extrapolation to t=0 and helps to correctly determine the central 
compartment volume. Very early sampling may however introduce inaccuracies due to 
incomplete mixing of the drug in the blood stream. In our study, by using a priori 
simulations to determine the best dosing scheme and sampling times, we were able to 
determine that an initial short infusion and early sampling after this initial infusion 
would enable us to optimally describe the volume of the central compartment, V1. This 
likely enabled us to describe front-end kinetics more accurately than standard dosing 
would. 
An interesting finding in Chapter 2 was that the variability between sessions 
(interoccasion variability) was greater than interindividual variability for the central 
compartment volume V1. We did not find a systematic change between session 1 and 
session 2, but the greater interoccasion variability does suggest that unknown factors 
changing over time have a greater influence on pharmacokinetics of dexmedetomidine 
than differences between individuals. What these factors are, can only be guessed at.  
Chapters 3 and 4 expand on the pharmacokinetic model that was developed in chapter 
2, by adding several pharmacodynamic profiles to the model, resulting in PKPD models 
of both sedative and hemodynamic effects. These are the first PKPD models that have 
been developed for dexmedetomidine. 
Chapter 3 focusses on the sedative effects, and describes two pharmacodynamic 
models, which are linked to the PK model through the use of two effect-site 
compartments each with their own equilibration rate constant. The first model is based 
on the effect of dexmedetomidine on the bispectral index (BIS), an EEG-derived hypnotic 
monitor, the second model is based on the Modified Observer’s Assessment of 
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Alertness/Sedation score (MOAA/S), a score which assesses the level of sedation based 
on responses to verbal, tactile and noxious stimuli. 
The unique sedative effects of dexmedetomidine in maintaining rousability provided its 
challenges. Not only was this the case for ‘planned’ stimuli, when MOAA/S scores were 
assessed, but also other uncontrollable stimuli, both external (sudden loud sounds 
filtering through the headset) and internal (thirst, pruritus etc.). As a result of these 
stimuli, the BIS would increase, and as the study subject settled down again, the BIS 
would slowly decrease again. A second form of (continuous) stimulation performed 
during the study, was the presence or absence of recorded operating room background 
noise. 
The effect of dexmedetomidine on BIS is best described by an Emax model, with a C50BIS 
of 2.63 ng/ml and a rather slow effect-site equilibration rate (ke0BIS of 0.120 min-1; T½ 
5.8 min). We were able to implement the phenomenon of increased BIS due to sudden 
stimulation by introducing a stimulated and unstimulated state, where a subject would 
immediately go into a stimulated state after MOAA/S scoring with a 2.7-fold increase in 
C50BIS, and over time revert back to an unstimulated state when no further stimulation 
took place, with a half-time of 5.3 minutes. We did not find an effect of the continuous 
background noise on the BIS model, neither did we find other covariates for the model 
(inter-occasion variability, age, weight, height, gender). 
The MOAA/S model is different from most models, because the MOAA/S score is not 
dichotomous like the probability of tolerance of laryngoscopy, nor is it a continuous 
scale such as the BIS, MAP or HR, but an ordinal parameter. Therefore, we used logit 
transformations and assessed cumulative probabilities (i.e. probability of MOAA/S ≤ 3). 
The effect of dexmedetomidine on MOAA/S is best described by an Emax model, with a 
C50MOAA/S of 0.428 ng/ml and a ke0MOAA/S of 0.0428 min-1 (T½ 16.2 min). Contrary to the 
BIS model, we found that adding effects of a previous stimulation only minimally 
improved the model for MOAA/S, without increase in predictive value and with 
increased numerical difficulties during modeling; therefore, we did not include this in 
the model. As for the BIS-model, inter-occasion variability, age, weight, height and 
gender were not significant covariates. 
In contrast, however, we found that background noise did influence the MOAA/S model. 
Whereas our initial hypothesis was that the presence of background noise would lessen 
the effect of dexmedetomidine by increasing the C50 (the noise would keep the 
volunteer ‘more awake’), we found that noise increased the effect of dexmedetomidine, 
and the C50 was increased for the sessions where background noise was absent. A 
possible theory is that the auditory stimuli (volunteer’s name being spoken) produce a 
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greater change in relative volume against a silent environment than against the 
presence of background noise, thereby causing the subject to be more responsive. 
However, we found that the difference remained for noxious stimuli, with a difference 
in frequency of MOAA/S 0 (no response to trapezius squeeze), suggesting that other 
mechanisms may modulate the effect of background noise on responsiveness during 
dexmedetomidine sedation. 
An interesting finding was that the probability of observing an MOAA/S score of 1 (the 
subject responds to a noxious stimulus but not to a non-noxious (tactile) or verbal 
stimulus) was very small. The model thus shows that subjects are far more likely to either 
respond to a non-noxious stimulus (MOAA/S ≥ 2) or tolerate a noxious stimulus 
(MOAA/S = 0). During the study, a MOAA/S score of 1 was rare (about 10% of all 
observations), and we commonly observed a subject progressing from MOAA/S 2 
(response to shake and shout) directly to a MOAA/S 0 (no response to trapezius squeeze) 
with increasing dexmedetomidine concentrations. Clinically, this would indicate that 
although subjects sedated with dexmedetomidine remain rousable at relatively higher 
doses, once they no longer respond to verbal or tactile stimuli, they are unlikely to 
respond to noxious stimuli. 
In contrast to PD models for other anesthetic drugs such as propofol2 and remifentanil3, 
in our study age was not found to be a significant covariate for the relationship between 
dexmedetomidine concentration and either BIS or MOAA/S. By using age-stratified 
inclusion of volunteers, we assumed a high a priori chance of identifying whether age is 
a covariate for the sedative effects of dexmedetomidine. The fact that age was not a 
significant covariate in our model, may be due to the small number of subjects, or 
perhaps there truly is no effect of age. It might be that whereas the neuronal pathways 
that mediate sedation caused by propofol and other sedatives are influenced by age-
related factors, the different pathways mediating dexmedetomidine-induced sedation 
are not. 
Chapter 4 focusses on modeling the hemodynamic side effects of dexmedetomidine, 
namely mean arterial pressure (MAP) and heart rate (HR).  
For the MAP model, we were able to model the biphasic effect through the use of two 
Emax models with two different effect-sites for hypotension and hypertension. The 
effect-site for hypertension has a faster ke0 and a higher C50 and Emax than the effect-
site for hypotension. This allows for a mathematical explanation of the clinical 
observation that a bolus or rapid infusion of dexmedetomidine results initially in a short 
hypertensive phase, changing to hypotension after a few minutes, as well as the biphasic 
effect in that at higher concentrations, the hypertensive effect is stronger than the 
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hypotensive effect. This is also compatible with the physiologic substrate of the biphasic 
effect: the hypertensive effect is mainly through receptors in the arterial smooth muscle 
cells, while the hypotensive effect is partly through receptor activation in the vascular 
endothelium, and in a large part by activation of adrenoceptors in the central nervous 
system. It is likely that the effect-site for hypertension rises faster than the 
concentration in the central nervous system. The ‘turning point’ was reached at an 
average concentration of 2.4 ng/ml, where the MAP returned to baseline, and at higher 
concentrations changed to hypertension. There was a correlation between the baseline 
MAP and size of effect on hypotension, where subjects with higher baseline MAP 
experienced a more profound hypotensive effect. The maximum hypertensive effect 
was 43% above baseline. The only covariate found was an effect of age on baseline MAP, 
where MAP increased by 5.2% for every 10 years. No other covariates (weight, height, 
gender) were found for the MAP model. 
Our model also describes the lengthy duration of hypotension after termination of 
dexmedetomidine infusion adequately. It is known from previous publications4, 5 that 
the hypotensive effects persist for up to 4-5.5 hours after the start of infusion. 
Extrapolation of our model, as seen in Table 2 of Chapter 4 shows that it could take up 
to 10 hours for MAP to return to within 5% of baseline. As there are no studies, including 
our own, with a follow-up beyond 5-6 hours after termination of dexmedetomidine 
infusion, the time to recovery of MAP remains to be validated. 
Applying an Emax or sigmoid Emax model for HR resulted in numerical instability. The use 
of a non-linear effect model according to Schoemaker6 resulted in better goodness of fit 
than a linear model. The Schoemaker model stabilizes the modeling when data near Emax 
is sparse, as is the case in this study, where we found a lower boundary of HR of 22.5 
bpm while HR in our subjects did not reach below 40, as that was a criterium for stopping 
dexmedetomidine infusion. The effect-site equilibration rate constant was relatively 
high, indicating faster changes in heart rate with changes in plasma concentration. None 
of the possible covariates, age, weight, height and gender, were found to be significant 
covariates. 
Chapter 4 also focusses in part on the combined PKPD of sedation and hemodynamics 
by demonstrating through the use of simulations – which are available in the online 
supplement – how certain dosing strategies affect dexmedetomidine plasma 
concentrations, BIS, MOAA/S scores, MAP and HR. This simulation can help to determine 
the best dosing strategies, considering the need for fast clinical sedative effect, without 
compromising safety in the form of hemodynamic problems. The simulations also allow 
for different infusion rates, to determine the effects on mainly heart rate and 
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hypertension of rapid infusions or bolus doses. Although our model does show an initial 
hypertension from rapid infusions as is compatible with clinical data, it is still an 
extrapolation from the study, as we only used 6 – 10 µg kg-1 h-1 as maximum infusion 
rates, and these simulations should be considered with that in mind. 
Chapter 5 moves away from single-drug modeling, and advances into the realm of drug 
interaction modeling. The study is an extension of a previous sevoflurane-remifentanil 
interaction study. In the initial study, the interaction between these two drugs on the 
tolerance of several stimuli (both non-noxious and noxious) was assessed. In Chapter 5, 
the effect of the drug combinations on continuous parameters was investigated. The 
continuous parameters consist of 3 measurements marketed as (mainly) hypnotic 
monitors, namely the electroencephalograph (EEG) derived bispectral index (BIS), state 
entropy (SE) and response entropy (RE), and 2 marketed as (mainly) analgesic monitors, 
the composite variability index (CVI) and the surgical pleth index (SPI). CVI is calculated 
from BIS variability and frontal electromyographic activity, whereas the SPI is derived 
from plethysmographic pulse wave characteristics and heart rate variability. 
Response surface modeling methodology was used to describe the interaction between 
sevoflurane and remifentanil for each continuous parameter. For this, several different 
interaction models were explored, as explained in detail in the Appendix of the original 
interaction study by Heyse et al.7, and in short in Chapter 1 of this thesis. These models 
result in a parameter U, which is the combined potency of both drugs, normalized to 
their own C50s, and may be seen as a ‘virtual’ new drug with concentration U. U can 
then be used to describe the concentration-effect relationship. 
For the three hypnotic monitors, BIS, SE and RE, the interaction was found to be additive, 
and best described by the Greco model, and the effect was best described by a sigmoid 
Emax model. The C50s for remifentanil for each of these monitors was high, especially in 
the case of BIS, where the C50 exceeded the concentrations used in the study (27.3 
ng/ml). This suggests that EEG, in particular BIS, is only minimally influenced by 
remifentanil. Similar C50s for sevoflurane suggest that all three parameters are equally 
sensitive for sevoflurane. For CVI, the interaction was found to be moderately 
synergistic, and best described by the reduced Greco model. The effect was also best 
described by a sigmoid Emax model. This model had large variability and a poorer fit than 
the hypnotic monitors. SPI modeling did not result in reliable parameters, and plotting 
of the SPI with sevoflurane and remifentanil concentrations showed no reliable 
influence of either drug on SPI.  
The effect of (noxious) stimulation, namely laryngoscopy, on the continuous parameters 
was also assessed, and the same modeling techniques were applied to the post-
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stimulation data, to explore changes in model parameters after noxious stimulation. For 
the BIS, SE and RE, all model parameters were found to be similar, except for the C50SEVO, 
which was consistently higher post-stimulation, by an average of 0.3 vol%. In contrast, 
for CVI, the C50SEVO was the only parameter that remained the same post-stimulation, 
whereas C50REMI decreased, and γ and E0 increased. The already large variability of CVI 
increased further after stimulation. The increased slope and larger difference between 
baseline effect and maximal effect post-stimulation suggest that for CVI, noxious 
stimulation is necessary to be able to assess the balance between nociception and 
antinociception. SPI post-stimulation remained the same, and like pre-stimulation, 
modeling did not provide reliable results. 
Whereas the interaction between sevoflurane and remifentanil is known to be 
synergistic for clinical dichotomous endpoints such as tolerance of noxious stimuli, this 
study shows the interaction on continuous hypnotic monitors to be additive, with only 
a small effect of remifentanil on these parameters. This is consistent with previous 
findings, not only on the interaction between sevoflurane and opioids8, but also 
between propofol and opioids.9, 10 This may explain why EEG-derived parameters in 
general are poor predictors of these clinical dichotomous endpoints when hypnotic-
opioid combinations are used. 
Chapter 6 investigates the triple interaction between sevoflurane, propofol and 
remifentanil on the tolerance of laryngoscopy. It combines three previous two-drug 
interaction studies, propofol-remifantanil10, propofol-sevoflurane11 and sevoflurane-
remifentanil.7  
Based on the findings in the original three studies (propofol-remifentanil: synergistic 
interaction, best described by Hierarchical model; propofol-sevoflurane: additive 
interaction, best described by Greco model; sevoflurane-remifentanil: synergistic 
interaction, best described by Hierarchical model), the hypothesis was that the triple 
interaction would be best described by a Hierarchical model between hypnotics 
(propofol and sevoflurane) and opioids (remifentanil), and an additive model between 
the two hypnotics: 
𝑈𝑈 = � 𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂
𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 + 𝐶𝐶𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀𝐶𝐶50𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀� × �1 + � 𝐶𝐶𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁�𝛾𝛾𝑜𝑜�   (1) 
where U is the combined potency of the drugs, normalized to their respective C50s and 
γo is the slope of the opioid concentration-effect curve. The effect, probability of 
tolerance of laryngoscopy, or PTOL was calculated as follows: 
Summary, discussion and future perspectives 
151 
7 
𝑃𝑃𝑁𝑁𝑂𝑂𝐿𝐿 = 𝑈𝑈𝛾𝛾1 + 𝑈𝑈𝛾𝛾  (2) 
where, γ is the slope parameter, or steepness of the concentration-effect relationship 
for the combined drug effect. Because C50REMI, γo and γ differed in the models between 
the propofol-remifentanil and sevoflurane-remifentanil interaction, we assumed a priori 
that this would also differ in the model, where the ‘total’ C50REMI, γo and γ would be a 
combination of the values for propofol and sevoflurane, depending on the 
propofol:sevoflurane ratio. 
In the final triple interaction model, C50REMI and γ for sevoflurane and propofol were not 
found to be significantly different from each other. Also, γo was found not to be 
significantly different from 1, which means the model can be simplified to a reduced 
Greco model with an additive interaction between sevoflurane and propofol:  
𝑈𝑈 = � 𝐶𝐶𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂
𝐶𝐶50𝑁𝑁𝐿𝐿𝑅𝑅𝑂𝑂 + 𝐶𝐶𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀𝐶𝐶50𝑀𝑀𝑅𝑅𝑂𝑂𝑀𝑀� × �1 + 𝐶𝐶𝑅𝑅𝑁𝑁𝑁𝑁𝐶𝐶50𝑅𝑅𝐿𝐿𝑁𝑁𝑁𝑁�   (3) 
Chapter 6 also reintroduces the Noxious Stimulation Response Index (NSRI), which has 
previously been published by Luginbühl et al.12 The NSRI as published by Luginbühl was 
based on a propofol-remifentanil interaction study by Struys et al.13 and in our study, 
we used the triple interaction study as basis for the new NSRI. Contrary to most 
parameters used in clinical practice for the assessment of anesthesia, NSRI is not a 
measured but a calculated parameter. It is a transformation of PTOL (Eq. 2): 
𝑁𝑁𝐵𝐵𝑅𝑅𝐵𝐵 = 1001 + � 𝑃𝑃𝑁𝑁𝑂𝑂𝐿𝐿1 − 𝑃𝑃𝑁𝑁𝑂𝑂𝐿𝐿�𝑜𝑜   (4) 
where s = 0.63093, so that a PTOL of 0.5 corresponds with an NSRI of 50 and a PTOL of 0.9 
results in an NSRI of 20. 
The NSRI is scaled from 100 to 0, where at 100 there is no drug effect, and the patient is 
very likely to be awake (barring other circumstances inducing reduced consciousness), 
and 0 indicates profound drug effect, with near 0 probability that the patient will 
respond to laryngoscopy. The NSRI has potential clinical use as an alternative to MAC, 
which is the minimum alveolar concentration of a volatile anesthetic at which 50% of 
patients do not move during surgical incision. MAC is, like the NSRI, a calculated 
parameter derived from population studies, in this case with volatile anesthetics. It has 
been used in daily clinical practice for decades, and every anesthesiologist is familiar 
with the concept of MAC. A downside of MAC is that it is only one point on the 
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concentration-effect relationship, namely C50. Other points have been distinguished in 
the past, such as MAC95, or the concentration of a volatile anesthetic where 95% of 
patients tolerate skin incision, but these values are rarely used in clinical practice, and 
volatile anesthetic delivery devices often only show end-tidal concentrations and end-
tidal concentrations relative to MAC. Another issue is that MAC itself does not take any 
interactions into account. Numerous MAC-reduction studies have been performed, 
which assess the reduction in MAC due to for instance opioids or nitrous oxide, but like 
MAC95, they are not used in clinical practice beyond the knowledge of the type of 
interaction (synergistic, additive). 
The NSRI with the triple interaction model provides information about not only one 
drug, but (currently) up to three drugs, and not only at the level of C50 or 50% probability 
of tolerance of laryngoscopy, but the full range of effect. An NSRI of 20 indicates a 90% 
probability of tolerance of laryngoscopy, regardless of whether this NSRI is achieved by 
sevoflurane alone or any combination of two or even all three drugs. Because the 
anesthesiologist is already used to working with a population-derived calculated 
parameter in MAC, the step towards using the NSRI to guide anesthesia should not be a 
large one, with the additional advantages to guide not only one drug but multiple drugs 
with changing concentrations as may happen during induction of anesthesia, where 
anesthesia is induced with propofol and maintained using a volatile anesthetic, 
combined with opioid administered through bolus doses or continuous infusion. 
A limitation of this study is that no patients received all three drugs together in the 
whole study population, so an additional triple interaction on top of the currently 
modeled interaction cannot be excluded definitively. A study by Minto et al.14 on the 
interaction between midazolam, propofol and alfentanil did not find a triple interaction 
when all three drugs were combined, on top of the synergistic interactions between the 
pairs of drugs. Considering the similarly strong synergistic interaction between 
remifentanil and both hypnotics in our study, and the additive interaction between 
propofol and sevoflurane, an additional triple interaction on top of this is unlikely. 
Finally, as an initial method of validation Chapter 6 investigates the performance of 
multiple parameters from the three original 2-drug interaction studies (effect-site 
concentrations of the three drugs, the three hypnotic monitors BIS, SE and RE, and the 
analgesic monitors CVI and SPI, where available), and the PTOL/NSRI from this study, to 
predict the probability of tolerance of laryngoscopy, using the prediction probability PK, 
as described by Smith et al.15 A PK of 1 means there is a perfect correlation; a PK of 0.5 
means 50-50 chance, thus equal to flipping a coin. For the PTOL/NSRI predictions, the 
dataset was divided into two groups, one for modeling and the second to assess the 
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performance of the calculated parameters, to ensure the parameter is not based on the 
same dataset on which it is then tested. Bootstrapping was then used to determine 
whether there was a significant difference in PK between two different parameters. In 
all comparisons, PTOL/NSRI were significantly better predictors compared to any of the 
other parameters, with a PK higher than 0.9, with all other parameters having a PK lower 
than 0.8. This is a promising initial validation for the use of NSRI as a clinical parameter 
to help guide anesthesia. 
Conclusions and future perspectives 
In the first part of this thesis we developed a comprehensive PKPD model for 
dexmedetomidine. Not only is this the first PKPD model for dexmedetomidine, but there 
are several rather unique components to this model, like the description of the 
arousability in BIS, the effect of background noise on MOAA/S, and the biphasic effect 
of dexmedetomidine on MAP. When used in target-controlled infusion, likely only one 
part of the model (BIS or probability of a certain MOAA/S score) may be targeted, but 
the hemodynamic part of the model may facilitate implementation of limitations to the 
infusion to enhance the safety of dexmedetomidine infusion. Aside from use in TCI, 
simulations using the model may help to better understand the characteristics of 
dexmedetomidine on sedation and hemodynamics, and visualization of the model in 
realtime displays may guide dexmedetomidine sedation and its hemodynamic side 
effects with or without the use of TCI. However, the model still has to be validated in 
another population, as only limited internal validation has taken place by use of 
graphical analysis and out-of-sample validation techniques. The model is also able to 
describe the initial hypertension after a bolus or rapid infusion. As the infusion rate was 
limited in the study, this is an extrapolation of the model and also needs to be validated. 
Also, since the model was developed in a healthy volunteer population, the model will 
have to be validated in a patient population to evaluate its performance in the presence 
of possible comorbidities. Future uses of the dexmedetomidine PKPD model are not only 
in clinical practice as mentioned before, but also in future interaction studies between 
dexmedetomidine and other anesthetic drugs such as propofol or opioids. A good PK or 
PKPD model is essential for adequate interaction modeling.  
The second part of this thesis describes such interaction modeling studies and 
techniques on the interaction between sevoflurane and remifentanil, as well as the 
triple interaction sevoflurane-propofol-remifentanil. The sevoflurane-remifentanil 
interaction study focusses on the effect on continuous measurements, as well as the 
effect of noxious stimulation on this interaction. It is mainly descriptive, but clearly 
demonstrates that while it is known that opioids have a strong effect on clinical 
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anesthetic endpoints such as tolerance of noxious stimuli, the effect on hypnotic EEG-
derived monitors is weak. This enforces the notion that EEG-monitors are poor 
predictors of anesthetic depth which includes analgesia in the presence of noxious 
stimulation (the balance between nociception and antinociception). The analgesic 
monitor CVI can also only describe the antinociceptive effect in the presence of a 
noxious stimulus, reducing its use to predict beforehand whether a patient will respond, 
and the poor fit and high variability suggests that it is also not a very strong predictor. 
The analgesic monitor SPI is unable to describe the interaction between sevoflurane and 
remifentanil, nor the effect of noxious stimulation. This study therefore shows that there 
still is not a good monitor that can predict adequacy of anesthesia of both the hypnotic 
and the analgesic component. Studies like this may be used in the future to investigate 
whether newer monitors are perhaps better at assessing depth of anesthesia. 
The triple interaction study and the use of the triple interaction NSRI may help guide 
depth of anesthesia in the absence of adequate monitoring. Our study shows that NSRI 
is a better predictor of tolerance of laryngoscopy than currently used monitors of drug 
effect and single-drug effect-site concentrations. The NSRI also has to be validated in 
separate studies and populations, as again only internal validation using cross-
evaluations have been performed. But if NSRI proves to be a valuable guide to 
anesthesia, the possibilities for this parameter may be endless, as other drugs may be 
included into the calculations after interaction studies with these other drugs have been 
performed. For instance, if interaction studies with dexmedetomidine and any of the 
three drugs currently in the NSRI have been performed, dexmedetomidine can be added 
to the NSRI (limited to the drug combinations with which interaction studies have been 
performed). 
In all, every study in this thesis focusses on reaching the same goal: more accurate drug 
titration towards what is deemed adequate anesthesia and increasing the safety of 
anesthesia. In 2003 and again in 2016, Talmage Egan and Steve Shafer coined the 
process of drug titration towards a point on the Emax curve ‘surfing the concentration-
response curve’,16, 17 or ‘surfing the wave’. This is not only the case for single drug 
titration; it can also be an analogy for drug titration with multiple drugs, where the 
‘wave’ is not a two-dimensional concentration-effect curve, but a three-dimensional 
response surface model. This thesis therefore provides the means to facilitate surfing 
the wave in anesthesia practice. 
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Samenvatting en discussie 
Naast de ontwikkeling van nieuwe medicijnen binnen de anesthesiologie, ligt de nadruk 
in wetenschappelijk onderzoek binnen de anesthetische farmacologie op het 
nauwkeuriger toedienen en titreren van anesthetische middelen. Dit gebeurt aan de 
hand van onderzoeken naar de farmacokinetische (PK) en farmacodynamische (PD) 
kenmerken van de bestaande middelen en het ontwikkelen van zogenoemde PKPD 
modellen (farmacokinetiek/farmacodynamiek modellen), om de verhouding tussen 
dosering en het effect beter te begrijpen. Daarnaast omvat het ook onderzoeken naar 
interacties tussen verschillende middelen en het ontwikkelen van interactiemodellen. 
Uiteindelijk kan dit in de klinische praktijk toegepast worden door het gebruik van TCI 
pompen (target-controlled infusion, ofwel titratie op een bepaalde spiegel in het bloed 
of een bepaalde mate van effect) en door het visualiseren van interacties tijdens een 
narcose. Zo kan de nauwkeurigheid van de toediening van één of meerdere middelen 
tegelijk verbeterd worden. Het belangrijkste doel van dit proefschrift is om op meerdere 
vlakken in deze tak van wetenschap een bijdrage te leveren: het ontwikkelen van PKPD 
modellen, interactiemodellen tussen meerdere anesthetische middelen, en het 
uitbreiden van een bestaande interactieparameter welke gebruikt kan worden om een 
narcose te sturen. 
Hoofdstuk 1 geeft een basale weergave over de huidige kennis betreffende 
farmacokinetiek (hoe een bepaalde dosering resulteert in een bepaalde spiegel in het 
bloed), farmacodynamiek (hoe een bepaalde spiegel in het bloed of in een orgaan een 
effect bewerkstelligt), het ontwikkelen van farmacokinetische, farmacodynamische en 
gecombineerde PKPD modellen, evenals wat er bekend is over interacties en het 
ontwikkelen van interactiemodellen. Ook geeft het een overzicht over 
dexmedetomidine, wat één van de middelen is waar in dit proefschrift onderzoek naar 
is gedaan. Heel kort samengevat wordt PK vaak beschreven door een compartimenteel 
model: een model met meerdere vaten met een bepaald volume, aan elkaar gekoppeld 
door leidingen (zie ook figuur 2 in hoofdstuk 1) die een bepaalde klaring leveren tussen 
de compartimenten, plus een leiding die naar ‘buiten’ loopt (waardoor het middel het 
lichaam verlaat, in de praktijk meestal door verwerking door de lever of uitscheiding 
door de nieren). Het centrale compartiment (compartiment 1) komt ruwweg overeen 
met de bloedcirculatie, en vaak zijn er 1 of 2 perifere compartimenten. De 
farmacodynamiek wordt vaak beschreven door een zogenaamde ‘effect-site’ aan het 
centrale compartiment te koppelen, vanwaar het middel naar het orgaan/de receptoren 
gaat waar het zijn werk uitoefent. Dit zijn overigens allemaal wiskundige modellen die 
het beschrijven van het tijdsverloop van een spiegel of effect vereenvoudigen, maar de 
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compartimenten zijn niet rechtstreeks te vergelijken met een anatomisch of fysiologisch 
substraat. 
Hoofdstuk 2 begint met de basis, het ontwikkelen van een PK model. Immers, zonder 
goed PK model is er geen goed PKPD of interactiemodel te maken. Dexmedetomidine is 
een middel voor sedatie (‘roesje’ in de volksmond), dat tevens een angstverminderend 
en enig pijnstillend effect heeft. Voor dit middel zijn er al een aantal PK modellen, echter 
deze zijn onderhevig aan een aantal onnauwkeurigheden, wat het gebruik ervan in de 
klinische praktijk negatief beïnvloedt. Belangrijk voor het ontwikkelen van een goed 
model is het hebben van goede data. Slechte data kan een model geven dat de data 
goed beschrijft, maar slecht overeenkomt met de realiteit. Voor het ontwikkelen van 
ons dexmedetomidine-model hebben we daar zo goed mogelijk geprobeerd rekening 
mee te houden. Zo hebben we gezonde vrijwilligers onderzocht in plaats van patiënten, 
waardoor de invloed van ziekten of andere medicatie tot een minimum beperkt is. 
Daarnaast hebben we vrijwilligers met een brede verdeling van leeftijd, gewicht en 
lengte onderzocht, om zo te kunnen beoordelen of deze factoren invloed hebben op de 
farmacokinetiek. Het gebruik van bloedafnames uit de slagader in plaats van een ader 
kan zo ook fouten in de modellen verminderen, omdat het betere informatie geeft over 
de spiegels in het bloed dat naar de organen gaat waar het middel zijn werking op 
uitoefent. Het gebruik van TCI kan ook mogelijk de nauwkeurigheid van het nieuwe 
model verbeteren, en daarnaast hebben we van tevoren rekenkundige simulaties 
uitgevoerd om uit te zoeken met welke doseringsschema’s en tijdstippen voor 
bloedafname de meeste informatie over de verschillende parameters van het PK model 
gehaald konden worden. Bovendien hebben we elke vrijwilliger twee maal onderzocht, 
waardoor we ook de invloed van factoren als stress en ‘angst voor het onbekende’ 
tussen sessie 1 en sessie 2 op de farmacokinetiek van dexmedetomidine, wellicht door 
veranderingen in de hemodynamiek (= bloedcirculatie, zoals te beschrijven door 
bloeddruk en hartfrequentie). 
We hebben uiteindelijk een zogenoemd drie-compartiment PK model ontwikkeld, 
waarbij de parameters van de compartimenten (volumes en klaringen), deels indirect, 
afhankelijk zijn van het gewicht (door middel van allometrische schaling). Leeftijd en 
lengte hadden geen invloed op het model. Een probleem dat optreedt met 
compartimentele modellen, is dat het model er vanuit gaat dat een middel direct na 
toediening gelijk wordt verdeeld over de hele bloedsomloop. Dit komt niet overeen met 
de werkelijkheid, en kan voor fouten in het model zorgen. Een manier om dit deels te 
omzeilen is het gebruik van een langzamere toediening van het middel in plaats van een 
snelle toediening, gecombineerd met een bloedafname die niet te vroeg (het middel is 
nog niet verdeeld over het bloed) of te laat is (laat in het traject van een snelle daling 
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van de spiegel, waarmee een te hoog V1 geschat wordt). Ook in onze studie hebben we 
dit toegepast, met naar het lijkt een betere beschrijving van het volume van 
compartiment 1. 
Een interessante bevinding in hoofdstuk 2 is dat de variabiliteit tussen de twee sessies 
een grotere invloed had op V1 dan de variabiliteit tussen individuen. Dit verschil was 
niet systematisch tussen sessie 1 en 2, maar het suggereert wel dat er factoren zijn die 
met de tijd veranderen die van grotere invloed zijn op V1 dan de verschillen tussen twee 
personen. Wat deze factoren zijn, is op dit moment nog geheel onduidelijk. 
In hoofdstukken 3 en 4 gebruikten we het in hoofdstuk 2 ontwikkelde dexmedetomidine 
PK model en pasten daarop een PD model toe, om zo een uitgebreid PKPD model te 
kunnen maken, met de effecten van dexmedetomidine op sedatie (gewenst effect) en 
hemodynamiek (bijwerkingen). Dit zijn de eerste PKPD modellen die ontwikkeld zijn 
voor dexmedetomidine. 
Hoofdstuk 3 gaat vooral in op de invloed van dexmedetomidine op sedatie: de BIS 
(bispectral index), een meting die gebaseerd is op het elektro-encefalogram (EEG, 
‘hersenfilmpje’), en de MOAA/S score, de Modified Observer’s Assessment of 
Alertness/Sedation, een scoresysteem naar de reactie van een persoon op (luid) 
aanspreken, schudden en/of een pijnprikkel. Dexmedetomidine is een uniek 
sedatiemiddel in de zin dat een persoon zelfs bij vrij hoge doseringen wekbaar blijft. Dit 
maakte het ontwikkelen van de modellen ingewikkelder, omdat bij elke prikkel (door 
het uitvoeren van een MOAA/S score, maar ook andere ‘ongeplande’ prikkels als ander 
geluid, dorst of jeuk) de persoon wakkerder wordt, en daarmee de BIS ook stijgt. Dit 
effect hebben we ook in ons model kunnen implementeren, door een factor toe te 
voegen die de invloed van zulke stimulatie weergeeft. Indien een stimulatie plaatsvindt, 
springt het model over naar de ‘gestimuleerde toestand’, wat effectief betekent dat de 
C50, of de concentratie die nodig is voor 50% van het maximale effect, met ruim 2,5 keer 
vermenigvuldigd wordt, ofwel: er is ruim 2,5 keer zo hoge concentratie nodig om 50% 
van het maximale effect te bewerkstelligen. Wordt de persoon met rust gelaten, dan 
daalt de factor ‘gestimuleerde toestand’ langzaam weer naar ‘ongestimuleerde 
toestand’. Door elke vrijwilliger twee keer te onderzoeken, hebben we ook kunnen 
kijken naar het effect van continu achtergrond geluid op de sedatie (opname van geluid 
op een operatiekamer). Dit bleek geen effect te hebben op de BIS. 
In tegenstelling tot de BIS, vonden we dat stimulatie door plotselinge prikkeling slechts 
weinig effect had op de MOAA/S score tijdens dexmedetomidine sedatie, en zodanig 
veel rekenkundige problemen in het model teweegbracht, dat we dit niet in het 
uiteindelijke model hebben toegevoegd. De continue achtergrondgeluiden hadden 
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daarentegen wel invloed op de MOAA/S score. Vooraf was de verwachting dat 
achtergrondgeluid ervoor zou zorgen dat de vrijwilligers minder diep gesedeerd zouden 
zijn; dat het geluid de patiënten wakkerder zou houden. Echter lijkt het effect 
omgekeerd te zijn: vrijwilligers met achtergrondgeluid hebben minder 
dexmedetomidine nodig om gesedeerd te raken. Mogelijk komt dit doordat het verschil 
in volume bij het aanspreken voor de MOAA/S score gecombineerd met 
achtergrondgeluid kleiner is dan gecombineerd met stilte, en er daardoor een groter 
‘schrikeffect’ is, en de vrijwilliger vaker zal reageren. Opvallend hierbij is wel dat het 
effect niet alleen bij het aanspreken was, maar ook wanneer een vrijwilliger niet meer 
op aanspreken reageerde: er lijkt ook een effect te zijn op schudden of een pijnprikkel. 
Waar dit door komt, is nog onduidelijk. 
Opmerkelijk genoeg, blijkt uit het model de kans op een MOAA/S score van 1 (niet 
reageren op luid aanspreken en schudden, wel op een pijnprikkel) erg klein te zijn. Dit 
komt ook overeen met de resultaten uit de studie, namelijk dat maar een klein deel van 
de reacties een MOAA/S 1 was. Mogelijk is het zo bij dexmedetomidine, dat een persoon 
zo lang wekbaar blijft, dat wanneer dit effect verdwijnt, iemand al zodanig diep 
gesedeerd is dat een pijnprikkel ook niet meer tot een reactie zal leiden. 
In tegenstelling tot andere anesthetische middelen zoals propofol en remifentanil, bleek 
er voor dexmedetomidine geen effect te zijn van leeftijd op de sedatie. Door leeftijd 
gestratificeerd te werk te gaan, en dus een brede verdeling van de leeftijd van de 
vrijwilligers te includeren, hoopten we een eventueel effect ook te kunnen vinden in ons 
model. Mogelijk betekent dit dat het effect er in werkelijkheid ook niet is, verklaarbaar 
door een ander werkingsmechanisme van dexmedetomidine in vergelijking met 
propofol en remifentanil, maar wellicht is het aantal vrijwilligers te klein geweest om het 
effect aan te kunnen tonen. 
Hoofdstuk 4 is toegespitst op de effecten van dexmedetomidine op de hemodynamiek 
of bloedcirculatie, met name op de bloeddruk (MAP, mean arterial pressure) en de 
hartfrequentie (HR, heart rate). Dexmedetomidine heeft als bijzonder effect dat het in 
lage concentraties een verlaging van de bloeddruk (hypotensie) geeft ten opzichte van 
de startwaarde (baseline), maar in hoge concentraties juist een belangrijke verhoging 
van de bloeddruk (hypertensie) tot boven baseline. Dit bifasische effect hebben we in 
het model kunnen toepassen door het gebruik van twee ‘effect-sites’, voor hypotensie 
en voor hypertensie. Dit past ook bij de fysiologie erachter, namelijk dat beide effecten 
ontstaan op verschillende plaatsen in het lichaam (de hoge bloeddruk met name in de 
vaatwand, de lage bloeddruk vooral in het centraal zenuwstelsel). 
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Tevens beschrijft het model de langdurige hypotensie na het stoppen van de toediening. 
Het model laat zien dat het tot ruim 10 uur kan duren voordat de bloeddruk weer binnen 
5% van baseline komt. Echter, aangezien er geen studies zijn met een zodanig lange 
follow-up, is dit puur extrapolatie, en moet dit nog gevalideerd worden. 
Voor het effect van dexmedetomidine op de hartfrequentie was een aanpassing van het 
model nodig naar een non-lineair model volgens Schoemaker, vanwege beperkte data 
nabij het maximale effect (in het model: 22,5 slagen per minuut), aangezien de grens 
van 40 slagen per minuut werd gehandhaafd om uit veiligheidsoverwegingen de 
toediening van dexmedetomidine te staken. 
In hoofdstuk 4 keken we ook naar de gecombineerde effecten van sedatie en 
hemodynamiek door het gebruik van simulaties. Dit stelt gebruikers in staat om 
dexmedetomidine dosering te baseren op plasma concentraties, BIS, MOAA/S, 
bloeddruk en hartfrequentie tegelijk. Zo kan gesimuleerd worden welke 
doseringsstrategie het snelst tot het beoogde sedatie-effect leidt, met de minste 
negatieve invloed op de hemodynamiek. Het model is ook in staat om de initiële 
kortdurende hypertensie te beschrijven die ontstaat na een bolus of snelle toediening 
van dexmedetomidine. Echter, ook dit betreft een extrapolatie van het model, omdat in 
de studie alleen 6 of 10 μg/kg/h als maximale toedieningssnelheid is gebruikt. Dit moet 
in acht genomen worden bij het gebruik van deze simulaties. 
In hoofdstuk 5 wordt vervolgens gekeken naar interactie modellen. De studie is een 
voortzetting van een eerdere sevofluraan-remifentanil interactie studie. In het 
oorspronkelijke artikel wordt het effect van de interactie op dichotome eindpunten 
beschreven, namelijk het wel of niet reageren op diverse prikkels, zowel niet-pijnlijke als 
pijnlijke prikkels. In hoofdstuk 5 ligt de nadruk op het effect van sevofluraan en 
remifentanil op continue monitoring. Het gaat hier om 3 monitoren die afgeleid zijn van 
het EEG (‘hersenfilmpje’) en voornamelijk de hypnotische (‘slaap’ inducerende) 
component van anesthesie beschrijven, namelijk de bispectral index (BIS), state entropy 
(SE) en response entropy (RE), en 2 monitoren die op de markt worden gebracht als 
‘analgetische’ monitoren (effect van pijnstilling): de composite variability index (CVI, 
gebaseerd op de variaties in de BIS en de spieractiviteit ter hoogte van het voorhoofd) 
en de surgical pleth index (SPI, gebaseerd op het plethysmogram of golfpatroon 
gemeten door de saturatiemeter en de variaties in de hartfrequentie). 
Er zijn verschillende vormen van interacties: ‘additief’ betekent dat de interactie 
simpelweg een optelsom is van de effecten van beide middelen, ‘synergistisch’ of 
‘supra-additief’ betekent dat het gecombineerde effect van de interactie groter is dan 
additief en de middelen elkaar dus versterken, en ‘antagonistisch’ of ‘infra-additief’ 
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betekent dat het gecombineerde effect kleiner is dan additief en de middelen elkaar dus 
tegenwerken. Verschillende mogelijke interactiemodellen zijn hierin te onderzoeken om 
dit effect te beschrijven. De belangrijkste component van deze modellen is de parameter 
U. U is het beste te beschrijven als een ‘nieuw’ middel, met de karakteristieken van de
onderzochte middelen en hun concentraties, genormaliseerd naar hun eigen C50
(concentratie die 50% van het maximale effect bewerkstelligt). U kan dan als maat voor
concentratie weer gebruikt worden om de concentratie-effect verhouding te
beschrijven.
Het effect van sevofluraan en remifentanil blijkt voor BIS, SE en RE additief te zijn. De 
hoge C50 voor remifentanil toont aan dat remifentanil slechts een klein effect heeft op 
deze EEG-gebaseerde monitoren. Dit is in tegenstelling tot het bekende synergistische 
effect van beide middelen op reactie op pijnprikkels, zoals in het originele artikel is 
beschreven. Zo heeft remifentanil een sterk effect op de reactie op pijnprikkels, en is de 
interactie met sevofluraan sterk synergistisch. Ook voor andere interacties zoals 
propofol-remifentanil is deze tweedeling beschreven. Hieruit past ook het klinische 
beeld dat deze drie hypnotische monitoren geen goede voorspeller zijn of een patiënt 
wel of niet zal reageren op (pijn)prikkels. 
Voor CVI blijkt de interactie matig synergistisch te zijn. Wat hierbij opvalt, is dat er na 
een pijnlijke stimulus een forse verandering van het model optreedt, waarbij bijna alle 
parameters veranderen. Dit in tegenstelling tot de 3 hypnotische monitors, waar alleen 
de C50 voor sevofluraan stijgt met gemiddeld 0,3 vol%. In het geval van CVI, lijkt het 
erop dat een pijnlijke stimulus nodig is om het analgetische effect goed te kunnen 
beschrijven. Voor SPI is zowel voor als na een pijnlijke stimulus geen goed model te 
maken, en lijkt er dus weinig effect van zowel sevofluraan als remifentanil op de SPI te 
zijn. 
Hoofdstuk 6 is gericht op de drievoudige interactie tussen sevofluraan, propofol en 
remifentanil op het wel of niet tolereren van laryngoscopie, wat een pijnlijke prikkel is. 
De studie is een combinatie van 3 eerdere studies naar de interactie tussen propofol-
remifentanil (synergistische interactie), propofol-sevofluraan (additieve interactie) en 
sevofluraan-remifentanil (synergistische interactie). Gezien de bevindingen uit de 
eerdere studies is de hypothese dat de interactie propofol-sevofluraan onderling nog 
steeds additief zal zijn, en dat beide middelen in verschillende mate een synergistische 
interactie met remifentanil hebben. Uit hoofdstuk 6 blijkt dat het eerste correct is (de 
additieve interactie tussen propofol en sevofluraan), en het tweede gedeeltelijk, 
namelijk dat zowel propofol als sevofluraan een synergistische interactie hebben met 
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remifentanil, maar de mate is gelijk voor propofol en sevofluraan. Dat wil zeggen: de 
interactie tussen 1 van beide met remifentanil is niet sterker dan de andere. 
In hoofdstuk 6 herintroduceren we ook de term Noxious Stimulation Response Index 
(NSRI), welke reeds eerder is gepubliceerd op basis van de interactie tussen propofol en 
remifentanil. NSRI is een berekende parameter, gebaseerd op de PTOL (waarschijnlijkheid 
van tolereren van laryngoscopie) uit het interactiemodel, geschaald van 100 naar 0, 
waar 100 betekent dat er geen anesthetische middel is toegediend, en de patiënt 
normaal gesproken wakker zou zijn, en 0 betekent een zeer sterk anesthetisch effect, 
met nagenoeg geen kans dat de patiënt reageert op laryngoscopie. In onze studie wordt 
deze term uitgebreid om ook de drievoudige interactie te beschrijven. In de huidige 
klinische praktijk wordt voor inhalatie-anesthetica, zoals sevofluraan, de term MAC 
gebruikt (minimum alveolar concentration). Dit is, net als NSRI, een berekende 
parameter, alleen in dit geval voor 1 middel (het inhalatie-anestheticum) en beschrijft 
enkel de dosering waarop er 50% kans is dat de patiënt reageert op een chirurgische 
prikkel. NSRI beschrijft daarentegen niet alleen 1 middel, maar tot 3 verschillende 
middelen, voor zover toegediend, en niet alleen op het niveau van 50% kans op 
wel/geen reactie, maar het hele bereik van klinisch gebruikelijke doseringen. Hierbij is 
het ook belangrijk dat een anesthesioloog geen genoegen neemt met 50% kans op 
wel/geen reactie op een bepaalde prikkel, maar liever richting of boven de 95% kans dat 
de patiënt niet reageert. Het feit dat de MAC reeds in de klinische praktijk gebruikt 
wordt, maakt dat NSRI, welke op dezelfde basis is gefundeerd en juist meer informatie 
geeft, mogelijk makkelijker geaccepteerd wordt als maat voor anesthesie. 
Tot slot beschrijven we in hoofdstuk 6 in hoeverre verschillende parameters in staat zijn 
de waarschijnlijkheid van tolereren van laryngoscopie te voorspellen. De verschillende 
parameters zijn de concentraties van de drie verschillende middelen, de hypnotische 
monitoren BIS, SE en RE, de analgetische monitoren CVI en SPI, waar beschikbaar uit de 
oorspronkelijke studies, en de NSRI (en daarmee PTOL) uit deze studie. Uit deze evaluatie 
blijkt dat NSRI een significant betere voorspeller was dan elke andere parameter. Dit is 
een hoopgevende eerste validatie voor het gebruik van NSRI als klinisch bruikbare 
parameter om anesthesie op te sturen. 
 
Conclusie en mogelijkheden voor de toekomst 
In het eerste deel van dit proefschrift hebben we een uitgebreid PKPD model voor 
dexmedetomidine ontwikkeld. Niet alleen is dit het allereerste PKPD model voor dit 
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middel, er zitten ook een aantal unieke aspecten aan dit model. Zo beschrijft het model 
de wekbaarheid die kenmerkend is voor dexmedetomidine, en het effect van 
achtergrondgeluid op reactie op stimuli. Tevens beschrijft het model het bifasisch effect 
op de bloeddruk. Dit model kan in target-controlled infusion (TCI) gebruikt worden. 
Hierop kan bijvoorbeeld 1 deel van het model als doel gebruikt worden, zoals de BIS of 
de waarschijnlijkheid van het behalen van een bepaalde MOAA/S score, terwijl het 
hemodynamische deel gebruikt kan worden om beperkingen aan de toediening 
(toedieningssnelheid, piekconcentraties) te implementeren om de veiligheid te 
verbeteren. Naast het gebruik in TCI kunnen simulaties van het model helpen om de 
karakteristieken van dexmedetomidine beter te begrijpen op het gebied van sedatie en 
hemodynamiek. Visualisatie van het model en de simulaties in realtime kunnen helpen 
met het sturen van dexmedetomidine, met of zonder gebruik van TCI. Hoewel beperkte 
validatie van het model heeft plaatsgevonden tijdens deze studie, moet het model nog 
wel gevalideerd worden in een andere populatie, om aan te tonen dat het model ook 
buiten de onderzochte populatie goede voorspellingen van plasmaspiegels en effect 
geeft. Het model beschrijft ook de initiële kortdurende hypertensie na een bolus 
toediening of snelle infusie. Aangezien dit een extrapolatie van het model is waarbij 
tijdens de studie alleen langzame toediening is toegepast, moet ook dit gevalideerd 
worden in een studie met verschillende infusiesnelheden. In de toekomst kan het 
model, naast toepassing in de klinische praktijk, ook gebruikt worden om de interactie 
tussen dexmedetomidine en andere anesthetische middelen, zoals propofol of 
remifentanil, te onderzoeken. Een goed PK of PKPD model is hierin essentieel als basis 
voor interactiemodellen. 
Het tweede deel van dit proefschrift beschrijft zulke interactie studies, en de technieken 
om interacties in een model te kunnen beschrijven. De sevofluraan-remifentanil 
interactie studie is gericht op continue metingen, evenals de invloed van pijnlijke 
stimulatie op de interactie. Het hoofdstuk is voornamelijk beschrijvend, maar het laat 
duidelijk zien dat hoewel opiaten zoals remifentanil een sterk effect hebben op klinische 
meetpunten zoals het tolereren van pijnlijke stimuli, het effect op hypnotische EEG-
afgeleide monitoring slechts zwak is. Dit ondersteunt de gedachte dat EEG-monitoring 
een slechte voorspeller is van ‘diepte van narcose’, wat naast de hypnotische 
component ook de pijnstilling in aanwezigheid van pijnlijke stimuli (de zogenoemde 
balans tussen nociceptie – de pijnprikkel cq. pijngewaarwording – en antinociceptie – 
pijnstilling cq. het niet gewaarworden van pijn). De analgetische monitor CVI kan het 
analgetische effect alleen beschrijven in aanwezigheid van een pijnlijke prikkel. Dit 
beperkt het gebruik van CVI als voorspeller van pijn voordat de prikkel is toegediend, 
naast dat er heel veel variabiliteit in het CVI model zit. De analgetische monitor SPI is in 
zijn geheel niet in staat om de interactie tussen sevofluraan en remifentanil, noch het 
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effect van pijnlijke stimulatie te beschrijven. Deze studie toont derhalve aan dat er nog 
altijd geen goede monitoring systemen zijn die zowel de hypnotische als analgetische 
component van anesthesie goed kunnen weergeven, en daarmee de adequaatheid van 
anesthesie kunnen voorspellen. Studies zoals deze kunnen in de toekomst gebruikt 
worden om te onderzoeken of nieuwe monitoring systemen beter in staat zijn 
anesthesie diepte te beoordelen.  
De drievoudige interactie tussen sevofluraan, propofol en remifentanil, en de NSRI die 
uit het interactiemodel voortkomt, kunnen wellicht helpen om de diepte van narcose te 
beoordelen in afwezigheid van goede monitorsystemen. Onze studie toont aan dat NSRI 
beter kan voorspellen of iemand wel of niet zal reageren op laryngoscopie dan huidige 
hypnotische en analgetische monitoren en effect-site concentraties van de individuele 
middelen. Uiteraard zal ook de NSRI in andere studies en populaties gevalideerd moeten 
worden. Als NSRI een goede maat voor anesthesie blijkt te zijn uit deze validatiestudies, 
dan zijn de mogelijkheden voor de NSRI bijna eindeloos, aangezien nieuwe 
interactiestudies met andere middelen hieraan toegevoegd kunnen worden en de NSRI 
hiermee uitgebreid kan worden. Als voorbeeld: als er interactie studies zijn gedaan met 
dezelfde opzet als de huidige interactiestudies met dexmedetomidine en 1 van de 3 
middelen die nu in de NSRI zitten, dan kan dexmedetomidine ook aan de NSRI 
toegevoegd worden (met als limitatie dat alleen de middelen waarmee de onderlinge 
interactiestudies zijn uitgevoerd worden toegediend). 
Alle studies in dit proefschrift zijn gericht op hetzelfde doel: nauwkeurigere toediening 
van anesthetische middelen, voor de juiste diepte van anesthesie en verbeterde 
veiligheid van de patiënt onder narcose. In het recente verleden is het titreren van een 
anestheticum met behulp van PKPD modellen ook wel beschreven als het ‘surfen op een 
golf’ [Egan, Shafer; Anesthesiology 2003], oftewel: proberen rondom een gewenst punt 
op de concentratie-effect curve (figuur 3 in hoofdstuk 1) te blijven zitten gedurende de 
narcose. Niet alleen is dit toepasbaar op titratie van 1 middel, maar ook in het geval van 
interacties tussen meerdere middelen, waarbij gesurft wordt op een driedimensionale 
golf in de vorm van een response-surface model (figuur 7 in hoofdstuk 1). Dit 
proefschrift helpt derhalve met het surfen in de klinische anesthesiologische praktijk. 
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List of abbreviations 
ABP arterial blood pressure 
BIS bispectral index 
BMI body mass index 
C concentration 
C50 concentration resulting in 50% of maximum effect 
Ce effect-site concentration 
CL clearance 
CMT compartment 
Cp plasma concentration 
CVI composite variability index 
D50 dose resulting in 50% of maximum effect 
E effect 
E0 effect at baseline (no drug present) 
ECG electrocardiograph 
EEG electroencephalograph 
Emax maximum effect 
HR heart rate 
ICU intensive care unit 
IIV interindividual variability 
IOV interoccasion variability 
IV intravenous 
ke0 equilibration rate constant for the effect-site compartment 
kij equilibration rate constant between compartment i and compartment j 
MAC minimum alveolar concentration 
MAP mean arterial pressure 
MOAA/S modified observer’s assessment of alertness/sedation 
NONMEM non-linear mixed effects modeling 
NSRI noxious stimulation response index 
PD pharmacodynamics 
PK pharmacokinetics 
PK prediction probability 
PKPD pharmacokinetics/pharmacodynamics 
PROP propofol 
PTOL probability of tolerance of laryngoscopy 
RE response entropy 
REMI remifentanil 
SE state entropy 
SEVO sevoflurane 
SPI surgical pleth index 
TCI target-controlled infusion 
U combined potency of multiple drugs in an interaction model 
V volume 
WT weight 
γ steepness of concentration-effect relationship 
168 
List of publications 
• Colin P, Hannivoort LN, Eleveld DJ, Reyntjens KMEM, Absalom AR, Vereecke HEM,
Struys MMRF. Dexmedetomidine pharmacokinetic-pharmacodynamic modelling
in healthy volunteers: 1. Influence of arousal on bispectral index and sedation. Br
J Anaesth. 2017 Aug;119(2):200-10.
• Colin P, Hannivoort LN, Eleveld DJ, Reyntjens KMEM, Absalom AR, Vereecke HEM,
Struys MMRF. Dexmedetomidine pharmacodynamics in healthy volunteers: 2.
Haemodynamic profile. Br J Anaesth. 2017 Aug;119(2):211-20.
• Weerink MAS, Struys MMRF, Hannivoort LN, Barends CRM, Absalom AR, Colin P.
Clinical pharmacokinetics and Pharmacodynamics of Dexmedetomidine. Clin
Pharmacokinet. 2017 Aug;56(8):893-913.
• Hannivoort LN, Vereecke HEM, Proost JH, Heyse BEK, Eleveld DJ, Bouillon TW, Struys 
MMRF, Luginbühl M. Probability to tolerate laryngoscopy and noxious stimulation
response index as general indicators of the anaesthetic potency of sevoflurane,
propofol, and remifentanil. Br J Anaesth. 2016 May;116(5):624-31.
• Hannivoort LN, Eleveld DJ, Proost JH, Reyntjens KMEM, Absalom AR, Vereecke HEM, 
Struys MMRF. Development of an Optimized Pharmacokinetic Model of
Dexmedetomidine Using Target-controlled Infusion in Healthy Volunteers.
Anesthesiology. 2015 Aug;123(2):357-67.
• Vos JJ, Poterman M, Hannivoort LN, Renardel De Lavalette VW, Struys MMRF,
Scheeren TWL, Kalmar AF. Hemodynamics and tissue oxygenation during balanced 
anesthesia with a high antinociceptive contribution: an observational study.
Perioper Med (Lond). 2014 Oct;3:9.
• Heyse B, Proost JH, Hannivoort LN, Eleveld DJ, Luginbühl M, Struys MMRF, Vereecke
HEM. A response surface model approach for continuous measures of hypnotic
and analgesic effect during sevoflurane-remifentanil interaction: quantifying the
pharmacodynamic shift evoked by stimulation. Anesthesiology. 2014
Jun;120(6):1390-9.
• Hannivoort LN, Vermeijden JW. Iatrogenic perforation of a Zenker’s diverticulum
with a nasogastric tube. Neth J Crit Care 2012 Apr;16:52-3.
169 
Curriculum vitae 
Laura Naomi Hannivoort werd op 6 september 1984 geboren, als jongste dochter van 
Diana en Evertjan Hannivoort. Zij groeide op in Boekelo, samen met oudere zus Rebekka 
en oudste broer Iskander. Ruim zeventien jaar wonend in een huisartsenpraktijk met 
apotheek aan huis maakte het moeilijk een andere toekomst te verzinnen dan één in de 
medische wereld. Na het cum laude behalen van het diploma aan het Gymnasium van 
het Bonhoeffer College in Enschede in 2002, koos zij dan ook voor de studie 
geneeskunde in Groningen. In de eerste twee jaar van de studie zat zij in de organisatie 
van het International Student Congress of Medical Sciences (ISCOMS), waarvan het 
tweede jaar in het bestuur, als voorzitter van de commissie International Contacts. De 
wetenschappelijke stage in het laatste jaar van de studie, welke werd uitgevoerd in het 
Children's Cancer Center van het Royal Children's Hospital in Melbourne, Australië, in 
combinatie met een keuzecoschap kinderoncologie, deed een carrière in de wetenschap 
kriebelen. 
Eenmaal terug in Nederland, na het behalen van de artsenbul in 2009, startte Laura het 
werkende leven als arts-assistent op de Intensive Care in het Medisch Spectrum Twente 
in Enschede. Twee jaar later, in 2011, begon ze aan een promotietraject binnen de 
farmacologische onderzoekslijn van de afdeling Anesthesiologie in het Universitair 
Medisch Centrum Groningen, onder de bezielende leiding van Prof. Dr. Michel Struys, 
Prof. Dr. Tony Absalom en Dr. Hugo Vereecke. In 2013 behaalde zij de tweede plaats in 
de Best Abstract competitie van Euroanaesthesia, het jaarlijks congres van de European 
Society of Anaesthesiology. 
Inmiddels is Laura sinds 2013 in opleiding tot anesthesioloog onder het opleiderschap 
van Prof. Dr. Götz Wietasch. Het tweede jaar van de opleiding genoot zij gedeeltelijk in 
het land van 3 van haar uiteindelijke (co)promotores: België, in Gent om precies te zijn. 
In dezelfde periode trok de afdeling Dr. Pieter Colin vanuit Gent aan ter aanvulling van 
het wetenschappelijk team; hij nam eveneens gedeeltelijk de begeleiding van het 
wetenschappelijk traject van Laura voor zijn rekening. Na nog een korte tussenstop in 
het tweede opleidingsjaar in de Isala in Zwolle, vervolgt Laura de opleiding weer in het 
UMCG, inmiddels in het laatste jaar van de opleiding. 
170 
Acknowledgments/Dankwoord 
Daar ligt ‘ie dan, na ruim 6,5 jaar hard werk, vele uren slaap – in het geval van de patiënten en 
vrijwilligers – en een lading (virtuele) inkt: het proefschrift. Uiteraard schrijft een proefschrift niet 
zichzelf, en daarom wil ik iedereen die een steentje, van kiezel tot rots, inhoudelijk of 
ondersteunend heeft bijgedragen aan de onderzoeken en het uiteindelijke proefschrift, hartelijk 
bedanken. Promoveren tijdens een fulltime opleiding is niet makkelijk, maar met de juiste mensen 
om je heen zeker te doen. En dat ik de juiste mensen om mij heen heb, daar ben ik in de afgelopen 
6,5 jaar absoluut van overtuigd geraakt. 
Allereerst wil ik mijn eerste promotor, Prof. Dr. M.M.R.F. Struys, bedanken. Michel, vanaf dag 1, 
nee daarvoor al, halverwege mijn sollicitatiegesprek, heb jij me het gevoel gegeven dat je de 
onderzoeker in me zag, nog voordat ik daar zelf van overtuigd was. Dat je vertrouwen in mijn 
kunnen had, voordat ik zelf dat vertrouwen had. Binnen de kortste tijd had je door dat het initiële 
onderzoeksplan onder de omstandigheden van 6,5 jaar geleden niet de juiste kans van slagen had, 
en dat mijn handigheid met computers en ICT bovendien een weg in een andere richting opende. 
Het roer ging om, je stuurde me naar de NONMEM-cursus, en ik denk dat dat de beste keuze in 
mijn wetenschappelijke carrière is geweest. “The rest is history”, maar wel een geschiedenis 
waarin ik ontzettend veel van jou en de onderzoeksgroep heb kunnen leren, op een 
onderzoeksgebied waarvan ik nooit had geweten dat het zo interessant was, maar toch perfect 
bij mijn past. Bedankt dat je de wetenschapper in mij beter kende dan ikzelf, en daar het maximale 
hebt weten uit te halen. 
Vervolgens alle dank aan mijn tweede promotor, Prof. Dr. A.R. Absalom. Tony, voor mij ben je 
precies wat een goede professor zou moeten zijn voor zijn pupillen: een encyclopedie aan kennis, 
en altijd bereid om die kennis te delen, met het enthousiasme die alleen iemand kan tonen die 
met hart voor het vak en voor onderwijs. Je bijdragen aan onderzoeksprotocollen en 
manuscripten waren daarmee ook uiterst leerzaam voor een beginnend onderzoeker als ik. Naast 
dat je een onuitputtelijke bron van meer algemene anesthesiologische en farmacologische kennis 
bent, ben jij ook degene met verreweg de meeste kennis en ervaring met dexmedetomidine in dit 
ziekenhuis, wellicht zelfs in het hele land. Je bent een belangrijke spil geweest rondom de 
dexmedetomidine studie, en daarmee een zeer groot deel van mijn promotietraject. Bedankt voor 
alles wat je me geleerd hebt, en je onuitputtelijke enthousiasme. 
Mijn beide copromotores, Hugo Vereecke en Pieter Colin, zonder jullie zou dit proefschrift er zeker 
niet zijn gekomen. Hugo, jij was degene die mij alle kneepjes van het vak moest leren. Ik, net twee 
jaar uit de studiebanken, wist nog net dat farmacologie ‘iets met absorptie, distributie, 
metabolisme en excretie, en zo’ was, en mijn beeld van farmacologie in de klinische praktijk was 
‘geef de patiënt een pilletje en kijk een paar weken of maanden later of je het moet ophogen of 
verlagen’. Natuurlijk is dat in de anesthesiologie anders, en dat heb jij op mij zeer succesvol weten 
over te brengen en enthousiast voor weten te krijgen. Niet alleen heb je me van alles geleerd over 
farmacologie in de anesthesiologie, maar ook over onderzoek doen in het algemeen, en je 
begeleiding hieromtrent, en in het bijzonder het dexmedetomidine onderzoek, is daarbij 
onmisbaar geweest. Pieter, jij nam het stokje deels over van Hugo na zijn verhuizing naar het 
171 
zuiden. Ik heb genoten van onze gedachtewisselingen, met name tijdens de dexmedetomidine PD 
modeling. Als ik met een idee kwam, dan wist jij dat om te zetten in een model waar ik bij lange 
na niet op zou zijn gekomen. Ik heb in relatief korte tijd veel van je geleerd, en het besef gekregen 
dat er nog zo veel meer te leren is op het gebied van modeling. 
Leden van de Beoordelingscommissie, members of the Assessment Committee, thank you very 
much for the time and effort you have invested into reading and assessing my thesis. 
Douglas en Hans, vanaf het begin van mijn promotietraject de modeling-guru’s. Bedankt voor alles 
wat jullie me geleerd hebben op het gebied van modeling, en jullie zeer waardevolle bijdrage aan 
de studies, van planning tot modeling tot publicaties. Als ik weer eens in NONMEM verzandde, 
wisten jullie me te helpen het beter te begrijpen, of op een andere manier naar de oplossing te 
zoeken. Ik denk dat jullie niet eens weten hoeveel jullie me geleerd hebben. 
Koen, bedankt voor alle hulp tijdens de dexmedetomidine studie. Het maakt het een stuk 
makkelijker voor alle betrokkenen van zo’n studie om hun werk te doen, wanneer er een 
anesthesioloog ‘aan het hoofd’ staat waar je op kan vertrouwen, en die rust behoud en uitstraalt, 
ook tijdens de meer hectische momenten. 
De in wetenschappelijke publicaties vaak onzichtbaar maar o zo waardevolle personen van het 
onderzoeksbureau. Froukje, partner-in-crime in de dexmedetomidine studie, en 
‘onderzoekskamergenoot’. Samen waren we de meest constante factor in de Dex-studie. Ik kon 
altijd op je rekenen dat de onderzoekssessie goed uitgevoerd werd, en we waren elkaars 
geheugensteun voor het handhaven van het tijdsschema. De gezelligheid op de kamer kon er 
natuurlijk ook niet aan ontbreken! Ans, bedankt voor de ondersteuning tijdens de 
dexmedetomidine studie, waar je altijd tijd voor wist te maken ondanks de vele andere studies 
waar je actief bij betrokken was. Last but not least in het onderzoeksbureau: Rob, bedankt voor – 
ja, wat eigenlijk niet? – ondersteuning bij het opzetten van protocollen en METc-aanvragen, ICT- 
en HR-gerelateerde zaken, contacten met QPS, en vast nog genoeg waar ik nu niet op kan komen. 
Daarnaast ook bedankt voor de ondersteuning bij de dexmedetomidine studie, als manusje-van-
alles. Je hielp mee waar handen te kort kwamen, en kon voor zowel Froukje als Ans invallen, en 
moest dus ongeveer alles aspecten van de studie kennen. 
Mijn opleider, Prof. Dr. JKG Wietasch, Götz, dankzij jou heb ik niet alleen de kans gekregen om 
anesthesioloog te worden, maar je hebt me ook rijkelijk de ruimte gegeven om aan artikelen en 
het proefschrift te werken. Daarnaast zal ik ook nooit vergeten dat het welzijn van je assistenten 
voor jou echt van belang is, en de support die ik op dat vlak heb kunnen ontvangen, tijdens mijn 
eigen ‘dip’, ben ik je zeer dankbaar voor. 
Minke, een vaste pijler in de bijna 7 jaar dat ik al op de afdeling ben. Altijd bereid om een handje 
te helpen, of de weg te wijzen (letterlijk of figuurlijk), daar waar nodig. Bedankt! 
Bedankt aan alle mede-auteurs die ik niet specifiek genoemd heb. Jullie bijdragen aan de artikelen 
waar dit proefschrift op gestoeld is, zijn onmisbaar. 
172 
Aan alle stafleden en AIOS van de afdeling anesthesiologie en zeker niet te vergeten, 
anesthesiemedewerkers en PACU-verpleegkundigen, bedankt voor het zorgen voor een sfeer op 
de afdeling waarbij klinisch werk, opleiding en onderzoek vaak goed te combineren zijn, en 
natuurlijk voor alles wat jullie me op het gebied van anesthesiologie hebben bijgebracht. Bedankt 
voor de medewerking aan diverse studies in de afgelopen jaren, jullie geduld, en het invullen van 
eindeloze extra formulieren.  
Aan de stafleden, AIOS en verpleegkundigen van de Intensive Care Volwassenen, bedankt voor 
alles wat jullie hebben bijgeleerd over de zorg van de kritisch zieke patiënt tijdens mijn opleiding. 
Jaap, bedankt voor de tijd om aan mijn proefschrift te werken. 
Mijn dank ook aan de intensivisten en IC-verpleegkundigen van het MST Enschede, van wie ik 
ontzettend veel heb geleerd, altijd met een overschot aan enthousiasme!  
Dit geldt zeker ook voor de afdelingen anesthesiologie in het UZ Gent en de Isala, waar ik mijn 
tweede jaar heb kunnen genieten van twee nieuwe, uiterst leerzame centra. 
Bedankt QPS voor de medewerking aan de dexmedetomidine studie: het screenen van de 
vrijwilligers en het uitvoeren van de concentratiebepalingen van dexmedetomidine. 
Aan alle patiënten en vrijwilligers die hebben meegedaan aan de studies, zonder jullie geen 
onderzoek, zonder jullie geen proefschrift. Bedankt voor jullie medewerking! 
Last but not least: vrienden en familie, in het bijzonder: 
Mijn paranimfen, Rebekka en Carlijn. Rebekka, je bent altijd mijn grote voorbeeld geweest. Alles 
wat jij ging doen, wilde ik ook, zoals kleine zusjes graag doen. Dit gold voor bijna alles, van studie 
tot sport. Zelfs mijn keuze voor anesthesiologie heb ik voor een belangrijk deel aan jou te danken, 
al was jij toen nog niet van plan om anesthesioloog te worden. Daarin heb jij mij voor de 
verandering gevolgd. Je bent altijd een grote steun voor me, ik kan altijd kwijt wat me dwars zit. 
Je bent de spiegel om voor te oefenen voor een belangrijk praatje, en hoewel ik daar een hekel 
aan heb, helpt het wel. Bedankt voor alle onvoorwaardelijke support. 
Carlijn, ik herinner me nog goed die eerste keer in Café Marleen, maandagavond na een repetitie 
van Bragi. Sindsdien zijn we geloof ik nooit meer gestopt met kletsen. Over en weer hebben we 
elkaar gesteund over de jaren. Buiten mijn familie zijn er weinig waar ik zo vrij over alles kan 
praten, over alle onzekerheden omtrent beslissingen over opleiding en toekomst, of presentaties 
op congressen, je weet altijd het juiste te zeggen. Bedankt voor alle steun, in het verleden en nu! 
Iskander, als grote broer heb je voor mij het voorbeeld gegeven hoe je kan excelleren in wat je 
echt leuk vindt. Ik heb altijd met bewondering naar je opgekeken hoe je na de middelbare school 
alles hebt aangegrepen om je droom te volgen, met geweldige studieresultaten, een topbaan, 
gekroond met een geweldig gezinnetje: je lieve vrouw Moniek, en de schattigste en slimste 
kinderen, Madison en Tyler. Pap, mam, bedankt voor het creëren van een omgeving waarin ik heb 
kunnen opgroeien tot wie ik nu ben. Jullie onvoorwaardelijke liefde en steun zijn onbeschrijfelijk 
belangrijk voor mij geweest. Jullie hebben me de mogelijkheid gegund om mijn grenzen te 
verleggen, zelfs een klein duwtje richting Australië gegeven. Ik bof maar met ouders zoals jullie! 
